

Thiazolidinones, Their Production and Use as Pharmaceutical Agents

This application claims the benefit of the filing date of U.S. Provisional Application Serial No. 60/517,061 filed November 5, 2003 which is incorporated by reference herein.

The invention relates to thiazolidinones, their production and use as inhibitors of polo-like kinase (Plk) for treating various diseases.

Tumor cells are distinguished by an uninhibited cell-cycle process. This is based on, on the one hand, the loss of control proteins, such as RB, p16, p21, p53, etc., as well as the activation of so-called accelerators of the cell-cycle process, the cyclin-dependent kinases (Cdks). The Cdks are an anti-tumor target protein that is acknowledged in pharmaceuticals. In addition to the Cdks, serine/threonine kinases that regulate the new cell cycle, so-called 'polo-like kinases,' were described, which are involved not only in the regulation of the cell cycle but also in the coordination with other processes during mitosis and cytokinesis (formation of the spindle apparatus, chromosome separation). This class of proteins therefore represents an advantageous point of application for therapeutic intervention of proliferative diseases such as cancer (Descombes and Nigg. *Embo J*, 17; 1328 ff, 1998; Glover et al. *Genes Dev* 12, 3777 ff, 1998).

A high expression rate of Plk-1 was found in 'non-small cell lung' cancer (Wolf et al. *Oncogene*, 14, 543ff, 1997), in melanomas (Strebhardt et al. *JAMA*, 283, 479ff, 2000), in 'squamous cell carcinomas' (Knecht et al. *Cancer Res*, 59, 2794ff, 1999) and in 'esophageal carcinomas' (Tokumitsu et al. *Int J Oncol* 15, 687ff, 1999).

A correlation of a high expression rate in tumor patients with poor prognosis was shown for the most varied tumors (Strebhardt et al. *JAMA*, 283, 479ff, 2000, Knecht et al. *Cancer Res*, 59, 2794ff, 1999 and Tokumitsu et al. *Int J Oncol* 15, 687ff, 1999).

The constitutive expression of Plk-1 in NIH-3T3 cells resulted in a malignant transformation (increased proliferation, growth in soft agar, colony formation and tumor development in hairless mice (Smith et al. *Biochem Biophys Res Comm*, 234, 397ff., 1997).

Microinjections of Plk-1 antibodies in HeLa cells resulted in improper mitosis (Lane et al.; *Journal Cell Biol*, 135, 1701ff, 1996).

With a '20-mer' antisense oligo, it was possible to inhibit the expression of Plk-1 in A549 cells, and to stop their ability to survive. It was also possible to show a significant anti-tumor action in hairless mice (Mundt et al., *Biochem Biophys Res Comm*, 269, 377ff., 2000).

The microinjection of anti-Plk antibodies in non-immortalized human Hs68 cells showed, in comparison to HeLa cells, a significantly higher fraction of cells, which remained in a growth arrest at G2 and showed far fewer signs of improper mitosis (Lane et al.; *Journal Cell Biol*, 135, 1701ff, 1996).

In contrast to tumor cells, antisense-oligo-molecules did not inhibit the growth and the viability of primary human mesangial cells (Mundt et al., *Biochem Biophys Res Comm*, 269, 377ff., 2000).

In mammals, to date in addition to the Plk-1, three other polo-kinases were described that are induced as a mitogenic response and exert their function in the G1 phase of the cell cycle. These are, on the one hand, the so-called Prk/Plk-3 (the human homologue of the mouse-Fnk= fibroblast growth factor-induced kinase; Wiest et al, *Genes, Chromosomes & Cancer*, 32: 384ff, 2001), Snk/Plk-2 (serum-induced kinase, Liby et al., *DNA Sequence*, 11, 527-33, 2001) and sak/Plk4 (Fode et al., *Proc.Natl.Acad.Sci. U.S.A.*, 91, 6388ff; 1994).


The inhibition of Plk-1 and the other kinases of the polo family, such as Plk-2, Plk-3 and Plk-4, thus represents a promising approach for the treatment of various diseases.

The sequence identity within the Plk domains of the polo family is between 40 and 60%, so that partial interaction of inhibitors of a kinase occurs with one or more other kinases of this family. Depending on the structure of the inhibitor, however, the action can also take place selectively or preferably on only one kinase of the polo family.

In International Application WO03/093249, thiazolidinone compounds that inhibit the kinases of the polo family are disclosed.

The object of this invention consists in that additional substances that inhibit the kinases of the polo family in the nanomolar range are available.

It has now been found that compounds of general formula I



(I),

in which

Q stands for aryl or heteroaryl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro,

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for $-\text{NR}^3(\text{CO})-\text{L}$, $-\text{NR}^3(\text{CO})-\text{NR}^3-\text{L}$, $-\text{COR}^6$, $-\text{CO}(\text{NR}^3)-\text{M}$, $-\text{NR}^3(\text{CS})\text{NR}^3\text{R}^4$,
 $-\text{NR}^3\text{SO}_2-\text{M}$, $-\text{SO}_2-\text{NR}^3\text{R}^4$ or $-\text{SO}_2(\text{NR}^3)-\text{M}$,

- L** stands for C_1 - C_6 -alkyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with C_1 - C_6 -hydroxyalkoxy, C_1 - C_6 -alkoxyalkoxy, C_3 - C_6 -heterocycloalkyl or with the group $-\text{NR}^3\text{R}^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(\text{CO})-$ or $-\text{SO}_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_1 - C_6 -hydroxyalkyl or with the group $-\text{NR}^3\text{R}^4$,
- M** stands for C_1 - C_6 -alkyl that is optionally substituted in one or more places, in the same way or differently, with the group $-\text{NR}^3\text{R}^4$ or C_3 - C_6 -heterocycloalkyl,
- X** stands for $-\text{NH}-$ or $-\text{NR}^5-$,
- R¹** stands for C_1 - C_4 -alkyl, C_3 -cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,
- R²** stands for hydrogen or for C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, C_1 - C_6 -alkenyl, C_1 - C_6 -alkynyl, C_3 - C_6 -cycloalkyl, C_3 - C_6 -heterocycloalkyl, aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, C_1 - C_6 -hydroxyalkyl, C_3 - C_6 -cycloalkyl, C_3 - C_6 -heterocycloalkyl, C_1 - C_6 -alkynyl, aryl, aryloxy, heteroaryl or with the group $-\text{S}-\text{C}_1$ - C_6 -alkyl, $-\text{COR}^6$, $-\text{NR}^3\text{R}^4$, $-\text{NR}^3(\text{CO})-\text{L}$ or $-\text{NR}^3\text{COOR}^7$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(\text{CO})-$ or $-\text{SO}_2-$ groups in the ring, and/or

optionally one or more double bonds can be contained in the ring, and whereby aryl, heteroaryl, C₃-C₆-cycloalkyl- and/or the C₃-C₆-heterocycloalkyl ring in each case itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl or C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl, benzyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen,

or

for the group -NR³R⁴, -NR³(CO)-L, or -NR³(CS)NR³R⁴,

or

R² and R⁵ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted at least one time by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more-(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl or with the group -NR³R⁴ or -COR⁶, and/or can be substituted with aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, C₁-C₆-alkoxy or with the group -COR⁶, R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, -CO-C₁-C₆-alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by

one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C_3-C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C_1-C_6 -alkyl, C_1-C_6 -hydroxyalkyl, C_1-C_6 -alkoxy, C_3-C_6 -cycloalkyl, or with the group $-NR^3R^4$ or $-CO-NR^3R^4$,
or

R^3 and R^4 together form a C_3-C_6 -heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring,
and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C_1-C_6 -alkyl, C_3-C_6 -cycloalkyl, C_1-C_6 -hydroxyalkyl, C_1-C_6 -alkoxyalkyl, cyano, hydroxy or with the group $-NR^3R^4$,

R^5 stands for C_1-C_6 -alkyl, C_1-C_6 -alkenyl, or C_1-C_6 -alkinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C_1-C_6 -alkoxy, C_3-C_6 -cycloalkyl, C_3-C_6 -heterocycloalkyl, or with the group $-NR^3R^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C_3-C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with

cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

R⁶ stands for hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy or the group -NR³R⁴,

R⁷ stands for -(CH₂)_n-aryl or -(CH₂)_n-heteroaryl and

n stands for 1 - 6,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts, with the stipulation that the following compounds do not fall under general formula (I):

{2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetyl-amino}-acetic acid methyl ester,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-pyridin-3-ylmethyl-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(3-imidazol-1-yl-propyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(4-fluoro-benzyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(3-morpholin-4-yl-propyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(2-morpholin-4-yl-ethyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-acetamide,

2-Cyano-N-cyclohexyl-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

4-{2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetyl-amino}-piperidine-1-carboxylic acid ethyl ester,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(3-hydroxy-propyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(4-methoxy-benzyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-[2-(4-hydroxy-phenyl)-ethyl]-acetamide,

N-Allyl-2-cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(2-hydroxy-ethyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(4-hydroxy-butyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(6-hydroxy-hexyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

2-Cyano-2-[3-ethyl-5-[1-(4-methoxy-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide,

6-{[2-[1-Cyano-1-dimethylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-naphthalene-2-carboxylic acid,

4-{[2-[1-Cyano-1-dimethylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-benzoic acid,

2-Cyano-2-[3-ethyl-5-[1-(4-hydroxy-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide,

4-{{2-[1-Cyano-1-dimethylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-benzamide,

2-Cyano-2-[3-ethyl-5-[1-(4-hydroxymethyl-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide,

are suitable inhibitors of the kinases of the polo family.

The compounds of general formula I according to the invention essentially inhibit the polo-like kinases, upon which is based their action against, for example, cancer, such as solid tumors and leukemia; auto-immune diseases, such as psoriasis, alopecia, and multiple sclerosis, chemotherapy agent-induced alopecia and mucositis; cardiovascular diseases, such as stenoses, arterioscleroses and restenoses; infectious diseases, such as, e.g., by unicellular parasites, such as trypanosoma, toxoplasma or plasmodium, or produced by fungi; nephrological diseases, such as, e.g., glomerulonephritis, chronic neurodegenerative diseases, such as Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease; acute neurodegenerative diseases, such as ischemias of the brain and neurotraumas; viral infections, such as, e.g., cytomegalic infections, herpes, hepatitis B and C, and HIV diseases.

Stereoisomers can be defined as E/Z- and R/S-isomers as well as mixtures that consist of E/Z- and R/S-isomers.

Alkyl is defined in each case as a straight-chain or branched alkyl radical, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec.-butyl, tert.-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl and decyl.

Alkoxy is defined in each case as a straight-chain or branched alkoxy radical, such as, for example, methyloxy, ethyloxy, propyloxy, isopropyloxy, butyloxy, isobutyloxy, sec.-butyloxy, pentyloxy, isopentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy or decyloxy.

The alkenyl substituents in each case are straight-chain or branched, and, for example, the following radicals are meant: vinyl, propen-1-yl, propen-2-yl, but-1-en-1-yl, but-1-en-2-yl, but-2-en-1-yl, but-2-en-2-yl, 2-methyl-prop-2-en-1-yl, 2-methyl-prop-1-en-1-yl, but-1-en-3-yl, but-3-en-1-yl, and allyl.

Alkynyl is defined in each case as a straight-chain or branched alkynyl radical that contains 2-6, preferably 2-4 C atoms. For example, the following radicals can be mentioned: acetylene, propin-1-yl, propin-3-yl, but-1-in-1-yl, but-1-in-4-yl, but-2-in-1-yl, but-1-in-3-yl, etc.

Heterocycloalkyl stands for an alkyl ring that comprises 3 – 6 carbon atoms, which instead of carbon contains one or more heteroatoms, the same or different, such as, e.g., oxygen, sulfur or nitrogen, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and can contain another substituent on one or more carbon, nitrogen or sulfur atoms, optionally independently of one another. Substituents on the heterocycloalkyl ring can be: cyano, halogen, hydroxy, C_1-C_6 -alkyl, C_1-C_6 -alkoxy, C_1-C_6 -alkoxyalkyl, C_1-C_6 -hydroxyalkyl, C_3-C_6 -cycloalkyl, aryl or the group $-NR^3R^4$, $-CO-NR^3R^4$, $-SO_2R^3$ or $-SO_2NR^3R^4$.

As heterocycloalkyls, there can be mentioned, e.g.: oxiranyl, oxethanyl, aziridinyl, azetidiny, tetrahydrofuranyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, dioxanyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, trithianyl, quinuclidinyl, pyrrolidonyl, N-methylpyrrolidinyl, 2-hydroxymethylpyrrolidinyl, 3-hydroxypyrrolidinyl, N-methylpiperazinyl, N-acetylpiperazinyl, N-methylsulfonylpiperazinyl, 4-hydroxypiperidinyl, 4-aminocarbonylpiperidinyl, 2-hydroxyethylpiperidinyl, 4-hydroxymethylpiperidinyl, nortropinyl, 1,1-dioxo-thiomorpholinyl, etc.

Cycloalkyls are defined as monocyclic alkyl rings, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, but also bicyclic rings or tricyclic rings, such as, for

example, adamantanyl. The cycloalkyl can optionally also be benzocondensed, such as, e.g. (tetralin)yl, etc.

Halogen is defined in each case as fluorine, chlorine, bromine or iodine.

The aryl radical in each case has 6 - 12 carbon atoms, such as, for example, naphthyl, biphenyl and in particular phenyl.

In each case, the heteroaryl radical comprises 3-16 ring atoms and, instead of carbon, can contain one or more heteroatoms, the same or different, such as oxygen, nitrogen or sulfur in the ring, and can be mono-, bi- or tricyclic, and can in addition in each case be benzocondensed.

For example, there can be mentioned:

Thienyl, furanyl, pyrrolidinyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, etc., and benzo derivatives thereof, such as, e.g., benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl, indazolyl, indolyl, isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and benzo derivatives thereof, such as, e.g., quinolyl, isoquinolyl, etc.; or oxepinyl, azocinyl, indolizinyl, indolyl, indolinyl, isoindolyl, indazolyl, benzimidazolyl, purinyl, etc., and benzo derivatives thereof; or quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, xanthenyl, tetralinyl, etc.

Preferred heteroaryl radicals, are, for example, 5-ring heteroaromatic compounds, such as thiophene, furanyl, oxazolyl, thiazole, imidazolyl and benzo derivatives thereof, and 6-ring-heteroaromatic compounds, such as pyridinyl, pyrimidinyl, triazinyl, quinolinyl, isoquinolinyl and benzo derivatives thereof.

The aryl radical comprises 3-12 carbon atoms in each case and can be benzocondensed in each case.

For example, there can be mentioned: cyclopropenyl, cyclopentadienyl, phenyl, troyl, cyclooctadienyl, indenyl, naphthyl, azulenyl, biphenyl, fluorenyl, anthracenyl, tetralinyl, etc.

Isomers are defined as chemical compounds of the same summation formula but different chemical structure. In general, constitutional isomers and stereoisomers are distinguished.

Constitutional isomers have the same summation formula but are distinguished by the way in which their atoms or groups of atoms are linked. These include functional isomers, positional isomers, tautomers or valence isomers.

In principle, stereoisomers have the same structure (constitution) – and thus also the same summation formula – but are distinguished by the spatial arrangement of the atoms.

In general, configurational isomers and conformational isomers are distinguished. Configurational isomers are stereoisomers that can be converted into one another only by bond breaking. These include enantiomers, diastereomers and E/Z (cis/trans) isomers.

Enantiomers are stereoisomers that behave toward one another like image and mirror image and do not have any symmetry plane. All stereoisomers that are not enantiomers are referred to as diastereomers. E/Z (cis/trans) isomers of double bonds are a special case.

Conformational isomers are stereoisomers that can be converted into one another by the turning of single bonds.

To differentiate the types of isomerism from one another, see also the IUPAC rules, Section E (Pure Appl. Chem. **45**, 11-30, 1976).

The compounds of general formula I according to the invention also contain the possible tautomeric forms and comprise the E or Z isomers or, if a chiral center is present, also the racemates and enantiomers. Among the latter, double-bond isomers are also included.

The compounds according to the invention can also be present in the form of solvates, in particular hydrates, whereby the compounds according to the invention consequently

contain polar solvents, in particular water, as structural elements of the crystal lattice of the compounds according to the invention. The proportion of polar solvent, in particular water, can be present in a stoichiometric or even an unstoichiometric ratio. In the case of stoichiometric solvates and hydrates, hemi-, (semi-), mono-, sesqui-, di-, tri-, tetra-, penta, etc., solvates or hydrates are also indicated.

If an acid group is included, the physiologically compatible salts of organic and inorganic bases are suitable as salts, such as, for example, the readily soluble alkali and alkaline-earth salts, as well as N-methyl-glucamine, dimethyl-glucamine, ethyl-glucamine, lysine, 1,6-hexadiazine, ethanolamine, glucosamine, sarcosine, serinol, tris-hydroxy-methyl-amino-methane, aminopropane diol, Sovak base, and 1-amino-2,3,4-butanetriol.

If a basic group is included, the physiologically compatible salts of organic and inorganic acids are suitable, such as hydrochloric acid, sulfuric acid, phosphoric acid, citric acid, tartaric acid, i.a.

Preferred in particular are those compounds of general formula I, in which

Q stands for phenyl, naphthyl, quinoliny, benzimidazolyl, indolyl, indazolyl, thiazolyl, imidazolyl or pyridyl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be

substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for -NR³(CO)-L, -NR³(CO)-NR³-L, -COR⁶, -CO(NR³)-M, -NR³(CS)NR³R⁴, -NR³SO₂-M, -SO₂-NR³R⁴ or -SO₂(NR³)-M,

- L stands for C₁-C₆-alkyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-C₆-alkoxyalkoxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,
- M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -NR³R⁴ or C₃-C₆-heterocycloalkyl,
- X stands for -NH- or -NR⁵-,
- R¹ stands for C₁-C₄-alkyl, C₃-cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,
- R² stands for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-alkenyl, C₁-C₆-alkinyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-hydroxyalkyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, C₁-C₆-alkinyl, aryl, aryloxy, heteroaryl or with the group -S-C₁-C₆-alkyl, -COR⁶, -NR³R⁴, -NR³(CO)-L or

-NR³COOR⁷, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby aryl, heteroaryl, C₃-C₆-cycloalkyl- and/or the C₃-C₆-heterocycloalkyl ring in each case itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, or C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl, benzyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen,

or

for the group -NR³R⁴, -NR³(CO)-L, or -NR³(CS)NR³R⁴,

or

R² and R⁵ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl or with the group -NR³R⁴ or -COR⁶, and/or with aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, C₁-C₆-alkoxy or with the group -COR⁶,

R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, -CO-C₁-C₆-alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-

heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

or

R³ and R⁴ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted by nitrogen at least once and optionally can be interrupted in one or more places by oxygen or sulfur, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl, cyano, hydroxy or with the group -NR³R⁴,

R⁵ stands for C₁-C₆-alkyl, C₁-C₆-alkenyl, or C₁-C₆-alkinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can

be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

R⁶ stands for hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy or the group -NR³R⁴,

R⁷ stands for -(CH₂)_n-aryl or -(CH₂)_n-heteroaryl and

n stands for 1 - 6,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

Especially preferred are those compounds of general formula I, in which

Q stands for phenyl, naphthyl or indolyl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,
or

for -NR³(CO)-L, -NR³(CO)-NR³-L, -COR⁶, -CO(NR³)-M, -NR³(CS)NR³R⁴, -NR³SO₂-M, -SO₂-NR³R⁴ or -SO₂(NR³)-M,

L stands for C₁-C₆-alkyl or heteroaryl that is optionally substituted in one or

more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-C₆-alkoxyalkoxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -NR³R⁴ or C₃-C₆-heterocycloalkyl,

X stands for -NH- or -NR⁵-,

R¹ stands for C₁-C₄-alkyl, C₃-cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,

R² stands for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-alkenyl, C₁-C₆-alkinyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-hydroxyalkyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, C₁-C₆-alkinyl, aryl, aryloxy, heteroaryl or with the group -S-C₁-C₆-alkyl, -COR⁶, -NR³R⁴, -NR³(CO)-L or -NR³COOR⁷,

whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring,

and whereby aryl, heteroaryl, C₃-C₆-cycloalkyl- and/or the C₃-C₆-heterocycloalkyl ring in each case itself optionally can be substituted in one or

more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, or C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl, benzyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen,

or

for the group -NR³R⁴, -NR³(CO)-L, or -NR³(CS)NR³R⁴,

or

R² and R⁵ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl or with the group -NR³R⁴ or -COR⁶, and/or can be substituted with aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, C₁-C₆-alkoxy or with the group -COR⁶,

R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, -CO-C₁-C₆-alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-

heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

or

R³ and R⁴ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted at least once by nitrogen, and optionally can be interrupted in one or more places by oxygen or sulfur, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring,

and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl, cyano, hydroxy or with the group -NR³R⁴,

R⁵ stands for C₁-C₆-alkyl, C₁-C₆-alkenyl, or C₁-C₆-alkinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

R⁶ stands for hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy or the group -NR³R⁴,

R^7 stands for $-(CH_2)_n$ -aryl or $-(CH_2)_n$ -heteroaryl and

n stands for 1 - 6,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

In particular, those compounds of general formula (I) are preferred in which

Q stands for phenyl, naphthyl or indolyl,

A and B , independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro

or

for C_1 - C_3 -alkyl or C_1 - C_6 -alkoxy that is optionally substituted in one or more places, in the same way or differently, with pyrrolidinyl, piperidinyl, piperazinyl or with the group $-N(C_1-C_6-alkyl)_2$, whereby pyrrolidinyl, piperidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkyl or C_1 - C_6 -hydroxyalkyl,

or

for $-CO(NH)-M$, $-CO(NCH_3)-M$, $-NH(CO)-L$, $-NH(CO)-NH-L$, $-SO_2(NH)-M$ or $-SO_2(NCH_3)-M$,

L stands for C_1 - C_6 -alkyl or pyridyl that is optionally substituted in one or more places, in the same way or differently, with C_1 - C_6 -hydroxyalkoxy, C_1 - C_6 -alkoxyalkoxy, pyrrolidinyl, piperazinyl or with the group $-N(C_1-C_6-alkyl)_2$, whereby the pyrrolidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkyl,

M stands for C_1 - C_6 -alkyl that is optionally substituted in one or more places, in the same way or differently, with the group $-N(C_1-C_6-alkyl)_2$ or pyrrolidinyl,

X stands for $-NH-$ or $-NR^5-$,

R^1 stands for C_1 - C_4 -alkyl that is optionally substituted in one or more places, in

the same way or differently, with halogen,

R^2 stands for hydrogen or for C_1 - C_6 -alkyl, C_1 - C_6 -alkenyl, C_1 - C_6 -alkinyl, C_3 - C_6 -cycloalkyl, pyrrolidinyl, piperidinyl, phenyl, tetralinyl or indolyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, C_1 - C_6 -hydroxyalkyl, C_3 - C_6 -cycloalkyl, tetrahydrofuranyl, pyrrolidinyl, piperazinyl, morpholinyl, phenyl, phenoxy, biphenyl, naphthyl, thienyl, furanyl, tetrazolyl, pyridyl or with the group $-S-C_1-C_6$ -alkyl, $-CONH_2$, $-COO-C_1-C_6$ -alkyl, $-N(C_1-C_6-alkyl)_2$, $-N(C_1-C_6-alkyl)phenyl$, or $-NH(CO)-L$, whereby phenyl, furanyl, C_3 - C_6 -cycloalkyl, piperidinyl or piperazinyl in each case itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, cyano, halogen, hydroxy, phenyl, benzyl, or morpholinyl, and the C_1 - C_6 -alkyl or C_1 - C_6 -alkoxy itself optionally can be substituted in one or more places, in the same way or differently, with halogen,

or

for the group $-N(C_1-C_6-alkyl)_2$, $-NH(CO)-L$, or $-NCH_3(CS)NHCH_3$,

or

R^2 and R^5 together form aziridinyl, azetidiny, morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl, whereby aziridinyl, azetidiny, morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with hydroxy, C_1 - C_6 -alkyl, C_1 - C_6 -hydroxyalkyl, C_1 - C_6 -alkoxyalkyl or with the group $-CONH_2$, $-CO-C_1-C_6$ -alkyl or $-COO-C_1-C_6$ -alkyl, and/or can be substituted with phenyl, benzyl or pyridyl that is optionally substituted in one or more places, in the same way or differently, with halogen or C_1 - C_6 -alkoxy, and

R^5 stands for C_1 - C_6 -alkyl or C_1 - C_6 -alkenyl that is optionally substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkoxy, as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

Primarily those compounds of general formula (I) are preferred, in which

Q stands for phenyl, naphthyl or indolyl,


A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro,

or


for C_1 - C_3 -alkyl or C_1 - C_3 -alkoxy that is optionally substituted in one or more places, in the same way or differently, with pyrrolidinyl, piperidinyl, piperazinyl or with the group $-N(CH_3)_2$, whereby pyrrolidinyl, piperidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_3 -alkyl or C_1 - C_3 -hydroxyalkyl,

or

for the group $-CO-NH-(CH_2)_2-N(CH_3)_2$, $-CO-NH-(CH_2)_2-N(C_2H_5)_2$, $-CO-N(CH_3)-(CH_2)_2-N(CH_3)_2$,



$-NH(CO)-C(CH_3)_3$, $-NH(CO)-(CH_2)-O(CH_2)_2-OCH_3$, $-NH(CO)-(CH_2)_2-N(C_2H_5)_2$,



or $-\text{SO}_2\text{-NH-(CH}_2)_2\text{-N(CH}_3)_2$ or $-\text{SO}_2\text{-N(CH}_3\text{)-(CH}_2)_2\text{-N(CH}_3)_2$,

X stands for $-\text{NH}-$ or $-\text{NR}^5-$,

R^1 stands for $\text{C}_1\text{-C}_3\text{-alkyl}$ that is optionally substituted in one or more places, in the same way or differently, with halogen,


R^2 stands for hydrogen or for $\text{C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_1\text{-C}_4\text{-alkenyl}$, $\text{C}_1\text{-C}_4\text{-alkinyl}$, $\text{C}_3\text{-C}_6\text{-cycloalkyl}$, piperidinyl, phenyl, pyrrolidinyl, indolyl or tetralinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, $\text{C}_1\text{-C}_6\text{-alkyl}$, $\text{C}_1\text{-C}_6\text{-hydroxyalkyl}$, methoxy, $\text{C}_3\text{-C}_6\text{-cycloalkyl}$, tetrahydrofuranyl, pyrrolidinyl, piperazinyl, morpholinyl, phenyl, phenoxy, biphenyl, naphthyl, thienyl, furanyl, tetrazolyl or pyridyl or with the group $-\text{S-CH}_3$, $-\text{COOCH}_3$, $-\text{COOC}_2\text{H}_5$, $-\text{CO-NH}_2$, $-\text{OCF}_3$, $-\text{N(CH}_3\text{)-phenyl}$, $-\text{N(C}_1\text{-C}_4\text{-alkyl)}_2$, or $-\text{NH(CO)-CH}_3$, whereby phenyl, furanyl, $\text{C}_3\text{-C}_6\text{-cycloalkyl}$, piperidinyl or piperazinyl optionally in each case itself can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, $\text{C}_1\text{-C}_3\text{-alkyl}$, $\text{C}_1\text{-C}_3\text{-hydroxyalkyl}$, methoxy, morpholinyl, phenyl or benzyl,

or

for the group $-\text{N}(\text{CH}_3)_2$, $-\text{N}(\text{CH}_3)(\text{CS})\text{NHCH}_3$, $-\text{NH}(\text{CO})-\text{CH}_3$, $-\text{NH}(\text{CO})$ -pyridyl, or $-\text{NH}(\text{CO})$ -pyridinyl,

or

R^2 and R^5 together form one of the following rings:



[or]

and

R⁵ stands for C₁-C₃-alkyl or C₁-C₃-alkenyl that is optionally substituted in one or

more places, in the same way or differently, with C₁-C₆-alkoxy, as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

The position that is identified by * in the formulas indicates the point of linkage to the remainder of the formula.

Also subjects of the invention are compounds of general formula I, in which

Q stands for phenyl, naphthyl, quinolinyl, benzimidazolyl, indolyl, indazolyl, thiazolyl, imidazolyl or pyridyl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro,

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with hydroxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴ or -CO(N R³)(CH₂)_nNR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for COR⁶, -CO(NR³)(CH₂)_nNR³R⁴, -NR³(CO)-C₁-C₆-alkyl, -NR³(CO)(CH₂)_nC₁-C₆-alkoxy, -NR³(CO)(CH₂)_nC₁-C₆-alkoxyalkoxy, -NR³(CO)(CH₂)_nNR³R⁴, -NR³(CO)NR³R⁴, -NR³(CS)NR³R⁴, -NR³SO₂-C₁-C₆-alkyl, -NR³SO₂-(CH₂)_nNR³R⁴, -SO₂-NR³R⁴ or -SO₂(N R³)(CH₂)_nNR³R⁴,

X stands for oxygen, -NH- or -NR⁵-,

R¹ stands for C₁-C₃-alkyl, C₃-cycloalkyl, allyl or propargyl that is optionally

substituted in one or more places, in the same way or differently, with halogen,

R^2 stands for hydrogen, or for C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, C_1 - C_6 -alkenyl, C_1 - C_6 -alkynyl, C_3 - C_6 -cycloalkyl, C_3 - C_6 -heterocycloalkyl, aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, C_1 - C_6 -hydroxyalkyl, C_3 - C_6 -cycloalkyl, C_3 - C_6 -heterocycloalkyl, aryl, heteroaryl or with the group $-S$ - C_1 - C_6 -alkyl, $-COR^6$, $-NR^3R^4$, $-NR^3(CO)-C_1-C_6$ -alkyl, $-NR^3(CO)$ -aryl, $-NR^3(CO)$ -heteroaryl, $-NR^3COOR^7$, $-NR^3(CS)NR^3R^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring,

and whereby the C_3 - C_6 -cycloalkyl ring, and/or the C_3 - C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C_1 - C_6 -alkyl, C_1 - C_6 -hydroxyalkyl, C_1 - C_6 -alkoxy, C_3 - C_6 -cycloalkyl, or with the group $-NR^3R^4$ or $-CO-NR^3R^4$,

or

for the group $-NR^3R^4$, $-NR^3(CO)$ -aryl, $-NR^3(CO)$ -heteroaryl, or $-NR^3(CS)NR^3R^4$,

or

R^2 and R^5 together form a C_3 - C_6 -heterocycloalkyl ring that is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring,

and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl, aryl or with the group -NR³R⁴,

R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy or -CO-C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO- NR³R⁴,

or

R³ and R⁴ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl, cyano, hydroxy or with the group -NR³R⁴,

R⁵ stands for C₁-C₆-alkyl, C₁-C₆-alkenyl, or C₁-C₆-alkinyl that is optionally

substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

R⁶ stands for hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy or the group -NR³R⁴,

R⁷ stands for -(CH₂)_n-aryl or -(CH₂)_n-heteroaryl and

n stands for 1 - 6,

as well as their stereoisomers, diastereomers, enantiomers and salts.

Especially preferred among them are those compounds of general formula I in which


Q stands for phenyl, naphthyl, quinoliny, benzimidazolyl or indolyl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro,

or


for C₁-C₃-alkyl or C₁-C₃-alkoxy that is optionally substituted in one or more places, in the same way or differently, with hydroxy, pyrrolidinyl, piperidinyl, piperazinyl or with the group -N(CH₃)₂, -N(C₂H₅)₂ or -CO(NH)(CH₂)₂N-(C₂H₅)₂, whereby pyrrolidinyl, piperidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₃-alkyl, C₃-C₆-cycloalkyl, C₁-C₃-hydroxyalkyl or with the group -N(C₂H₅)₂,
or

for the group COOH , $-\text{COOCH}_3$, $-\text{COOC}_2\text{H}_5$, $-\text{CONH}_2$,




$-\text{NH}(\text{CO})-\text{C}(\text{CH}_3)_3$, $-\text{NH}(\text{CO})-(\text{CH}_2)-\text{OCH}_3$, $-\text{NH}(\text{CO})-(\text{CH}_2)_2-\text{OCH}_3$,

$-\text{NH}(\text{CO})-(\text{CH}_2)-\text{O}(\text{CH}_2)_2-\text{OCH}_3$, $-\text{NH}(\text{CO})-(\text{CH}_2)_2-\text{N}(\text{C}_2\text{H}_5)_2$,




$-\text{NH}(\text{CO})-\text{NH}(\text{CH}_2)_2-\text{N}(\text{CH}_3)_2$, $-\text{NH}(\text{CO})-\text{NH}(\text{CH}_2)_2-\text{OH}$, $-\text{NH}(\text{CO})-$


$\text{NH}(\text{CH}_2)_2-\text{O}(\text{CH}_2)_2-\text{OH}$,



-NH(CS)NH(CH₂)₂-OH, -NH(CS)NH(CH₂)₂-O(CH₂)₂-OH,



-NHSO₂-C₁-C₆-Alkyl, -NHSO₂-CH₃,



or $-\text{SO}_2\text{NH}-(\text{CO})-\text{CH}_3$,

X stands for oxygen, $-\text{NH}-$ or $-\text{NR}^5-$,

R^1 stands for C_1 - C_3 -alkyl or C_3 -cycloalkyl that is optionally substituted in one or more places, in the same way or differently, with fluorine, chlorine, bromine, or iodine,

R^2 stands for C_1 - C_3 -alkyl, C_1 - C_3 -alkoxy, C_1 - C_3 -alkenyl, C_1 - C_3 -alkinyl, C_3 - C_6 -cycloalkyl, isoxazolyl, piperidinyl, phenyl, pyrazolyl, pyrrolyl, (tetralin)yl or thiazolyl that is optionally substituted in one or more places, in the same way or differently, with fluorine, chlorine, bromine, iodine, hydroxy, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -hydroxyalkyl, methoxy or

with the group $-\text{S}-\text{CH}_3$, $-\text{COOCH}_3$, COOC_2H_5 , $-\text{NH}(\text{CH}_3)$, $-\text{N}(\text{CH}_3)_2$,

$-\text{NHC}(\text{CH}_3)_3$, $-\text{NH}(\text{CO})-\text{CH}_3$, $-\text{NH}(\text{CO})$ -phenyl, $-\text{NH}(\text{CO})-\text{O}-(\text{CH}_2)$ -phenyl,

$-\text{N}(\text{CH}_3)-(\text{CS})-\text{NH}(\text{CH}_3)$, $-\text{N}(\text{CH}_3)-(\text{CS})-\text{N}(\text{CH}_3)_2$ or

with the following ring systems C_3 - C_6 -cycloalkyl, tetrahydrofuranyl,


pyrrolidinyl, piperidinyl, phenyl, biphenyl, furanyl, thienyl, pyrrolyl, or

pyridyl, whereby these ring systems optionally in each case themselves can be

substituted in one or more places, in the same way or differently, with C₁-C₃-alkyl, cyano, fluorine, chlorine, bromine, iodine, methoxy or -CO-NH₂,

or


for the group -N(CH₃)₂, -N(CH₃)(CS)NHCH₃, -NH(CS)N(CH₃)₂, -NH(CO)-phenyl, -NH-(CH₂)-CF₃, -NH-(CH₂)₂-CF₃, -NH-(CH₂)₂-OH, -NH(CO)-pyridinyl,



[or],

or

R² and R⁵ together form one of the following rings:




[or]

and

R^5 stands for C_1 - C_3 -alkyl, C_1 - C_3 -alkenyl, or C_1 - C_3 -alkinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C_1 - C_6 -alkoxy, C_3 - C_6 -cycloalkyl, C_3 - C_6 -heterocycloalkyl, or with the group $-N(CH_3)_2$,

as well as their stereoisomers, diastereomers, enantiomers and salts.

Compounds of general formula IA



in which

Q stands for aryl or heteroaryl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino

or nitro

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more

places, in the same way or differently, with halogen, hydroxy, C₃-C₆-

heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the

heterocycloalkyl itself optionally can be interrupted by one or more nitrogen,

oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or

more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double

bonds can be contained in the ring, and/or the ring itself optionally can be

substituted in one or more places, in the same way or differently, with C₁-C₆-

alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for -NR³(CO)-L, -NR³(CO)-NR³-L, -COR⁶, -CO(NR³)-M, -NR³(CS)NR³R⁴,

-NR³SO₂-M, -SO₂-NR³R⁴ or -SO₂(NR³)-M,

L stands for C₁-C₆-alkyl or heteroaryl that is optionally substituted in one or

more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-

C₆-alkoxyalkoxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴, whereby

the heterocycloalkyl itself optionally can be interrupted by one or more

nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by

one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more

double bonds can be contained in the ring, and/or the ring itself optionally can

be substituted in one or more places, in the same way or differently, with C₁-

C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

- M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -NR³R⁴ or C₃-C₆-heterocycloalkyl,
- R¹ stands for C₁-C₄-alkyl, C₃-cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,
- R^{2a} stands for allyl or propargyl,
- R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, -CO-C₁-C₆-alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,
- or
- R³ and R⁴ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring,
- and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-

cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl, cyano, hydroxy or with the group -NR³R⁴, and

R⁶ stands for hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy or the group -NR³R⁴, as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts, are another subject of this invention.

These compounds exhibit an allyl ester or a propargyl ester in contrast to the compounds of general formula I. These compounds also inhibit kinases of the polo family and are better suitable for cleavage into the free acid and thus for the production of compounds of general formula I in particular because of the presence of allyl ester.

Preferred are those compounds of general formula IA in which

Q stands for phenyl, quinolinyl, indolyl or naphthyl,

A and B, independently of one another, stand for hydrogen or halogen,

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy or with the group -NC₁-C₆-alkyl)₂ or -CO(NH)-M,

or

for -NH(CO)-L, -NH(CO)-NH-L, -COR⁶, -CO(NH)-M, -CO(NCH₃)-M, -SO₂(NH)-M or -SO₂(NCH₃)-M,

L stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with pyrrolidinyl,

M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -N(C₁-C₆-alkyl)₂ or pyrrolidinyl,

R¹ stands for C₁-C₃-alkyl,

R^{2a} stands for allyl or propargyl, and


R⁶ stands for hydroxy, C₁-C₆-alkyl or C₁-C₆-alkoxy,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

In particular, preferred compounds are the compounds of production examples 77, 104, 105, 106, 107, 117, 119, 121, 123 - 131, 133, 135, 137, and 140.

Production examples 1 to 75, as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts, represent another subject of the invention. These compounds are distinguished from those of general formula I by the presence of an ester radical instead of an amide bond. These compounds are suitable for inhibiting kinases of the polo family. In addition, these compounds are suitable as intermediate products for the production of compounds of general formula I.


In particular R^1 as C_1 - C_4 -alkyl or C_3 -cycloalkyl that is optionally substituted with




halogen, as well as the secondary amine at Q represent essential features of the compounds according to the invention.

In particular, also those uses of the compounds of general formulas IIA, IIB, IIIA, IIIB, IVA, and IVB as well as compounds of general formula V, as intermediate products for the production of the compounds of general formula I, represent additional subjects of the invention:

Uses of the compounds of general formula IIA or IIB




oder



[or]

in which D stands for the group $-\text{NO}_2$, $-\text{NH}_2$ or $-\text{NH}(\text{CO})\text{OC}(\text{CH}_3)_3$ and E stands for C_1 - C_6 -alkoxy or halogen, and R^3 and R^4 have the meaning that is described in general formula I, as intermediate products for the production of the substances of general formula I according to the invention.


Uses of the compounds of general formula IIIA or IIIB



[or]

in which D stands for the group $-\text{NO}_2$, $-\text{NH}_2$ or $-\text{NH}(\text{CO})\text{OC}(\text{CH}_3)_3$ and G stands for the group $-\text{NR}^3\text{R}^4$, and R^3 , R^4 and n have the meaning that is described in general formula I, as intermediate products for the production of the substances of general formula I according to the invention.

Uses of the compounds of general formula IVA or IVB




[or]

in which D stands for the group $-\text{NO}_2$, $-\text{NH}_2$ or $-\text{NH}(\text{CO})\text{OC}(\text{CH}_3)_3$ and K stands for C_1 - C_6 -alkyl or C_1 - C_6 -alkenyl that is optionally substituted with the group $-\text{NR}^3\text{R}^4$ and L stands for C_1 - C_6 -alkyl or C_1 - C_6 -alkenyl that is optionally substituted with C_1 - C_6 -alkoxy, C_1 - C_6 -alkoxy-

C₁-C₆-alkoxy or the group -NR³R⁴, and R³ and R⁴ have the meaning that is described in general formula I, as intermediate products for the production of substances of general formula I according to the invention.

Compounds of general formula V



in which Q, A, B and R¹ have the meaning that is described in general formula I, as intermediate products for the production of the substances of general formula I according to the invention, with the proviso of cyano-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid, do not fall under general formula V:

To use the compounds of general formula I according to the invention as pharmaceutical agents, the latter are brought into the form of a pharmaceutical preparation, which in addition to the active ingredient for enteral or parenteral administration contains suitable pharmaceutical, organic or inorganic inert support media, such as, for example, water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols, etc. The pharmaceutical preparations can be present in solid form, for example as tablets, coated tablets, suppositories, or capsules, or in liquid form, for example as solutions, suspensions, or emulsions. Moreover, they optionally contain adjuvants, such as preservatives, stabilizers, wetting agents or emulsifiers; salts for changing the osmotic pressure or buffers.

These pharmaceutical preparations are also subjects of this invention.

For parenteral administration, especially injection solutions or suspensions, especially aqueous solutions of active compounds in polyhydroxyethoxylated castor oil, are suitable.

As carrier systems, surface-active adjuvants, such as salts of bile acids or animal or plant phospholipids, but also mixtures thereof, as well as liposomes or their components can also be used.

For oral administration, especially tablets, coated tablets or capsules with talc and/or hydrocarbon vehicles or binders, such as, for example, lactose, corn or potato starch, are suitable. The administration can also be carried out in liquid form, such as, for example, as a juice, to which optionally a sweetener is added.

Enteral, parenteral and oral administrations are also subjects of this invention.

The dosage of the active ingredients can vary depending on the method of administration, age and weight of the patient, type and severity of the disease to be treated and similar factors. The daily dose is 0.5-1000 mg, preferably 50-200 mg, whereby the dose can be given as a single dose to be administered once or divided into two or more daily doses.

Subjects of this invention also include the use of compounds of general formula I for the production of a pharmaceutical agent for treating cancer, auto-immune diseases, cardiovascular diseases, chemotherapy agent-induced alopecia and mucositis, infectious diseases, nephrological diseases, chronic and acute neurodegenerative diseases and viral infections, whereby cancer is defined as solid tumors and leukemia; auto-immune diseases are defined as psoriasis, alopecia and multiple sclerosis; cardiovascular diseases are defined as stenoses, arterioscleroses and restenoses; infectious diseases are defined as diseases that are caused by unicellular parasites; nephrological diseases are defined as glomerulonephritis; chronic neurodegenerative diseases are defined as Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease; acute neurodegenerative diseases are defined as ischemias of the brain and neurotraumas; and viral infections are defined as cytomegalic infections, herpes, hepatitis B or C, and HIV diseases.

Subjects of this invention also include pharmaceutical agents for treating the above-cited diseases, which contain at least one compound according to general formula I, as well as pharmaceutical agents with suitable formulation substances and vehicles.

The compounds of general formula I according to the invention are, i.a., excellent inhibitors of the polo-like kinases, such as Plk1, Plk2, Plk3, and Plk4.

If the production of the starting compounds is not described, the latter are known or can be produced analogously to known compounds or to processes that are described here. It is also possible to perform all reactions that are described here in parallel reactors or by means of combinatorial operating procedures.

The isomer mixtures can be separated into the isomers, such as, e.g., into the enantiomers, diastereomers or E/Z isomers, according to commonly used methods, such as, for example, crystallization, chromatography or salt formation, if the isomers are not in a state of equilibrium with one another.

The production of the salts is carried out in the usual way by a solution of the compound of formula I being mixed with the equivalent amount of or excess base or acid, which optionally is in solution, and the precipitate being separated or the solution being worked up in the usual way.

Production of the Compounds According to the Invention


The following examples explain the production of the compounds according to the invention, without the scope of the claimed compounds being limited to these examples.

The compounds of general formula I or IA according to the invention can be produced according to the following general diagrams of the process:

Reduktion = reduction

Kupplungsreaktion der Aminogruppe = Coupling reaction of the amino group

Diagram No. 1 for Synthesis of Anilines:




whereby A, Q, R³ and R⁴ have the meaning that is indicated in general formula I.

[Key to Diagram No. 1:]

Imidazol = Imidazole

Reduktion = Reduction

Diagram No. 2 for Synthesis of Anilines:




whereby A, Q, R³ and R⁴ have the meaning that is indicated in general formula I.

[Key to Diagram No. 2:]


Reduktion = Reduction

Diagram No. 3 For Synthesis of Anilines:



whereby A, Q, R³ and R⁴ have the meaning that is indicated in general formula I.


Diagram No. 4 for Synthesis of Anilines:



whereby A, Q, R³ and R⁴ have the meaning that is indicated in general formula I.

[Key to Diagram No. 4:]


Reduktion = Reduction

Diagram No. 5 for Synthesis of Anilines:

whereby A, Q, R³ and R⁴ have the meaning that is indicated in general formula I.

[Key to Diagram No. 5:]

Reduktion = Reduction


Diagram No. 6 for Synthesis of Anilines:

whereby A, Q, R³ and R⁴ have the meaning that is indicated in general formula I.

[Key to Diagram No. 6:]

Kupplungsreagenz = Coupling reagent

Reduktion = Reduction


Diagram No. 7 for Synthesis of Anilines:

$\text{R}^{\text{K}} = \text{C}^1 - \text{C}^6$ alkyl or $-(\text{CH}_2)_n \text{C}_1 - \text{C}_6 - \text{alkoxy}$ or $-(\text{CH}_2)_n \text{C}_1 - \text{C}_6 - \text{alkoxyalkoxy}$

whereby A, Q, R^3 and R^4 have the meaning that is indicated in general formula I.


[Key to Diagram No. 7:]

Kupplungsreagenz = Coupling reagent

Diagram No. 8 for Synthesis of Anilines:

$\text{R}^{\text{L}} = \text{C}^1 - \text{C}^6$ alkyl


whereby A and Q have the meaning that is indicated in general formula I.

Diagram No. 9 for Synthesis of Anilines:

whereby A, Q, R³ and R⁴ have the meaning that is indicated in general formula I.

[Key to Diagram No. 9:]


Reduktion = Reduction

Diagram No. 10 for Synthesis of Anilines:

whereby A, Q, R³ and R⁴ have the meaning that is indicated in general formula I.

[Key to Diagram No. 10:]


Reduktion = Reduction

Diagram No. 11 for Synthesis of Anilines:

whereby A, Q, R³ and R⁴ have the meaning that is indicated in general formula I.

[Key to Diagram No. 11:]

Reduktion = Reduction


Diagram No. 12 for Synthesis of Anilines:

R^K = C¹ – C⁶ alkyl or - (CH₂)_n C₁ – C₆ – alkoxy or - (CH₂)_n C₁ – C₆ – alkoxyalkoxy

whereby A and Q have the meaning that is indicated in general formula I.

[Key to Diagram No. 12:]

Kupplungsreagenz = Coupling reagent


Diagram No. 13 for Synthesis of Anilines:

whereby A and Q have the meaning that is indicated in general formula I.

[Key to Diagram No. 13:]

Kupplungsreagenz = Coupling reagent

Reduktion = Reduction

Diagram No. 14 for Synthesis of Anilines:

$R^K = C^1 - C^6$ alkyl or $-(CH_2)_n C_1 - C_6$ - alkoxy or $-(CH_2)_n C_1 - C_6$ - alkoxyalkoxy

whereby A, Q and R^3 have the meaning that is indicated in general formula I.

[Key to Diagram No. 14:]


Reduktion = Reduction

Synthesis of Intermediate Compounds

Production of the intermediate compounds (INT) that preferably can be used for the production of the thiazolidinone compounds according to the invention.

Example INT1

N-(3-Amino-phenyl)-2,2-dimethyl-propionamide




5.0 g of the 1,3-diaminobenzene is dissolved in 50 ml of dichloromethane and mixed at 0°C with 24 ml of diisopropylethylamine and 10.4 ml of pivalic acid anhydride. It is stirred for 2 hours at 0°C and for 18 hours at room temperature. The reaction mixture is mixed with semi-saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic solution is washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, and after purification by chromatography on silica gel, 5.7 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 1.20 (s, 9H); 4.98 (s, 2H); 6.24 (d, 1H); 6.70 (d, 1H); 6.83-6.96 (m, 2H) ppm.

Example INT2

1-(2-Iodo-ethyl)-4-nitro-benzene




15 g of 4-nitrophenylethanol, 28.1 g of triphenylphosphine and 9.2 g of imidazole are dissolved in 500 ml of THF, mixed in portions with 27.77 g of iodine and stirred for 2 hours

at room temperature. The reaction mixture is mixed with ammonium chloride solution and extracted with dichloromethane. The organic phase is washed in succession with sodium thiosulfate solution and water and dried on sodium sulfate. After purification by chromatography on silica gel, 23.22 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 3.30 (t, 2H); 3.54 (t, 2H); 7.57 (d, 2H); 8.18 (d, 2H) ppm.


Example INT3

1-[2-(4-Nitro-phenyl)-ethyl]-pyrrolidine




8 g of the compound that is described under Example **INT2**), 26.4 g of potassium carbonate and 3.6 ml of pyrrolidine are dissolved in 20 ml of DMF and stirred for 5 hours at room temperature. The solvent is condensed under high vacuum, the residue is taken up in ethyl acetate and washed three times with water. The organic phase is dried on sodium sulfate. After purification by chromatography on silica gel, 5.6 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 1.68 (m, 4H); 2.48 (m, 4H); 2.67 (t, 2H); 2.89 (t, 2H); 7.52 (d, 2H); 8.13 (d, 2H) ppm.

Example INT4**4-(2-Pyrrolidin-1-yl-ethyl)-phenylamine**


5.67 g of the compound that is described under Example **INT3**) is dissolved in 500 ml of ethanol and mixed with 1 g of palladium on carbon (10%). It is stirred for 2 hours under hydrogen atmosphere at room temperature. After filtration on diatomaceous earth and after the solvent is condensed in a rotary evaporator, 4.8 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 1.67 (m, 4H); 2.31-2.60 (m, 8H); 4.81 (s, 2H); 6.48 (d, 2H); 6.84 (d, 2H) ppm.

Example INT5**1-Methyl-4-[2-(4-nitro-phenyl)-ethyl]-piperazine**


5 g of the compound that is described under Example **INT2**), 6.2 ml of triethylamine and 2.4 ml of N-methylpiperazine are dissolved in 20 ml of tetrahydrofuran and stirred for 3 hours under reflux. Another 0.6 ml of N-methylpiperazine is added, and it is stirred for another 3 hours under reflux. The solvent is condensed in a rotary evaporator, the residue is taken up in ethyl acetate and washed with water. The organic phase is dried on sodium sulfate. After purification by chromatography on silica gel, 1.6 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 2.13 (s, 3H); 2.20-2.48 (m, 8H); 2.54 (t, 2H); 2.87 (t, 2H); 7.51 (d, 2H); 8.13 (d, 2H) ppm.

Example INT6**4-[2-(4-Methyl-piperazin-1-yl)-ethyl]-phenylamine**


6.37 g of the compound that is described under Example **INT5**) is dissolved in 500 ml of ethanol and mixed with 1.1 g of palladium on carbon (10%). It is stirred for 2 hours under hydrogen atmosphere at room temperature. After filtration on diatomaceous earth and after the solvent is condensed in a rotary evaporator, 5.6 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 2.15 (s, 3H); 2.20-2.59 (m, 12H); 4.80 (s, 2H); 6.48 (d, 2H); 6.83 (d, 2H) ppm.

Example INT7**{1-[2-(4-Nitro-phenyl)-ethyl]-piperidin-4-yl}-methanol**


8 g of the compound that is described under Example **INT2**), 26.4 g of potassium carbonate and 5.0 g of 4-hydroxymethylpiperidine are dissolved in 20 ml of DMF and stirred for 18 hours at room temperature. The solvent is condensed under high vacuum, the residue is taken up in ethyl acetate and washed three times with water. The organic phase is dried on sodium sulfate. After purification by chromatography on silica gel, 5.56 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 0.99-1.16 (m, 2H); 1.21-1.41 (m, 1H); 1.61 (d, 2H); 1.90 (t, 2H); 2.54 (t, 2H); 2.81-2.98 (m, 4H); 3.23 (d, 2H); 4.40 (s, 1H); 7.50 (d, 2H); 8.13 (d, 2H) ppm.

Example INT8**{1-[2-(4-Amino-phenyl)-ethyl]-piperidin-4-yl}-methanol**

6.56 g of the compound that is described under Example **INT7**) is dissolved in 500 ml of ethanol and mixed with 1.1 g of palladium on carbon (10%). It is stirred for 4 hours under hydrogen atmosphere at room temperature. After filtration on diatomaceous earth and after the solvent is condensed in a rotary evaporator, 4.67 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 0.99-1.20 (m, 2H); 1.20-1.41 (m, 1H); 1.61 (d, 2H); 1.87 (t, 2H); 2.36 (t, 2H); 2.50-2.60 (m, 2H); 2.88 (d, 2H); 3.23 (t, 2H); 4.40 (s, 1H); 4.80 (s, 2H); 6.47 (d, 2H); 6.84 (d, 2H) ppm.


Example INT9**(4-Ethenesulfonylamino-phenyl)-carbamic acid tert-butyl ester**

2.0 g of (4-aminophenyl)-carbamic acid (tert)butyl ester is dissolved in 60 ml of tetrahydrofuran, mixed with 6.74 ml of triethylamine and with 1.0 ml of 2-chloroethanesulfonic acid chloride and stirred for 2 hours at room temperature. The reaction mixture is mixed with water and extracted with ethyl acetate. The organic solution is washed in succession with 4N hydrochloric acid, with semi-saturated sodium bicarbonate solution and with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, and after recrystallization from ethanol/dichloromethane (1:3), 1.45 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ= 1.47 (s, 9H); 5.97 (d, 1H); 6.01 (d, 1H); 6.70 (dd, 1H); 7.03 (d, 2H); 7.35 (d, 2H); 9.28 (s, 1H); 9.70 (s, 1H) ppm.

Example INT10

[4-(2-Morpholin-4-yl-ethanesulfonylamino)-phenyl]-carbamic acid tert-butyl ester




107 mg of the compound that is described under Example **INT9**) is dissolved in 5 ml of tetrahydrofuran, mixed with 0.25 ml of triethylamine and 71 µl of morpholine and stirred under reflux for 24 hours. The reaction mixture is mixed with water and extracted with ethyl acetate. The organic solution is washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, and, after purification by chromatography on silica gel, 62 mg of the title compound is obtained.

¹H-NMR (DMSO-d₆, stored with K₂CO₃): δ= 1.47 (s, 9H); 2.30 (m, 4H); 2.63 (t, 2H); 3.14 (t, 2H); 3.50 (m, 4H); 7.08 (d, 2H); 7.37 (d, 2H); 9.25 (s, 1H); 9.52 (s, 1H) ppm.

Example INT11

[4-(2-Methoxyacetylamino)-phenyl]-carbamic acid tert-butyl ester




200 mg of (4-aminophenyl)-carbamic acid (tert)butyl ester is dissolved in 5 ml of tetrahydrofuran, mixed with 0.63 ml of triethylamine and 0.16 ml of methoxyacetyl chloride and stirred for 2 hours at room temperature. The reaction mixture is mixed with semi-saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic solution is washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by

evaporation, and after purification by chromatography on silica gel, 211 mg of the title compound is obtained.

$^1\text{H-NMR}$ (DMSO- d_6 , stored with K_2CO_3): δ = 1.48 (s, 9H); 3.38 (s, 3H); 3.97 (s, 2H); 7.37 (d, 2H); 7.52 (d, 2H); 9.25 (s, 1H); 9.61 (s, 1H) ppm.

Example INT12)

N-(4-Nitrophenyl)-acrylamide




First, 61 ml of triethylamine and then 14.6 ml of acrylic acid chloride are added to a solution of 20 g of 4-nitroaniline in 200 ml of THF. The mixture is stirred for 4 hours at room temperature, mixed with sodium chloride solution and extracted with ethyl acetate. The crude product that is obtained after the solvent is evaporated is recrystallized (dichloromethane). 18.5 g of the title compound is obtained.

$^1\text{H-NMR}$ (CDCl_3): δ = 5.87 (1H); 6.34 (1H); 6.47 (1H); 7.92 (2H); 8.23 (2H) ppm.

Example INT13)

3-(4-Methyl-piperazin-1-yl)-N-(4-nitro-phenyl)-propionamide




First, 31.2 ml of triethylamine and then 11.7 ml of 1-methylpiperazine are added to a solution of 8.6 g of N-(4-nitrophenyl)-acrylamide in 225 ml of THF. The mixture is stirred under reflux for 15 hours and evaporated to the dry state in a rotary evaporator. After dichloromethane is added, it is extracted with sodium bicarbonate solution and sodium

chloride solution, dried on sodium sulfate, and the solvent is evaporated. The crude product that is obtained is recrystallized (ethyl acetate). 8.0 g of the title compound is obtained.

Molar mass = 292.341; MS (ESI): $[M+1]^+ = 293$.

Example INT14)

N-(4-Amino-phenyl)-3-(4-methyl-piperazin-1-yl)-propionamide




A mixture of 8.6 g of N-(4-nitrophenyl)-acrylamide and 0.8 g of palladium on carbon (10%) in 150 ml of ethanol was stirred in a hydrogen atmosphere for 5 hours at room temperature. Then, the mixture was filtered on Celite, and the solvent was evaporated. 7.0 g of the title compound was obtained.

$^1\text{H-NMR}$ (CDCl_3): $\delta = 2.14$ (3H); 2.19-2.52 (10 H) 2.58 (2H); 4.92 (2H); 6.71 (2H); 7.05 (2H); 7.83 (1H); ppm.


Example INT15

N-(3-Nitro-phenyl)-acrylamide




Analogously to **Example INT12**), 18.5 g of the title compound is obtained from 20 g of 3-nitroaniline, 61 ml of triethylamine and 14.6 ml of acrylic acid chloride, after purification by recrystallization from dichloromethane.

$^1\text{H-NMR}$ (DMSO-d_6): $\delta = 5.84$ (dd, 1H); 6.32 (dd, 1H); 6.45 (dd, 1H); 7.62 (t, 1H); 7.89-8.02 (m, 2H); 8.70 (s, 1H); 9.6-11.0 (b, 1H) ppm.

Example INT16**N-(3-Nitro-phenyl)-3-pyrrolidin-1-yl-propionamide**


Analogously to **Example INT13**), after purification by chromatography on silica gel, 5.52 g of the title compound is obtained from 5.0 g of the compound that is produced under **Example INT15**), 18.2 ml of triethylamine and 2.56 ml of pyrrolidine.

¹H-NMR (DMSO-d₆): δ = 1.60-1.76 (m, 4H); 2.38-2.58 (m, 6H); 2.72 (t, 2H); 7.60 (t, 1H); 7.85-7.93 (m, 2H); 8.64 (s, 1H); 10.56 (s, 1H) ppm.

Example INT17**N-(3-Amino-phenyl)-3-pyrrolidin-1-yl-propionamide**

5.5 g of the compound that is described under **Example INT16**) is dissolved in 200 ml of ethanol and mixed with 450 mg of palladium on carbon (10%). It is stirred for 4 hours under hydrogen atmosphere at room temperature. After filtration on diatomaceous earth, and after the solvent is condensed in a rotary evaporator, 4.8 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 1.61-1.75 (m, 4H); 2.34-2.53 (m, 6H); 2.68 (t, 2H); 5.02 (s, 2H); 6.21 (d, 1H); 6.55 (d, 1H); 6.82-6.94 (m, 2H); 9.78 (s, 1H) ppm.


Example INT18**3-Nitro-N-(3-pyrrolidin-1-yl-propyl)-benzamide**

500 mg of 4-nitrobenzoic acid is dissolved in 20 ml of dimethylformamide, mixed with 370 μ l of triethylamine, 342 mg of N-(3-aminopropyl)-pyrrolidine and 866 mg of TBTU, and it is stirred for 20 hours at room temperature. The reaction mixture is mixed with semi-saturated sodium bicarbonate solution, and extracted with dichloromethane. The organic solution is washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, and after purification by chromatography on silica gel, 502 mg of the title compound is obtained.

¹H-NMR (DMSO): δ = 1.84 (m, 6H), 2.63 (m, 4H), 2.78 (m, 2H), 7.61 (m, 1H), 8.22 (dd, 1H), 8.32 (dd, 1H), 8.53 (m, 1H), 9.41 (s, 1H) ppm.


Example INT19

3-Amino-N-(3-pyrrolidin-1-yl-propyl)-benzamide




1 g of the compound that is described under Example **INT18**) is dissolved in 50 ml of THF and mixed with 1 g of Raney nickel. It is stirred for 3 hours under hydrogen atmosphere at room temperature. After filtration on diatomaceous earth and after the solvent is condensed in a rotary evaporator, 810 mg of the title compound is obtained.

¹H-NMR (DMSO d₆): δ = 1.79 (m, 6H), 2.57 (m, 4H), 2.69 (m, 2H), 3.55 (m, 2H), 3.73 (s, 2H), 6.76 (dd, 1H), 7.02 (m, 1H), 7.17 (m, 2H), 8.52 (s, 1H) ppm.

Example INT20**Pyrrolidine-1-carboxylic acid (4-nitro-phenyl)-amide**


1 g of para-nitrophenylisocyanate is dissolved in 10 ml of acetonitrile and slowly mixed at room temperature with pyrrolidine (1.51 ml). It is stirred overnight at room temperature, the solvent is distilled off in a rotary evaporator, and the residue is recrystallized from ethanol. 1.1 g of product is obtained.

¹H-NMR (DMSO d₆): δ = 1.82 (m, 4H), 3.48 (m, 4H), 7.79 (d, 2H), 8.12 (d, 2H), 8.80 (s, 1H) ppm.

Example INT21**Pyrrolidine-1-carboxylic acid (4-amino-phenyl)-amide**


1 g of the compound that is described under Example **INT20**) is dissolved in 50 ml of THF and mixed with 1 g of Raney nickel. It is stirred for 3 hours under hydrogen atmosphere at room temperature. After filtration on diatomaceous earth and after the solvent is condensed in a rotary evaporator, 790 mg of the title compound is obtained.

¹H-NMR (DMSO d₆): δ = 1.80 (m, 4H), 3.28 (m, 4H), 4.68 (s, 2H), 6.42 (d, 2H), 7.05 (d, 2H), 7.61 (s, 1H) ppm.

Example INT22**N-(3-Amino-5-chloro-phenyl)-2,2-dimethyl-propionamide (2056-1)**

5.0 g of 5-chloro-1,3-diaminobenzene is dissolved in 50 ml of dichloromethane and 5 ml of dimethylformamide and mixed at 0°C with 18.5 ml of diisopropylethylamine and 8.5 ml of pivalic acid anhydride. It is stirred for one hour at 0°C and for 5 hours at room temperature. The reaction mixture is mixed with semi-saturated sodium bicarbonate solution and extracted with a mixture that consists of ethyl acetate and hexane (1:3). The organic solution is washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, and after purification by chromatography on silica gel, 2.5 g of the title compound is obtained.

¹H-NMR (DMSO-d₆): (DMSO-d₆): δ = 5.37 (s,b, 2H); 6.28 (s,b, 1H); 6.88 (s,b, 1H); 7.48 (s, 1H); 9.00 (s, 1H) ppm.


Example INT23**Ethyl-(5-nitro-pyridin-2-yl)-amine**

395 mg of 2-chloro-5-nitro-pyridine and 2.5 ml of a 1 M solution of ethylamine in tetrahydrofuran are dissolved in 10 ml of DMSO and stirred for 4 hours at 50°C. The reaction mixture is mixed with ethyl acetate and washed three times with semi-saturated sodium bicarbonate solution. The organic phase is dried on sodium sulfate. After purification by chromatography on silica gel, 430 mg of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 1.17 (t, 3H); 3.40 (m, 2H); 6.53 (d, 1H); 8.00-8.23 (m, 2H); 8.91 (d, 1H) ppm.

Example INT24

N*2*-Ethyl-pyridine-2,5-diamine




420 mg of the compound that is described under Example **INT23**) is dissolved in 20 ml of ethanol and mixed with 120 mg of palladium on carbon (10%). It is stirred for 4 hours under hydrogen atmosphere at room temperature. After filtration on diatomaceous earth and after the solvent is condensed in a rotary evaporator, 340 mg of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 1.09 (t, 3H); 3.11 (m, 2H); 4.25 (s, 2H); 5.43 (t, 1H); 6.25 (d, 1H); 6.81 (dd, 1H); 7.45 (d, 1H) ppm.

Example INT25

N-(5-Nitro-pyridin-2-yl)-acetamide




1.12 g of 2-amino-5-nitro-pyridine, 5.1 ml of triethylamine, and a spatula-tip full of DMAP are dissolved in 20 ml of tetrahydrofuran. 0.86 ml of acetyl chloride is added, and it is stirred under reflux for 24 hours. The reaction mixture is mixed with ethyl acetate and washed three times with semi-saturated sodium bicarbonate solution. The organic phase is dried on sodium sulfate. After purification by chromatography on silica gel and after crystallization from ethanol, 340 mg of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 2.17 (s, 3H); 8.28 (d, 1H); 8.59 (dd, 1H); 9.16 (d, 1H); 11.25 (s, 1H) ppm.

Example INT26

N*2*-Ethyl-pyridine-2,5-diamine




340 mg of the compound that is described under Example **INT25**) is dissolved in 50 ml of ethanol and 10 ml of dichloromethane and mixed with 120 mg of palladium on carbon (10%). It is stirred for 4 hours under hydrogen atmosphere at room temperature. After filtration on diatomaceous earth and after the solvent is condensed in a rotary evaporator, 275 mg of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 2.00 (s, 3H); 5.14 (s, 2H); 6.95 (dd, 1H); 7.66 (d, 1H); 7.73 (d, 1H); 9.99 (s, 1H) ppm.

Example INT27

Bis-(5-nitro-pyridin-2-yl)-(2-pyrrolidin-1-yl-ethyl)-amine




395 mg of 2-chloro-5-nitro-pyridine and 2.70 mg of 2-pyrrolidin-1-yl-ethylamine are dissolved in 5 ml of DMSO and stirred for 6 hours at 100°C. The reaction mixture is mixed with dichloromethane and washed three times with semi-saturated sodium bicarbonate

solution. The organic phase is dried on sodium sulfate. After purification by chromatography on silica gel, 51 mg of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 1.59 (m, 4H); 2.43 (m, 4H); 2.75 (t, 2H); 4.42 (t, 2H); 7.56 (d, 2H); 8.48 (dd, 2H); 9.19 (d, 2H) ppm.

Example INT28

Bis-(5-amino-pyridin-2-yl)-(2-pyrrolidin-1-yl-ethyl)-amine




50 mg of the compound that is described under Example **INT27**) is dissolved in 10 ml of ethanol and mixed with 20 mg of palladium on carbon (10%). It is stirred for 4 hours under hydrogen atmosphere at room temperature. After filtration on diatomaceous earth and after the solvent is condensed in a rotary evaporator, 41 mg of the title compound is obtained.

¹H-NMR (DMSO-d₆): δ = 1.97 (m, 4H); 3.00-3.47 (m,b, 6H); 4.20 (t, 2H); 5.03 (s, 4H); 6.76 (d, 2H); 7.00 (dd, 2H); 7.77 (d, 2H) ppm.

Example INT29

rac-1,1,1-Trifluoro-2-[4'-nitrophenyl]-propan-2-ol




0.7 g of 4-nitroacetophenone is dissolved in 9 ml of THF and mixed with 3.2 ml of (trifluoromethyl)-trimethylsilane and 9 mg of tetra-n-butylammonium fluoride-trihydrate. The solution is stirred for 5 hours at room temperature. For working-up, it is mixed with 16 ml of dilute hydrochloric acid (9+1). After the addition of 200 ml of water, it is extracted

with ethyl acetate. The organic phase is washed with concentrated sodium bicarbonate solution and water, dried on magnesium sulfate and concentrated by evaporation. The oil that is obtained is taken up in 40 ml of acetone, mixed with 6.1 ml of hydrochloric acid and stirred for 2 hours at room temperature. It is mixed with sodium bicarbonate solution and extracted with ethyl acetate. The product that is obtained after drying on magnesium sulfate and evaporation of the solvent is purified on silica gel. 0.82 g of the title compound is obtained as almost colorless crystals.

$^1\text{H-NMR}$ (DMSO-d_6): $\delta=1.74$ (s, 3H); 6.99 (s, 1H); 7.88 (d, 2H); 8.26 (d, 2H) ppm.


Example INT30

4'-Nitro-N-methyacetanilide




2.5 g of N-(4-nitro-phenyl)-acetamide is dissolved in 50 ml of hot acetone and mixed with 3 g of potassium hydroxide and 3 g of methyl iodide. It is refluxed for 10 minutes. The residue that remains after the evaporation of the acetone is taken up in water. It is extracted with ethyl acetate. The organic phase is washed with saturated sodium chloride solution, dried on magnesium sulfate and concentrated by evaporation. 2.4 g of the title compound is obtained as yellow crystals.

$^1\text{H-NMR}$ (CDCl_3): $\delta=2.02$ (s, 3H); 3.34 (s, 3H); 7.39 (d, 2H); 8.28 (d, 2H) ppm.

Intermediate Compound INT31**N-(2-Dimethylamino-ethyl)-3-nitro-benzenesulfonamide**


A solution of 3-nitro-benzenesulfonyl chloride (1 equivalent) in acetonitrile is added in drops at 0°C to a solution of N,N-dimethyl-ethane-1,2-diamine (2.2 equivalents) in acetonitrile and stirred overnight at room temperature. The reaction is completed by adding sodium hydroxide solution (1N), and it is extracted three times with 2-methoxy-2-methylpropane. Solvent is removed from the combined organic phases in a rotary evaporator, and purified by column chromatography. The title compound is obtained with a yield of 43%.

¹H-NMR (CDCl₃, 300 MHz), (selected peaks) δ = 2.11 (s, 6H); 2.39 (m, 2H); 3.03 (m, 2H); 7.75 (t, 1H); 8.21 (dd, 1H); 8.42 (dd, 1H); 8.72 (m, 1H).

Intermediate Compound INT32**Dimethyl-[2-(4-nitro-phenoxy)-ethyl]-amine**

A suspension of 10 g of 4-nitrophenol, 11g of (2-chloro-ethyl)-dimethyl-amine and 27.1 g of potassium carbonate in 200 ml of acetone is refluxed for 15 hours. Solvent is removed from the batch in a vacuum, and the residue is taken up in ethyl acetate. It is extracted three times with 200 ml each of sodium hydroxide solution (1N), and the combined organic phases are dried on sodium carbonate, the solvent is distilled off in a rotary evaporator, and the title compound is obtained with a yield of 50%.








¹H-NMR (CDCl₃, 300 MHz), (selected peaks) δ = 2.35 (s, 6H); 2.78 (m, 2H); 4.16 (m, 2H); 6.97 (d, 2H); 8.19 (d, 2H).










Intermediate Compound INT33**4-(2-Dimethylamino-ethoxy)-phenylamine**









14.9 g of the compound that is produced under **Example INT LW32**) is dissolved in 300 ml of methanol and mixed with 2 g of palladium on carbon (10%), and it is stirred under hydrogen atmosphere at room temperature. After hydrogen absorption is completed, catalyst is filtered out, and solvent is removed from the crude product in a rotary evaporator. The title compound is obtained in a quantitative yield. The crude product is used without further purification in the next stage.








¹H-NMR (CDCl₃, 300 MHz), (selected peaks) δ = 2.35 (s, 6H); 2.70 (m, 2H); 4.00 (m, 2H); 6.63 (d, 2H); 6.79 (d, 2H).









The following intermediate compounds are produced analogously to the above-described processes.










Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT34		263.299	264	INT13
INT35		233.32	234	INT14
INT36		249.272	250	INT18
INT37		219.289	220	INT19
INT38		399.513	400	INT10
INT39		383.514	384	INT10
INT40		369.486	370	INT10









Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT41		294.354	295	INT11
INT42		324.38	325	INT11
INT43		383.514	384	INT10
INT44		398.528	399	INT10
INT45		286.352	287	INT9
INT46		413.54	414	INT10
INT47		399.513	400	INT10
INT48		277.33	278	INT20
INT49		225.203	226	INT20









Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT50		269.255	270	INT20
INT51		264.283	265	INT20
INT52		347.417	348	INT20
INT53		292.337	293	INT20
INT54		294.309	295	INT20
INT55		266.299	267	INT20
INT56		278.31	279	INT20
INT57		235.24	236	INT20






Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT58		347.42	348	INT20
INT59		284.49	285	INT20
INT60		271.30	272	INT20
INT61		297.34	298	INT20
INT62		310.38	311	INT20
INT63		281.34	282	INT20
INT64		315.35	316	INT20





Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT65		241.47	242	INT20
INT66		267.31	268	INT20
INT67		285.32	286	INT20
INT68		280.37	281	INT20
INT69		251.31	252	INT20
INT70		247.34	248	INT21
INT71		247.34	248	INT21
INT72		205.26	206	INT21







Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT73		195.221	196	INT21
INT74		239.273	240	INT21
INT75		234.301	235	INT21
INT76		317.434	318	INT21
INT77		262.355	263	INT21
INT78		264.327	265	INT21
INT79		236.317	237	INT21
INT80		248.328	249	INT21
INT81		221.26	222	INT21







Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT82		236.317	237	INT21
INT83		317.434	318	INT21
INT84		264.33	265	INT21
INT85		254.307	255	INT21
INT86		280.345	281	INT21
INT87		282.317	283	INT21
INT88		282.32	283	INT21
INT89		285.37	286	INT21




Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT90		251.35	252	INT21
INT91		267.35	268	INT21
INT92		280.39	281	INT21
INT93		237.33	238	INT21
INT94		211.29	212	INT21
INT95		255.34	256	INT21
INT96		250.37	251	INT21
INT97		221.33	222	INT21

Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT98		287.34	288	INT31
INT99		273.31	274	INT31
INT100		287.34	288	INT31
INT101			277	167
INT102			267	167

Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT103			267	167
INT104			363	167
INT105			291	167
INT106			277	167

Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT107			363	167
INT108			247	INT8
INT109			244	INT8
INT110			244	INT8
INT111			258	INT8
INT112			258	INT8


Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT113			333	INT8
INT114			192	INT8
INT115			261	INT8
INT116			247	INT8
INT117			333	INT8
INT118		205.181	206	INT4

Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Synthesis as in the Case of
INT119		235.164	236	INT29
INT120		205.181	206	INT4
INT121		164.208	165	INT4

The following intermediate compounds are already disclosed in Patent Application PCT/EP03/04450 and are not claimed in this application.

Example INT122)

Cyano-ethylthiocarbamoyl-acetic acid ethyl ester




4.25 ml of ethyl isothiocyanate is added at 25°C to a mixture that consists of 5 g of cyanoacetic acid ethyl ester and 5 ml of triethylamine. Then, it is allowed to stir for 6 more hours at 50°C. Then, the reaction mixture is concentrated by evaporation in a vacuum. The residue is taken up in ethanol and poured onto 150 ml of ice-cold 1N hydrochloric acid. It is

allowed to stir for 3 more hours at 25°C, and then the residue is filtered off. The solid that is obtained is rewashed with water. 7 g of product is obtained.

Molar mass = 200.261; MS (ESI): $[M+1]^+ = 201$.

Example INT123)

(E or Z)-Cyano-(3-ethyl-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester




7.82 g of the compound that is described under **Example INT122)** is dissolved in 100 ml of tetrahydrofuran. A solution of 3.9 ml of bromoacetyl chloride is slowly added and allowed to stir for 8 more hours at 25°C. Then, the reaction mixture is poured onto saturated aqueous sodium bicarbonate solution. It is allowed to stir for 1 more hour and then extracted with ethyl acetate. The organic phase is washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. The crude product that is obtained is recrystallized from a mixture of ethyl acetate/diisopropyl ester. 7.7 g of product is obtained.

$^1\text{H-NMR}$ (CDCl_3): $\delta = 1.36$ (6H); 3.70 (2H); 4.32 (4H) ppm.

Example INT124)

(E or Z)-Cyano-(5-(E/Z)-ethoxymethylene-3-ethyl-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester




A mixture that consists of 1.54 g of the substance that is described under **Example INT123**), 2.5 ml of triethyl orthoformate and 3.5 ml of acetic acid anhydride are refluxed for 8 hours. Then, the reaction mixture is poured onto ice water. It is allowed to stir for 3 more hours, and then the residue is filtered off. The solid that is obtained is rewashed with water. 1.28 g of product is obtained.

$^1\text{H-NMR}$ (CDCl_3): δ = 1.38 (9H); 4.20-4.40 (6H); 7.72 (1H) ppm.

Example INT125)

(E or Z)-Cyano-(3-ethyl-4-oxo-thiazolidin-2-ylidene)-acetic acid allyl ester




A solution of 37.6 ml of cyanoacetic acid allyl ester in 60 ml of dimethylformamide is added to a suspension of 12.8 g of sodium hydride (60%) in 200 ml of dimethylformamide at 0°C. It is stirred for 10 more minutes at 0°C, and then a solution of 28.0 ml of ethyl isothiocyanate in 60 ml of dimethylformamide is added. Then, it stirred for 2 more hours at 25°C. Then, a solution of 32 ml of bromoacetyl chloride in 60 ml of dimethylformamide is added at 0°C, and it is stirred for 15 more hours at 25°C. Then, the reaction mixture is poured onto saturated sodium bicarbonate solution. It is extracted with ethyl acetate, the organic phase is washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. The crude product is purified by column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate. 33.9 g of product is obtained.

$^1\text{H-NMR}$ (CDCl_3): δ = 1.23 (3H); 4.11 (2H); 4.71 (2H); 5.25 (1H); 5.37 (1H); 5.90-6.04 (1H) ppm.

Example INT126)

(E or Z)-Cyano-(5-(E/Z)-ethoxymethylene-3-ethyl-4-oxo-thiazolidin-2-ylidene)-acetic acid allyl ester




Analogously to **Example INT124**), 14.8 g of product is obtained from 12.8 g of the compound that is described under **Example INT125**), 20.9 ml of triethyl orthoformate and 29.4 ml of acetic acid anhydride.

¹H-NMR (CDCl₃): δ = 1.32-1.45 (6H); 4.23 (2H); 4.38 (2H); 4.73 (2H); 5.29 (1H); 5.41 (1H), 5.92-6.05 (1H); 7.72 (1H) ppm.

Example INT127)

(E or Z)-Cyano-(3-ethyl-4-oxo-thiazolidin-2-ylidene)-acetic acid benzyl ester




A solution of 1.75 g of cyanoacetic acid benzyl ester in 10 ml of dimethylformamide is added to a suspension of 0.4 g of sodium hydride (60%) in 5 ml of dimethylformamide at 0°C. It is stirred for 10 more minutes at 0°C, and then a solution of 876 μ l of ethyl isothiocyanate in 5 ml of dimethylformamide is added. Then, it is stirred for 2 more hours at 25°C. Then, a solution of 1 ml of bromoacetyl chloride in 5 ml of dimethylformamide is added at 0°C, and it is stirred for 15 more hours at 25°C. Then, the reaction mixture is poured onto saturated sodium bicarbonate solution. It is extracted with dichloromethane, the organic phase is washed with saturated sodium chloride solution, dried on sodium sulfate and

concentrated by evaporation in a vacuum. The crude product is purified by column chromatography on silica gel with a mixture that consists of hexane/ethyl acetate. 1.1 g of product is obtained.

$^1\text{H-NMR}$ (CDCl_3): δ = 1.35 (3H); 3.70 (2H); 4.30 (2H); 5.31 (2H), 7.30-7.48 (5H) ppm.

Example INT128)

(E or Z)-Cyano-(5-(E/Z)-ethoxymethylene-3-ethyl-4-oxo-thiazolidin-2-ylidene)-acetic acid benzyl ester




Analogously to **Example INT124**), 1.26 g of product is obtained from 11 g of the compound that is described under **Example INT127**), 1.49 ml of triethyl orthoformate and 2.1 ml of acetic acid anhydride.

$^1\text{H-NMR}$ (CDCl_3): δ = 1.30-1.45 (6H); 4.25 (2H); 4.38 (2H); 5.29 (2H); 7.30-7.48 (5H), 7.72 (1H) ppm.

Example INT129)

[3-Butyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester




Analogously to the above-described process, the production can be obtained.

¹H-NMR (DMSO-d₆): δ = 0.90 (t, 3H); 1.25 (t, 3H); 1.32 (m, 2H); 1.59 (m, 2H); 3.97 (s, 2H); 4.15 (t, 2H); 4.22 (q, 2H) ppm.

Example INT130)

[3-Butyl-5-[1-ethoxy-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester




Analogously to **Example INT124**), the product can be obtained from **Example INT129**).

¹H-NMR (DMSO-d₆): δ = 0.90 (t, 3H); 1.20-1.40 (m, 8H); 1.61 (m, 2H); 4.15 (t, 2H); 4.23 (q, 2H); 4.39 (q, 2H) ppm.

Example INT131

(E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester




3.43 g of the compound that is described under Example **INT4**) is dissolved in 60 ml of ethanol. 4.11 g of the compound that is described under Example **INT124**) is added, and it is stirred under reflux for 15 hours. After cooling, the reaction mixture is filtered, and the solid is recrystallized from ethanol. 4.95 g of the title compound is obtained as a pH-dependent 5-(E/Z)-isomer mixture.

¹H-NMR (DMSO-d₆, stored with K₂CO₃, main isomer): δ = 1.16-1.33 (m, 6H); 1.59-1.75 (m, 4H); 2.38-2.50 (m, 4H); 2.59 (t, 2H); 2.69 (t, 2H); 4.13-4.31 (m, 4H); 7.10-7.29 (m, 4H); 8.19 (s, 1H); 10.53 (s, 1H) ppm.

Example INT132



(E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester





3.0 g of the compound that is described under Example **INT17**) is dissolved in 50 ml of ethanol. 3.82 g of the compound that is described under Example **INT124**) is added and stirred under reflux for 4 hours. The solvent is condensed in a rotary evaporator. After purification by chromatography on silica gel, 5.3 g of the title compound is obtained as a pH-dependent 5-(E/Z)-isomer mixture.



¹H-NMR (DMSO-d₆, stored with K₂CO₃, main isomer): δ = 1.18-1.34 (m, 6H); 1.62-1.78 (m, 4H); 2.48-2.62 (m, 6H); 2.78 (t, 2H); 4.16-4.32 (m, 4H); 6.99 (d, 1H); 7.18 (d, 1H); 7.29 (t, 1H); 7.75 (s, 1H); 8.10 (s, 1H); 10.19 (s, 1H); 10.60 (s, 1H) ppm.

The following compounds were produced analogously to the above-described process.

Example No.	Structure and Name	¹ H-NMR	Molecular Weight/MS (ESI) [M+1] ⁺	Educt/Synthesis as in the Case of
INT133	 (E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-acetic acid ethyl ester	1.18-1.31 (m, 6H); 4.15-4.31 (m, 4H); 7.10 (m, 1H); 7.28-7.41 (m, 4H); 8.20 (d, 1H); 10.52 (d, 1H) ppm.	MW: 343.41 MS (ESI) [M+1] ⁺ : 344	INT124/ INT132
INT134	 (E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-[3-(3-pyrrolidin-1-yl-propylcarbamoyl)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester	1.15-1.32 (m, 6H); 1.61-1.75 (m, 6H); 2.38-2.49 (m, 6H); 3.18-3.33 (m, 2H); 4.18 (q, 2H); 4.23 (q, 2H); 7.29 (d, 1H); 7.38 (t, 1H);	MW: 497.62 MS (ESI) [M+1] ⁺ : 498	INT124/ INT132

Example No.	Structure and Name	¹ H-NMR	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
		7.48 (d, 1H); 7.61 (s, 1H); 8.36 (s, 1H); 8.58 (t, 1H); 10.61 (s, 1H) ppm.		
INT135	 (E or Z)-Cyano-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester	1.16-1.33 (m, 15H); 4.17-4.32 (m, 4H); 6.97 (d, 1H); 7.27 (t, 1H); 7.38 (d, 1H); 7.75 (s, 1H); 8.13 (s, 1H); 9.26 (s, 1H); 10.65 (s, 1H) ppm.	MW: 442.54 MS (ESI) [M+1] ⁺ : 443	INT124/ INT132
INT136		1.00-1.38 (m, 9H); 1.63 (d, 2H); 1.90 (t, 2H); 2.39-2.48 (m, 2H); 2.62-2.75 (m, 2H);	MW: 484.62 MS (ESI)	INT124/ INT132


Example No.	Structure and Name	¹ H-NMR	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
	(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(4-hydroxymethyl-piperidin-1-yl)-ethyl]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	2.85-2.98 (m, 2H); 3.23 (t, 2H); 4.15-4.30 (m, 4H); 4.40 (t, 1H); 7.12-7.29 (m, 4H); 8.18 (s, 1H); 10.50 (s, 1H) ppm.	[M+1] ⁺ : 485	

Example No.	Structure and Name	¹ H-NMR	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
INT137	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.17-1.31 (m, 6H); 2.15 (s, 3H); 2.20-2.49 (m, 10H); 2.68 (t, 2H); 4.16-4.32 (m, 4H); 7.15-7.31 (m, 4H); 8.18 (s, 1H); 10.50 (s, 1H) ppm.	MW: 469.61 MS (ESI) [M+1]⁺: 470	INT124/ INT132
INT138			MW: 315.35 MS (ESI) [M+1]⁺: 316	INT133/ 142

The following examples describe the production of compounds according to the invention without the latter being limited to these examples. These compounds can also be used as intermediate substances in the production of substances of general formula (I) according to the invention. In this connection, the ester is cleaved into the free acids. Noteworthy is the fact that the compounds that have an allyl ester can be better cleaved into the free acid than ethyl ester.

Example 1

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[4-(2-morpholin-4-yl-ethanesulfonylamino)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester




58 mg of the compound that is described under Example **INT10**) is dissolved in 2 ml of dichloromethane, mixed with 5 ml of trifluoroacetic acid, and stirred for 30 minutes at room temperature. The reaction mixture is concentrated by evaporation in a rotary evaporator. The residue is dissolved in 3 ml of ethanol. 0.7 ml of triethylamine and 36 mg of the compound that is described under Example **INT124**) are added and stirred under reflux for 3 hours. The solvent is condensed in a rotary evaporator. After purification by chromatography on silica gel, 55 mg of the title compound is obtained as a pH-dependent 5-(E/Z)-isomer mixture.

¹H-NMR (DMSO-d₆, stored with K₂CO₃, main isomer): δ= 1.15-1.31 (m, 6H); 2.30 (m, 4H); 2.66 (t, 2H); 3.22 (t, 2H); 3.50 (m, 4H); 4.14-4.31 (m, 4H); 7.19 (d, 2H); 7.29 (d, 2H); 8.18 (s, 1H); 9.50-10.75 (b, 2H) ppm.

Example 2

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-({4-[(pyrrolidine-1-carbonyl)-amino]-phenylamino}-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester




205 mg of the compound that is described under Example **INT21**) is dissolved in 10 ml of ethanol. 100 mg of the compound that is described under Example **INT124**) is added, and it is stirred under reflux for 15 hours. After cooling, the reaction mixture is filtered, and the solid is recrystallized from ethanol. 118 mg of the title compound is obtained as a pH-dependent 5-(E/Z)-isomer mixture.

¹H-NMR (DMSO-d₆, stored with K₂CO₃, main isomer): δ = 1.21 (m, 6H), 1.81 (m, 4H), 3.32 (m, 4H), 4.20 (m, 2H), 7.18 (d, 2H), 7.50 (d, 2H), 8.12 (s, 1H) ppm.

Example 3

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-({4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene)-acetic acid allyl ester




1 g of the compound that is described under Example **INT126**) and 0.93 g of the compound that is described under Example **INT14**) are stirred in 20 ml of ethanol for 15 hours at 100°C. The reaction mixture is evaporated to the dry state in a rotary evaporator. The thus obtained crude product is purified by chromatography on silica gel. 1.6 g of the title compound is obtained as a pH-dependent 5-(E/Z)-isomer mixture.

¹H-NMR (DMSO-d₆, main isomer): δ = 1.25 (3H); 2.12 (3H); 2.21-2.55 (10 H) 2.60 (2H); 4.23 (2H); 4.70 (2H); 5.25 (1H); 5.88 (1H); 5.90-6.06 (1H); 7.27 (2H); 7.55 (2H); 8.16 (1H); ppm.

Example 4

(E or Z)-Cyano-(3-ethyl-5-(E/Z-({4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene)-acetic acid benzyl ester




Analogously to Example 3), 7.4 g of the title compound is obtained by reaction of 5 g of the compound in 100 ml of ethanol that is described in **Example INT128)** and 4 g of the compound in 100 ml of ethanol that is described in Example **INT14)**.

1H-NMR (DMSO-d₆, main isomer): δ = 1.23 (3H); 2.16 (3H); 2.22-2.57 (10 H); 2.61 (2H); 4.23 (2H); 5.28 (2H); 7.26 (2H); 7.31-7.48 (5H); 7.58 (2H); 8.16 (1H); ppm.

Example 5

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[4-(2-pyrrolidin-1-yl-ethylcarbamoyl)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid allyl ester





12.2 g of the compound that is described under Example 50), 5.5 ml of triethylamine and 12.8 g of TBTU are introduced into 150 ml of DMF and stirred for 30 minutes at room temperature. 4.5 g of N-(2-aminoethyl)-pyrrolidine is added, and it is stirred overnight at



room temperature. The reaction mixture is mixed with sodium chloride solution and extracted with a dichloromethane/methanol mixture. After purification by chromatography on silica gel, 13.2 g of the title compound is obtained as a pH-dependent 5-(E/Z)-isomer mixture.



¹H-NMR (DMSO-d₆, main isomer): δ = 1.23 (3H); 1.75-2.33 (4H); 2.90-3.13 (4H); 3.52 (2H); 4.23 (2H); 4.72 (2H); 5.26 (1H). 5.89 (1H); 5.91-6.07 (1H); 7.40 (2H); 7.90 (2H); 8.25 (1H); 8.69 (1H); ppm.



The following compounds are produced analogously to the above-described


process.



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
6	 (E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(p-tolylamino-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.16-1.32 (m, 6H); 2.27 (s, 3H); 4.15-4.31 (m, 4H); 7.17 (d, 2H); 7.21 (d, 2H); 8.16 (s, 1H); 10.50 (s, 1H) ppm.	MW: 357.43 MS (ESI) [M+1] ⁺ : 358	INT124/ INT131
7	 (E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(m-tolylamino-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.20-1.31 (m, 6H); 2.30 (s, 3H); 4.20-4.29 (m, 4H); 6.92 (d, 1H); 7.10 (d, 1H); 7.16 (s, 1H); 7.25 (t, 1H); 8.20 (s, 1H);	MW: 357.43 MS (ESI) [M+1] ⁺ : 358	INT124/ INT131


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.50 (s, 1H) ppm.		
8	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(3-nitro-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.18-1.32 (m, 6H); 4.17-4.31 (m, 4H); 7.61 (t, 1H); 7.81 (d, 1H); 7.88 (d, 1H); 8.13 (s, 1H); 8.32 (s, 1H); 10.70 (s, 1H) ppm.	MW: 388.40 MS (ESI) [M+1] ⁺ : 389	INT124/ INT131
9	 (E or Z)-{5-(E/Z)-[(3-Chloro-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester	1.16-1.30 (m, 6H); 4.18 (q, 2H); 4.23 (q, 2H); 7.00 (d, 1H); 7.08 (d, 1H); 7.12 (s, 1H); 7.28 (t, 1H); 8.28 (s, 1H);	MW: 377.85 MS (ESI) [M+1] ⁺ :	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.51 (s, 1H) ppm.		
10	 5-{[2-((E or Z)-Cyanoethoxycarbonylmethylene)-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl]-amino}-1H-indole-2-carboxylic acid ethyl ester	1.16-1.30 (m, 6H); 1.35 (t, 3H); 4.17-4.30 (m, 4H); 4.35 (q, 2H); 7.12 (s, 1H); 7.28 (d, 1H); 7.45 (d, 1H); 7.58 (s, 1H); 8.20 (s, 1H); 10.61 (s, 1H); 11.93 (s, 1H) ppm.	MW: 454.51 MS (ESI) [M+1] ⁺ : 455	INT124/ INT131
11	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[2-(2-methyl-5-oxo-1H-indol-3-yl)amino]-2-oxo-1,3-dihydrothiazolidin-4-ylidene}-propanoic acid ethyl ester	1.13-1.34 (m, 6H); 2.38 (s, 3H); 4.12-4.32 (m, 4H); 6.12 (s, 1H); 6.96 (d, 1H);	MW: 396.47 MS (ESI)	INT124/ INT131


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	methyl-1H-indol-5-ylamino)- methylene]-4-oxo-thiazolidin-2- ylidene}-acetic acid ethyl ester	7.25 (d, 1H); 7.33 (s, 1H); 8.15 (s, 1H); 10.56 (s, 1H); 11.98 (s, 1H) ppm.	[M+1] ⁺ : 397	
12	 (E or Z)-{5-(E/Z)-[(3-Carbamoyl-1H-indol-5-ylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester	1.16-1.34 (m, 6H); 4.15-4.32 (m, 4H); 6.89 (s, 1H); 7.18 (d, 1H); 7.35-7.52 (m, 2H); 8.00-8.10 (m, 2H); 8.20 (d, 1H); 10.75 (d, 1H); 11.60 (s, 1H) ppm.	MW: 425.47 MS (ESI) [M+1] ⁺ : 426	INT124/ INT131
13		1.17-1.34 (m, 6H); 2.20 (s, 3H); 2.23-2.42 (m, 4H);	MW: 469.56	INT124/ 1



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[3-(4-methyl-piperazine-1-carbonyl)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester	3.61 (s, 1H); 4.15-4.32 (m, 2H); 7.01-7.10 (m, 1H); 7.31 (s, 1H); 7.47-7.36 (m, 2H); 8.25 (s, 1H); 10.57 (s, 1H) ppm.	MS (ESI) [M+1] ⁺ : 470	
14	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({3-[2-(2-hydroxymethyl-pyrrolidin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.14-1.32 (m, 6H); 1.44-1.90 (m, b, 5H); 2.50-3.50 (m, b, 9H); 4.12-4.31 (m, 4H); 6.91 (d, 1H); 7.09 (d, 1H); 7.18 (s, 1H); 7.31 (t, 1H); 8.12 (d, 1H); 9.91 (s, 1H);	MW: 549.67 MS (ESI) [M+1] ⁺ : 550	INT124/ 1


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.62 (d, 1H) ppm.		
15	 (E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[3-(2-piperidin-1-yl)ethanesulfonylamino]-phenylamino}-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester	1.15-1.53 (m, 12H); 2.25-2.50 (m, 6H); 2.68-2.85 (m, 2H); 4.18-4.31 (m, 4H); 6.92 (d, 1H); 7.08 (d, 1H); 7.17 (s, 1H); 7.31 (t, 1H); 8.12 (d, 1H); 10.01 (s, 1H); 10.62 (d, 1H) ppm.	MW: 533.67 MS (EI) [M+1] ⁺ : 534	INT124/ 1
16	 (E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[3-(2-pyrrolidin-1-yl)ethanesulfonylamino]-phenylamino}-methylene)-thiazolidin-2-ylidene)-acetic acid ethyl ester	1.15-1.31 (m, 6H); 1.52-1.68 (m, 4H); 2.27-2.89 (m, 4H); 2.76 (t, 2H); 3.29 (t, 2H);	MW: 556.11 MS (EI)	INT124/ 1


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethanesulfonylamino)-phenylamino]- methylene}-thiazolidin-2-ylidene)- acetic acid ethyl ester	4.15-4.31 (m, 4H); 6.90 (d, 1H); 7.01 (d, 1H); 7.12 (s, 1H); 7.29 (t, 1H); 8.14 (s, 1H); 10.10-10.90 (b, 2H) ppm.	[M+1] ⁺ : 557	
17	 (E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[4-(3-methoxy-propionylamino)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester	1.15-1.34 (m, 6H); 2.55 (t, 2H); 3.24 (s, 3H); 3.61 (t, 2H); 4.14-4.32 (m, 4H); 7.27 (d, 2H); 7.60 (d, 2H); 8.14 (s, 1H); 9.96 (s, 1H);	MW: 444.51 MS (ESI) [M+1] ⁺ : 445	INT124/ 1



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.53 (s, 1H) ppm.		
18	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(2-methoxy-ethoxy)-acetylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.15-1.32 (m, 6H); 3.30 (s, 3H); 3.52 (t, 2H); 3.67 (t, 2H); 4.08 (s, 2H); 4.17-4.32 (m, 4H); 7.29 (d, 2H); 7.63 (d, 2H); 8.15 (s, 1H); 9.67 (s, 1H); 10.53 (s, 1H) ppm.	MW: 474.54 MS (EI) [M+1] ⁺ : 475	INT124/1
19	 (E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[4-(2-methoxy-acetylamino)-	1.16-1.32 (m, 6H); 3.37 (s, 3H); 3.98 (s, 2H); 4.15-4.33 (m, 4H); 7.28 (d, 2H);	MW: 430.48 MS (EI)	INT124/1



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	phenylamino]-methylene}-4-oxo- thiazolidin-2-ylidene)-acetic acid ethyl ester	7.65 (d, 2H); 8.15 (s, 1H); 9.77 (s, 1H); 10.52 (s, 1H) ppm.	[M+1] ⁺ : 431	
20	 (E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[4-(2-piperidin-1-ylethanesulfonylamino)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester	1.11-1.35 (m, 8H); 1.35-1.47 (m, 4H); 2.20-2.32 (m, 4H); 2.54 (t, 2H); 3.20 (t, 2H); 4.14-4.31 (m, 4H); 7.19 (d, 2H); 7.28 (d, 2H); 8.18 (s, 1H); 9.5-10.0 (b, 1H); 10.35-10.75 (b, 1H) ppm.	MW: 533.67 MS (ESI) [M+1] ⁺ : 534	INT124/ 1




Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
21	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(4-methyl-piperazin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.16-1.31 (m, 6H); 2.10 (s, 3H); 2.13-2.40 (m, 8H); 2.65 (t, 2H); 3.20 (t, 2H); 4.13-4.30 (m, 4H); 7.19 (d, 2H); 7.29 (d, 2H); 8.18 (s, 1H); 9.5-10.8 (b, 2H) ppm.	MW: 548.69 MS (ESI) [M+1] ⁺ : 549	INT124/ 1
22	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-methanesulfonylamino-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.17-1.31 (m, 6H); 2.96 (s, 3H); 4.15-4.31 (m, 4H); 7.19 (d, 2H); 7.31 (d, 2H); 8.14 (s, 1H); 9.77 (s, 1H);	MW: 436.51 MS (ESI) [M+1] ⁺ : 437	INT124/ 1


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ylidene]-acetic acid ethyl ester	10.56 (s, 1H) ppm.		
23	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(2-hydroxymethyl)-piperidin-1-yl]-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.09-1.49 (m, 10H); 1.49-1.65 (m, 2H); 2.04-2.23 (m, 2H); 2.53-2.67 (m, 1H); 2.81-2.96 (m, 1H); 2.96-3.10 (m, 1H); 3.10-3.27 (m, 2H); 3.23-3.50 (m, 2H); 4.15-4.30 (m, 4H); 4.56 (s, 1H); 7.21 (d, 2H); 7.31 (d, 2H); 8.17 (s, 1H); 9.71 (s, 1H); 10.55 (s, 1H) ppm.	MW: 563.70 MS (EI) [M+1] ⁺ : 564	INT124/ 1



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
24	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(2-hydroxymethyl-pyrrolidin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.16-1.31 (m, 6H); 1.41-1.65 (m, 3H); 1.65-1.70 (m, 1H); 2.10-2.15 (m, 1H); 2.44 (m, 1H); 2.66 (m, 1H); 2.85 (m, 1H); 3.10-3.41 (m, 5H); 4.15-4.31 (m, 4H); 4.52 (s, 1H); 7.20 (d, 2H); 7.30 (d, 2H); 8.18 (s, 1H); 9.68 (s, 1H); 10.55 (s, 1H) ppm.	MW: 549.67 MS (ESI) [M+1] ⁺ : 550	INT124/ 1




Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
25	 disclosed but not claimed (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid propyl ester	0.93 (t, 3H); 1.22 (t, 3H); 1.66 (sextet, 2H); 4.12 (t, 2H); 4.24 (q, 2H); 6.77 (d, 2H); 7.15 (d, 2H); 8.07 (s, 1H); 9.41 (s, 1H); 10.46 (s, 1H) ppm.	MW: 373.43 MS (ESI) [M+1] ⁺ : 374	Educt as in the Case of INT124/ INT131
26	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-fluoro-4-hydroxy-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.14-1.32 (m, 6H); 4.10-4.34 (m, 4H); 6.59-6.72 (m, 2H); 7.21 (t, 1H); 7.91 (s, 1H); 9.98 (s, 1H); 10.25 (s, b, 1H) ppm.	MW: 377.39 MS (ESI) [M+1] ⁺ : 378	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
27	 (E or Z)-{5-(E/Z)-[(3-Chloro-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester	1.12-1.35 (m, 6H); 4.14-4.33 (m, 4H); 6.94 (d, 1H); 7.13 (d, 1H); 7.34 (s, 1H); 8.10 (s, 1H); 10.10 (s, 1H); 10.40 (s, 1H) ppm.	MW: 393.85 MS (ESI) [M+1] ⁺ : 394	INT124/ INT131
28	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-3-nitro-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.16-1.32 (m, 6H); 4.15-4.32 (m, 4H); 7.10 (d, 1H); 7.56 (dd, 1H); 7.84 (d, 1H); 8.18 (s, 1H); 10.10-10.70 (b, 2H) ppm.	MW: 404.40 MS (ESI) [M+1] ⁺ : 405	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
29	 (E or Z)-Cyano-{5-(E/Z)-[(3,5-dichloro-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.15-1.31 (m, 6H); 4.12-4.31 (m, 4H); 7.31 (m, 2H); 8.15 (s, 1H); 10.10-10.60 (b, 2H) ppm.	MW: 428.29 MS (EI) [M+1] ⁺ : 429	INT124/ INT131
30	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-3,5-dimethyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.17-1.31 (m, 6H); 2.17 (s, 6H); 4.12-4.31 (m, 4H); 6.90 (s, 2H); 8.08 (s, 1H); 8.20 (s, 1H); 10.38 (s, 1H) ppm.	MW: 387.46 MS (EI) [M+1] ⁺ : 388	INT124/ INT131
31		1.01 (t, 6H); 1.15-1.34 (m, 6H); 2.55 (q, 4H);	MW: 444.55	INT124/ INT132



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	(E or Z)-Cyano-{5-(E/Z)-[(3-diethylaminomethyl-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	3.70 (s, 2H); 4.13-4.31 (m, 4H); 6.68 (d, 1H); 7.02 (d, 1H); 7.09 (s, 1H); 8.08 (s, 1H); 10.45 (s, 1H) ppm.	MS (ESI) [M+1] ⁺ : 445	
32	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-3-methyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.18-1.31 (m, 6H); 2.12 (s, 3H); 4.15-4.30 (m, 4H); 6.75 (d, 1H); 6.95 (d, 1H); 7.07 (s, 1H); 8.06 (d, 1H); 9.30 (s, 1H); 10.40 (d, 1H) ppm.	MW: 373.43 MS (ESI) [M+1] ⁺ : 374	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
33	 (E or Z)-Cyano-{5-(E/Z)-[(3,5-dibromo-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.18-1.32 (m, 6H); 4.14-4.30 (m, 4H); 7.46 (m, 3H); 8.12 (s, 1H); 10.50 (s, b, 1H) ppm.	MW: 517.20 MS (EI) [M+1] ⁺ : 518	INT124/ INT131
34	 5-{[2-((E or Z)-Cyano-ethoxycarbonyl-methylene)-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl]-amino}-2-hydroxy-benzoic acid methyl ester	1.18-1.30 (m, 6H); 3.90 (s, 3H); 4.15-4.30 (m, 4H); 7.00 (d, 1H); 7.51 (d, 1H); 7.64 (s, 1H); 8.12 (s, 1H); 10.28 (s, 1H); 10.52 (s, 1H) ppm.	MW: 417.44 MS (EI) [M+1] ⁺ : 418	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
35	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-hydroxy-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.17-1.31 (m, 6H); 4.13-4.35 (m, 4H); 6.78-7.02 (m, 3H); 7.40 (d, 1H); 8.60 (s, 1H); 10.20 (b, 2H) ppm.	MW: 359.40 MS (ESI) [M+1] ⁺ : 360	INT124/ INT131
36	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-fluoro-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	Main Isomer: 1.16-1.32 (m, 6H); 4.15-4.32 (m, 4H); 7.10-7.60 (m, 4H); 8.06 (d, 1H); 10.49 (d, 1H) ppm.	MW: 361.40 MS (ESI) [M+1] ⁺ : 362	INT124/ INT131
37		Main Isomer: 1.17-1.33 (m, 6H); 2.30 (s, 3H);	MW: 357.43	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(o-tolylamino-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester	4.13-4.33 (m, 4H); 7.01-7.47 (m, 4H); 7.92 (s, 1H); 10.00 (s, 1H) ppm.	MS (ESI) [M+1] ⁺ : 358	
38	 (E or Z)-{5-(E/Z)-[(2-Chloro-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyanoacetic acid ethyl ester	Main Isomer: 1.16-1.35 (m, 6H); 4.15-4.33 (m, 4H); 7.08-7.65 (m, 4H); 8.65 (d, 1H); 10.92 (d, 1H) ppm.	MW: 377.85 MS (ESI) [M+1] ⁺ : 378	INT124/ INT131
39	 (E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(quinolin-8-ylaminomethylene)-thiazolidin-2-ylidene]-acetic acid ethyl	CDCl ₃ : 1.38 (t, 3H); 1.46 (t, 3H); 4.33 (q, 2H); 4.51 (q, 2H); 7.40-7.59 (m, 4H);	MW: 394.45 MS (ESI) [M+1] ⁺ :	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ester	7.87 (d, 1H); 8.18 (d, 1H); 9.00 (m, 1H); 12.26 (d, 1H) ppm.	395	
40	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-isopropyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	Main Isomer: 1.10-1.36 (m, 12H); 3.03-3.18 (m, 1H); 4.11-4.33 (m, 4H); 7.10-7.47 (m, 4H); 7.89 (s, 1H); 10.12 (s, 1H) ppm.	MW: 385.49 MS (ESI) [M+1] ⁺ : 386	INT124/ INT131
41	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-(naphthalen-1-ylaminomethylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid	Main Isomer: 1.16-1.35 (m, 6H); 4.12-4.35 (m, 4H); 7.44 (d, 1H); 7.50-7.68 (m, 3H); 7.85 (d, 1H);	MW: 393.47 MS (ESI) [M+1] ⁺ :	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethyl ester	7.94-8.05 (m, 1H); 8.05-8.20 (m, 2H); 10.73 (s, 1H) ppm.	394	
42	 disclosed but not claimed (E or Z)-Cyano-[3-ethyl-5-(E/Z)- (naphthalen-1-ylaminomethylene)-4- oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	Main Isomer: 1.16-1.45 (m, 6H); 4.13-4.32 (m, 4H); 7.12-7.23 (m, 1H); 7.80 (s, 1H); 7.92-8.01 (m, 1H); 8.59 (d, 1H); 12.60 (d, 1H); 13.5-14.0 (b, 1H) ppm.	MW: 421.86 MS (ESI) [M+1]⁺: 422	INT124/ INT131
43	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-ethylphenyl)aminomethylene]-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	Main Isomer: 1.10-1.32 (m, 9H); 2.70 (q, 2H); 4.12-4.33 (m, 4H);	MW: 371.46 MS	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethyl-phenylamino)-methylene]-4- oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	7.17-7.47 (m, 4H); 7.90 (s, 1H); 10.03 (s, b, 1H) ppm.	(ESI) [M+1] ⁺ : 372	
44	 (E or Z)-{5-(E/Z)-[(1H- Benzoimidazol-2-ylamino)- methylene]-3-ethyl-4-oxo-thiazolidin- 2-ylidene}-cyano-acetic acid ethyl ester	1.17-1.31 (m, 6H); 4.13-4.32 (m, 4H); 7.19 (m, 2H); 7.30 (m, 2H); 8.63 (s, 1H); 12.74 (s, 2H) ppm.	MW: 383.43 MS (ESI) [M+1] ⁺ : 384	INT124/ INT131
45	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(1- methyl-1H-benzimidazol-2-ylamino)- methylene]-3-ethyl-4-oxo-thiazolidin- 2-ylidene}-cyano-acetic acid ethyl ester	1.28-1.31 (m, 6H); 3.63 (s, 3H); 4.12-4.30 (m, 4H); 7.18 (m, 2H); 7.31 (m, 1H);	MW: 397.46 MS (ESI)	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	methyl-1H-benzoimidazol-2-ylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	7.46 (m, 1H); 8.60 (s, 1H); 12.91 (s, 1H) ppm.	[M+1] ⁺ : 398	
46	 Cyano-[3-ethyl-4-oxo-5-[1-[4-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester		MW: 495.60 MS (ESI) [M+1] ⁺ : 496	INT126/ 3
47	 Cyano-[3-ethyl-4-oxo-5-[1-{4-[3-(2-pyrrolidin-1-yl-ethyl)-ureido]-phenylamino}-meth-(E/Z)-ylidene]-		MW: 510.62 MS (ESI)	INT126/ 3



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	thiazolidin-(2-(E or Z))-ylidene]- acetic acid allyl ester		[M+1] ⁺ : 511	
48	 4-(4-{[2-[1-Allyloxycarbonyl-1-cyano-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/ Z)-ylidenemethyl]-amino}-phenyl)-butyric acid		MW: 441.51 MS (ESI) [M+1] ⁺ : 442	INT126/ 3
49	 Cyano-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester		MW: 495.60 MS (ESI) [M+1] ⁺ : 496	INT126/ 3



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
50	 4-([2-[1-Allyloxycarbonyl-1-cyano-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/ Z)-ylidenemethyl]-amino)-benzoic acid		MW: 399.43 MS (ESI) [M+1] ⁺ : 400	INT126/ 3
51	 6-([2-[1-Allyloxycarbonyl-1-cyano-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/ Z)-ylidenemethyl]-amino)-naphthalene-2-carboxylic acid		MW: 449.49 MS (ESI) [M+1] ⁺ : 450	INT126/ 3



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
52	 Cyano-[5-[1-{4-[3-(2-diethylamino-ethylcarbamoyl)-propyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester		MW: 539.70 MS (ESI) [M+1] ⁺ : 540	48/5
53	 Cyano-[3-ethyl-4-oxo-5-[1-[6-(2-pyrrolidin-1-yl-ethylcarbamoyl)-naphthalen-2-ylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester		MW: 545.67 MS (ESI) [M+1] ⁺ : 546	51/5



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
54	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[3-(2-hydroxy-ethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.24 (m, 6H), 3.12 (m, 2H), 3.42 (m, 2H), 4.20 (m, 4H), 4.72 (m, 1H), 6.13 (m, 1H), 7.21 (d, 2H), 7.38 (d, 2H), 8.12 (m, 1H), 8.59 (s, 1H), 10.50 (s, 1H).	MW: 445.50 MS (ESI) [M+1]⁺: 446	INT124/2
55	 (E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-({4-[(pyrrolidin-1-carbonyl)-amino]-phenylamino}-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.21 (m, 6H), 1.81 (m, 4H), 3.32 (m, 4H), 4.20 (m, 2H), 7.18 (d, 2H), 7.50 (d, 2H), 8.12 (s, 1H)	MW: 455.54 MS (ESI) [M+1]⁺: 456	INT124/2


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
56	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-methoxy-3-[(morpholin-4-carbothioyl)-amino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.28 (m, 6H), 3.63 (m, 4H), 3.38 (s, 3H), 3.90 (m, 4H), 4.21 (m, 4H), 7.0 (d, 1H), 7.16 (dd, 1H), 7.30 (d, 1H), 8.08 (m, 1H), 8.89 (d, 1H), 10.50 (d, 1H).	MW: 517.63 MS (ESI) [M+1]⁺: 518	INT124/ 2
57	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-{3-[2-(2-hydroxy-ethoxy)-ethyl]-ureido}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid	1.22 (m, 6H), 3.22 (m, 2H), 3.41 (m, 4H), 3.53 (m, 2H), 4.21 (m, 4H), 4.60 (m, 1H), 6.16 (m, 1H), 7.20 (d, 2H), 7.38 (d, 2H), 8.10 (s, 1H), 8.58 (s, 1H),	MW: 489.55 MS (ESI) [M+1]⁺: 490	INT124/ 2



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethyl ester	10.50 (s, 1H).		
58	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[(4-methyl-piperazine-1-carbothioyl)-amino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.22 (m, 6H), 2.20 (s, 3H), 2.35 (m, 4H), 3.82 (m, 4H), 4.21 (m, 4H), 7.22 (m, 4H), 8.14 (s, 1H), 9.28 (s, 1H), 10.55 (s, 1H).	MW: 500.65 MS (ESI) [M+1] ⁺ : 501	INT124/ 2
59	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[3-(2-hydroxy-ethyl)-thioureido]-phenylamino}-methylene)-4-oxo-	1.27 (m, 6H), 3.51 (m, 4H), 4.22 (m, 4H), 4.81 (s, 1H), 7.27 (d, 2H), 7.40 (d, 2H), 7.68 (s, 1H), 8.13 (d, 1H), 9.59 (s, 1H).	MW: 461.57 MS (ESI) [M+1] ⁺ :	INT124/ 2



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	thiazolidin-2-ylidene]-acetic acid ethyl ester	1H), 10.55 (d, 1H)	462	
60	 (E or Z)-{5-(E/Z)-[(4-Acetylsulfamoyl-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester	1.25 (m, 6H), 1.88 (m, 3H), 4.24 (m, 4H), 7.52 (d, 2H), 7.87 (d, 2H), 8.26 (d, 1H), 10.78 (d, 1H), 12.00 (s, 1H).	MW: 464.52 MS (ESI) [M+1]⁺: 465	INT124/2
61	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-{3-[2-(2-hydroxy-ethoxy)-ethyl]-thioamino-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester	1.24 (m, 6H), 3.50 (m, 8H), 4.21 (m, 4H), 4.60 (m, 1H), 7.27 (d, 2H), 7.40 (d, 2H), 7.70 (s, 1H), 8.17 (s, 1H), 9.58 (s, 1H).	MW: 505.62 MS (ESI) [M+1]⁺:	INT124/2



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	thioureido}-phenylamino)- methylene]-4-oxo-thiazolidin-2- ylidene}-acetic acid ethyl ester	1H), 10.52 (s, 1H).	506	
62	 (E or Z) -Cyano-(3-ethyl-5-(E/Z)-{[2-(2-hydroxy-ethyl)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester	1.22 (m, 6H), 2.81 (m, 2H), 3.69 (m, 2H), 4.21 (m, 4H), 7.29 (m, 4H), 8.00 (s, 1H).	MW: 387.46 MS (ESI) [M+1] ⁺ : 388	INT124/2
63	 Cyano-{3-ethyl-5-(E/Z)- [(2-ethyl-phenylamino)-methylene]-4-oxo-	1.27 (m, 9H), 2.68 (m, 2H), 4.22 (m, 4H), 7.27 (m, 4H), 7.88 (s, 1H).	MW: 371.46 MS (ESI) [M+1] ⁺ :	INT124/2


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	thiazolidin-2-ylidene}-acetic acid ethyl ester		372	
64	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-fluoro-3-[3-(2-morpholin-4-yl-ethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.25 (m, 6H), 2.40 (m, 6H), 3.26 (m, 2H), 3.58 (m, 4H), 4.22 (m, 4H), 6.70 (m, 1H), 6.84 (m, 1H), 7.18 (m, 1H), 8.02 (s, 1H), 8.19 (dd, 1H), 8.57 (d, 1H), 10.62 (s, 1H).	MW: 532.59 MS (ESI) [M+1]⁺: 533	INT124/ 2
65	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[3-(1-ethyl-pyrrolidin-2-ylmethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.05 (m, 3H), 1.22 (m, 6H), 1.52 (m, 1H), 1.66 (m, 2H), 1.80 (m, 1H), 2.16 (m, 2H), 2.49 (m, 1H), 2.80 (m, 1H),	MW: 512.63 MS (ESI) [M+1]⁺:	INT124/ 2



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	2.97 (m, 1H), 3.08 (m, 1H), 3.38 (m, 1H), 4.20 (m, 4H), 6.00 (m, 1H), 7.20 (d, 2H), 7.48 (d, 2H), 8.09 (s, 1H), 8.22 (s, 1H), 10.50 (s, 1H).	513	
66	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[4-{[4-(2-hydroxy-ethyl)-piperazin-1-carbonyl]-amino}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.21 (m, 6H), 2.40 (m, 4H), 3.50 (m, 2H), 4.21 (m, 4H), 4.42 (s, 1H), 7.20 (d, 2H), 7.45 (d, 2H), 8.12 (s, 1H), 8.50 (s, 1H).	MW: 514.60 MS (ESI) [M+1] ⁺ : 515	INT124/ 2



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
67	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({3-[3-(2-morpholin-4-yl-ethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.22 (m, 6H), 2.39 (m, 6H), 3.21 (m, 2H), 3.58 (m, 4H), 4.21 (m, 4H), 6.11 (m, 1H), 6.81 (dd, 1H), 6.93 (dd, 1H), 7.19 (m, 1H), 7.58 (s, 1H), 8.08 (m, 1H), 8.72 (d, 1H), 10.59 (d, 1H).	MW: 514.60 MS (ESI) [M+1]⁺: 515	INT124/2
68	 (E or Z)-Cyano-[5-(E/Z)-({3-[3-(3-dimethylamino-propyl)-ureido]-phenylamino}-methylene)-3-ethyl-4-oxo-thiazolidin-2-ylidene]-acetic acid	1.24 (m, 6H), 1.57 (m, 2H), 2.12 (s, 6H), 2.25 (m, 2H), 3.11 (m, 2H), 4.21 (m, 4H), 6.20 (m, 1H), 6.80 (d, 1H), 6.92 (d, 1H), 7.18 (m, 1H),	MW: 486.59 MS (ESI) [M+1]⁺: 487	INT124/2


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethyl ester	7.57 (s, 1H), 8.09 (s, 1H), 8.57 (s, 1H).		
69	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-{[4-(4-methyl-piperazin-1-yl)-piperidine-1-carbonyl]-amino}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.22 (m, 6H), 1.41 (m, 2H), 1.70 (m, 2H), 1.83 (m, 2H), 2.15 (s, 3H), 2.48 (m, 3H), 2.79 (m, 2H), 3.37 (m, 6H), 4.21 (m, 4H), 7.20 (d, 2H), 7.42 (d, 2H), 8.12 (s, 1H), 8.50 (s, 1H).	MW: 567.71 MS (ESI) [M+1] ⁺ : 568	INT124/2
70	 (E or Z)-Cyano-[5-(E/Z)-({4-[3-(3-dimethylamino-propyl)-ureido]-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	1.22 (m, 6H), 1.53 (m, 2H), 2.12 (s, 6H), 2.25 (m, 2H), 3.09 (m, 2H), 4.22 (m, 4H), 6.12 (m, 1H),	MW: 486.59 MS (ESI)	INT124/2


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	phenylamino}-methylene)-3-ethyl-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	8.10 (s, 1H), 8.48 (s, 1H).	[M+1] ⁺ : 487	
71	 (E or Z)-Cyano-[5-(E/Z)-({3-[3-(3-dimethylamino-propyl)-ureido]-4-fluoro-phenylamino}-methylene)-3-ethyl-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.22 (m, 6H), 1.58 (m, 2H), 2.12 (s, 6H), 2.25 (m, 2H), 3.12 (m, 2H), 4.21 (m, 4H), 6.70 (m, 1H), 6.83 (m, 1H), 7.16 (m, 1H), 8.06 (s, 1H), 8.19 (m, 1H), 8.39 (s, 1H).	MW: 504.58 MS (ESI) [M+1] ⁺ : 505	INT124/ 2
72	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-(4-(dimethylamino)butyl)-ureido)-4-fluoro-phenylamino]-methylene)-3-ethyl-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.28 (m, 6H), 1.41 (m, 2H), 1.62 (m, 2H), 1.76 (m, 1H), 1.91 (m, 1H), 2.08 (m, 2H), 2.22 (s, 3H),	MW: 530.62 MS (ESI)	INT124/ 2


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	fluoro-3-{3-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-ureido}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	2.93 (m, 1H), 3.12 (m, 2H), 4.21 (m, 4H), 6.68 (m, 1H), 6.82 (m, 1H), 7.17 (m, 1H), 10.59 (s, 1H).	[M+1] ⁺ : 531	
73	 (E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-fluoro-3-{[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-amino}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester	In MeOH: 1.32 (m, 6H), 2.60 (m, 6H), 3.59 (m, 4H), 3.70 (m, 2H), 4.30 (m, 4H), 6.89 (m, 1H), 7.08 (m, 1H), 7.38 (m, 1H), 8.05 (s, 1H).	MW: 532.59 MS (ESI) [M+1] ⁺ : 533	INT124/ 2



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
74	 (E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-({4-[3-(2-pyrrolidin-1-yl)-ethyl]-ureido}-phenylamino)-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.21 (m, 6H), 1.70 (m, 4H), 3.18 (m, 4H), 4.21 (m, 4H), 6.08 (m, 1H), 7.19 (d, 2H), 7.38 (d, 2H), 8.10 (s, 1H), 8.65 (s, 1H), 10.50 (s, 1H).	MW: 498.61 MS (ESI) [M+1]⁺: 499	INT124/2
75	 (E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[(4-methyl-piperazine-1-carbonyl)-amino]-phenylamino)-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester	1.22 (m, 6H), 2.17 (s, 3H), 2.30 (m, 4H), 3.40 (m, 4H), 4.22 (m, 4H), 7.20 (d, 2H), 7.42 (d, 2H), 8.11 (s, 1H), 8.51 (s, 1H), 10.40 (s, 1H).	MW: 484.58 MS (ESI) [M+1]⁺: 485	INT124/2


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
76	 [5-[1-[3-Chloro-5-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.17-1.30 (m, 15H); 4.16-4.30 (m, 4H); 7.01 (s, 1H); 7.51 (s, 1H); 7.63 (s, 1H); 8.15 (s, 1H); 9.33 (s, 1H); 10.60 (s, 1H) ppm.	MW: 476.98 MS (ESI) [M+1]⁺: 477	INT124/ INT131
77	 [5-[1-[3-Chloro-5-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ =	MW: 488.99 MS	INT126/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	propionylamino)-phenylamino]-meth- (E/Z)-ylidene]-3-ethyl-4-oxo- thiazolidin-(2-(E or Z))-ylidene]- cyano-acetic acid allyl ester	1.17-1.31 (m, 12H); 4.26 (q, 2H); 4.72 (d, 1H); 5.26 (d, 1H); 5.38 (d, 1H); 5.91-6.08 (m, 1H); 7.06 (s, 1H); 7.52 (s, 1H); 7.70 (s, 1H); 8.13 (s, 1H); 9.38 (s, 1H); 10.61 (s, 1H) ppm.	(ESI) [M+1] ⁺ : 489	
78	 [5-[1-(6-Acetylamino-pyridin-3-ylamino)-meth-(E/Z)-ylidene]-3-ethyl-	(DMSO-d ₆ , Stored with K ₂ CO ₃ , Main Isomer): δ = 1.18-1.33 (m, 6H);	MW: 401.45 MS (ESI)	INT124/ INT131


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	2.08 (s, 3H); 4.15-4.33 (m, 4H); 7.78 (dd, 1H); 8.08 (d, 1H); 8.20 (s, 1H); 8.31 (d, 1H); 10.49 (s, 1H); 10.55 (s, 1H) ppm.	[M+1] ⁺ : 402	
79	 Cyano-[3-ethyl-5-[1-(6-ethylamino-pyridin-3-ylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.12 (t, 3H); 1.18-1.32 (m, 6H); 3.23 (m, 2H); 4.13-4.32 (m, 4H); 6.42-6.59 (m, 2H);	MW: 387.46 MS (ESI) [M+1]⁺: 388	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.45 (m, 1H); 7.94-8.06 (m, 2H); 10.40 (s, 1H) ppm.		
80	 [5-[1-{6-[(5-Amino-pyridin-2-yl)-(2-pyrrolidin-1-yl-ethyl)-amino]-pyridin-3-ylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.18-1.31 (m, 6H); 1.83 (m, 4H); 2.80-3.21 (m, 6H); 4.08-4.32 (m, 6H); 5.37 (s, 2H); 6.58 (d, 1H); 7.04 (m, 2H); 7.55 (m, 1H); 7.83 (s, 1H); 8.10 (s, 1H);	MW: 548.67 MS (ESI) [M+1]⁺: 549	INT124/INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		8.22 (s, 1H); 10.46 (s, 1H) ppm.		
81	 [5-[1-(3-Amino-5-chloro-phenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.02-1.30 (m, 6H); 4.14-4.30 (m, 4H); 5.50 (s, b, 2H); 6.29 (s, 1H); 6.37 (s, b, 2H); 8.09 (s, 1H); 10.40 (s, 1H) ppm.	MW: 392.87 MS (ESI) [M+1]⁺: 393	INT124/INT131
82		(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ =	MW: 359.41 MS	INT124/INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	[5-[1-(6-Amino-pyridin-3-ylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	1.17-1.32 (m, 6H); 4.13-4.32 (m, 4H); 5.44 (s, 2H); 6.47 (d, 1H); 7.44 (d, 1H); 7.92 (s, 1H); 8.03 (s, 1H); 10.38 (s, 1H) ppm.	(ESI) [M+1] ⁺ : 360	
83	 [5-[1-(Benzo[1,3]dioxol-5-ylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d ₆ , Stored with K ₂ CO ₃ , Main Isomer): δ = 1.07-1.33 (m, 6H); 4.17-4.31 (m, 4H); 6.02 (s, 2H); 6.77 (dd, 1H); 6.90 (d, 1H);	MW: 387.41 MS (ESI) [M+1] ⁺ : 388	INT124/ INT131


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.03 (d, 1H); 8.10 (s, 1H); 10.42 (s, 1H) ppm.		
84	 [5-[1-(6-Chloro-pyridazin-3-ylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.20-1.32 (m, 6H); 4.19-4.32 (m, 4H); 7.43 (d, 1H); 7.80 (d, 1H); 8.72 (s, 1H); 11.17 (s, 1H) ppm.	MW: 379.83 MS (ESI) [M+1]⁺: 380	INT124/INT131
85		(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ =	MW: 378.84 MS	INT124/INT131


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1.19-1.32 (m, 6H); 4.18-4.31 (m, 4H); 7.47 (d, 1H); 7.87 (dd, 1H); 8.24 (s, 1H); 8.41 (d, 1H); 10.58 (s, 1H) ppm.	(ESI) [M+1] ⁺ : 379	
86	 Cyano-[3-ethyl-5-[1-(3-fluoro-4-hydroxy-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d ₆ , Stored with K ₂ CO ₃ , Main Isomer): δ = 1.22 (b, 6H); 4.24 (b, 4H); 6.70-7.50 (m, 3H); 8.10 (s, b, 1H); 9.79 (s, b, 1H); 10.43 (s, b, 1H) ppm.	MW: 377.39 MS (ESI) [M+1] ⁺ : 378	INT124/ INT131


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
87	 [5-[1-(3-Chloro-4-hydroxy-5-methylphenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.17-1.31 (m, 6H); 2.30 (s, 3H); 4.14-4.30 (m, 4H); 7.11 (d, 1H); 7.19 (d, 1H); 8.12 (s, 1H); 9.07 (s, 1H); 10.46 (s, 1H) ppm.	MW: 407.88 MS (ESI) [M+1]⁺: 408	INT124/ INT131
88	 [3-Butyl-5-[1-(3-chloro-4-hydroxy-	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 0.92 (t, 3H);	MW: 421.90 MS (ESI)	INT130/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	1.27 (t, 3H); 1.33 (m, 2H); 1.62 (m, 2H); 4.12-4.30 (m, 4H); 6.95 (d, 1H); 7.13 (dd, 1H); 7.33 (d, 1H); 8.10 (s, 1H); 10.09 (s, 1H); 10.40 (s, 1H) ppm.	[M+1] ⁺ : 422	
89	 [3-Butyl-5-[1-(4-hydroxy-3-methylphenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-	(DMSO-d ₆ , Stored with K ₂ CO ₃ , Main Isomer): δ = 0.91 (t, 3H); 1.26 (t, 3H); 1.32 (m, 2H);	MW: 401.49 MS (ESI) [M+1] ⁺ : 402	INT130/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	cyano-acetic acid ethyl ester	1.61 (m, 2H); 2.11 (s, 3H); 4.12-4.28 (m, 4H); 6.64 (d, 1H); 6.92 (d, 1H); 7.23 (s, 1H); 8.09 (s, 1H); 9.23 (s, 1H); 10.42 (s, 1H) ppm.		
90	 [3-Butyl-5-[1-(3-diethylaminomethyl)-4-hydroxy-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl	(CDCl ₃ , Stored with K ₂ CO ₃ , Main Isomer): δ = 0.99 (t, 3H); 1.11 (t, 6H); 1.36 (t, 3H); 1.45 (m, 2H);	MW: 472.61 MS (ESI) [M+1] ⁺ : 473	INT130/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ester	1.76 (m, 2H); 2.63 (q, 4H); 3.77 (s, 2H); 4.25-4.46 (m, 4H); 6.72 (m, 1H); 6.76-6.97 (m, 2H); 7.50 (d, 1H); 10.54 (d, 1H) ppm.		
91	 [3-Butyl-5-[1-(4-hydroxy-3,5-dimethyl-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl	(DMSO-d ₆ , Stored with K ₂ CO ₃ , Main Isomer): δ = 0.92 (t, 3H); 1.26 (t, 3H); 1.32 (m, 2H); 1.61 (m, 2H); 2.27 (s, 6H);	MW: 415.51 MS (EI) [M+1] ⁺ : 416	INT130/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ester	4.12-4.28 (m, 4H); 6.91 (s, 2H); 8.08 (s, 1H); 8.21 (s, 1H); 10.39 (s, 1H) ppm.		
92	 [3-Butyl-5-[1-(1H-indol-5-ylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 0.92 (t, 3H); 1.27 (t, 3H); 1.33 (m, 2H); 1.61 (m, 2H); 4.10-4.31 (m, 4H); 6.41 (s, 1H); 7.06 (d, 1H); 7.32-7.42 (m, 2H);	MW: 410.50 MS (ESI) [M+1]⁺: 411	INT130/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.45 (s, 1H); 8.19 (s, 1H); 10.61 (s, 1H); 11.13 (s, 1H) ppm.		
93	 [3-Butyl-5-[1-(3-carbamoyl-1H-indol-5-ylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d6, Stored with K₂CO₃, Main Isomer): δ = 0.91 (t, 3H); 1.27 (t, 3H); 1.34 (m, 2H); 1.61 (m, 2H); 4.10-4.30 (m, 4H); 6.70-7.22 (m, 2H); 7.32-7.50 (m, 2H); 7.95-8.09 (m, 2H); 8.23 (s, 1H);	MW: 453.52 MS (ESI) [M+1]⁺: 454	INT130/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.77 (s, 1H); 11.58 (s, 1H) ppm.		
94	 [3-Butyl-5-[1-[3-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 0.90 (t, 3H); 1.24 (s, 9H); 1.26 (t, 3H); 1.33 (m, 2H); 1.62 (m, 2H); 4.13-4.28 (m, 4H); 6.94 (d, 1H); 7.26 (t, 1H); 7.38 (d, 1H); 7.73 (s, 1H); 8.12 (s, 1H);	MW: 470.59 MS (ESI) [M+1]⁺: 471	INT130/ INT132



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		9.26 (s, 1H); 10.63 (s, 1H) ppm.		
95	 [3-Butyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 0.91 (t, 3H); 1.26 (t, 3H); 1.33 (m, 2H); 1.61 (m, 2H); 1.69 (m, 4H); 2.49-2.57 (m, 6H); 2.72 (t, 2H); 4.11-4.29 (m, 4H); 6.93 (s, 1H); 7.13-7.30 (m, 2H); 7.68 (s, 1H);	MW: 511.64 MS (ESI) [M+1]⁺: 512	INT130/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		8.15 (s, 1H); 10.12 (s, 1H); 10.67 (s, 1H) ppm.		
96	 [5-[1-(3-Acryloylamino-phenylamino)-meth-(E/Z)-ylidene]-3-butyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 0.91 (t, 3H); 1.27 (t, 3H); 1.33 (m, 2H); 1.61 (m, 2H); 4.11-4.29 (m, 4H); 5.78 (dd, 1H); 6.28 (dd, 1H); 6.44 (dd, 1H); 6.99 (m, 1H); 7.22-7.31 (m, 2H);	MW: 440.52 MS (ESI) [M+1]⁺: 441	INT130/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.75 (s, 1H); 8.14 (s, 1H); 10.20 (s, 1H); 10.68 (s, 1H) ppm.		
97	 [3-Butyl-5-[1-(3,5-dichloro-4-hydroxy-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 0.91 (t, 3H); 1.27 (t, 3H); 1.33 (m, 2H); 1.61 (m, 2H); 4.10-4.30 (m, 4H); 7.37 (s, 2H); 8.15 (s, 1H); 9.50-10.70 (b, 2H) ppm.	MW: 456.35 MS (ESI) [M+1]⁺: 457	INT130/ INT132



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
98	 [3-Butyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 0.91 (t, 3H); 1.26 (t, 3H); 1.32 (m, 2H); 1.53-1.72 (m, 6H); 2.46 (m, 4H); 2.59 (m, 2H); 2.70 (m, 2H); 4.12-4.29 (m, 4H); 7.19 (m, 4H); 8.19 (s, 1H); 10.52 (s, 1H) ppm.	MW: 468.62 MS (ESI) [M+1]⁺: 469	INT130/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
99	 [5-[1-(4-Acetylamino-phenylamino)-meth-(E/Z)-ylidene]-3-butyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 0.91 (t, 3H); 1.26 (t, 3H); 1.33 (m, 2H); 1.62 (m, 2H); 2.03 (s, 3H); 4.12-4.28 (m, 4H); 7.23 (d, 2H); 7.55 (d, 2H); 8.15 (s, 1H); 9.94 (s, 1H); 10.54 (s, 1H) ppm.	MW: 428.51 MS (ESI) [M+1]⁺: 429	INT130/ INT132



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
100	 [3-Butyl-5-[1-[(4-hydroxy-phenyl)-methyl-amino]-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 0.89 (t, 3H); 1.18 (t, 3H); 1.29 (m, 2H); 1.55 (m, 2H); 3.53 (s, 3H); 4.00-4.22 (m, 4H); 6.86 (d, 2H); 7.21 (d, 2H); 7.98 (s, 1H); 9.92 (s, 1H) ppm.	MW: 401.49 MS (ESI) [M+1]⁺: 402	INT130/INT132
101		(DMSO-d₆, Stored with K₂CO₃, Main Isomer):	MW: 415.47	INT124/INT131


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	[5-[1-(Benzo[1,3]dioxol-5-yl-ethyl- amino)-meth-(E/Z)-ylidene]-3-ethyl- 4-oxo-thiazolidin-(2-(E or Z))- ylidene]-cyano-acetic acid ethyl ester	$\delta =$ 1.03-1.21 (m, 9H); 3.82 (q, 2H); 4.10 (q, 2H); 4.18 (q, 2H); 6.12 (s, 2H); 6.83 (dd, 1H); 7.01-7.10 (m, 2H); 8.00 (s, 1H) ppm.	MS (ESI) [M+1] ⁺ : 416	
102	 Cyano-[3-ethyl-5-[1-[(4-hydroxy- phenyl)-methyl-amino]-meth-(E/Z)- ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d ₆ , Stored with K ₂ CO ₃ , Main Isomer): $\delta =$ 1.10-1.23 (m, 6H); 3.53 (s, 3H); 4.09 (q, 2H); 4.20 (q, 2H);	MW: 373.43 MS (ESI) [M+1] ⁺ : 374	INT124/ INT131



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		6.87 (d, 2H); 7.20 (d, 2H); 7.99 (s, 1H); 9.99 (s, 1H) ppm.		
103	 [5-[1-[(4-Chloro-phenyl)-methyl-amino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	(CDCl₃, Stored with K₂CO₃, Main Isomer): δ = 1.30-1.47 (m, 6H); 3.68 (s, 3H); 4.30 (q, 2H); 4.43 (q, 2H); 7.17 (d, 2H); 7.43 (d, 2H); 7.91 (s, 1H) ppm.	MW: 391.88 MS (ESI) [M+1]⁺: 392	INT124/ INT132



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
104	 rac-Cyano-[3-ethyl-4-oxo-5-[1-[4-(2,2,2-tri-fluoro-1-hydroxy-1-methyl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d₆; Main Isomer): δ = 1.23-1.28 (m, 6H); 1.67 (s, 3H); 4.20-4.27 (m, 4H); 6.59 (s, 1H); 7.40 (dd, 2H); 8.21 (d, 1H); 10.59 (d, 1H) ppm.	455.459/ 456	INT124/ INT132
105	 rac-Cyano-[3-ethyl-4-oxo-5-[1-[4-(2,2,2-tri-fluoro-1-hydroxy-1-methyl-ethyl)-phenyl-amino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d₆; Main Isomer): δ = 1.24 (t, 3H); 1.66 (s, 3H); 4.26 (q, 2H); 4.70 (tt, 2H);	467.470/ 468	INT126/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ylidene]-acetic acid allyl ester	5.25 (qq, 1H); 5.37 (qq, 1H) 7.40 (dd, 2H); 5.96 (m, 1H); 6.56 (s, 1H); 7.31-7.54 (q, 4H) 8.20 (1H); 10.56 (1H) ppm.		
106	 rac-Cyano-[3-ethyl-4-oxo-5-[1-[3-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)-phenyl-amino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d ₆ ; Main Isomer): $\delta =$ 1.22-1.28 (m, 6H); 1.69 (s, 3H); 4.19-4.28 (m, 4H); 6.68 (s, 1H); 7.25-7.38 (m, 3H); 7.52 (s, 1H);	455.459/ 456	INT124/ INT132



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		8.19 (1H); 10.59 (s, 1H) ppm.		
107	 rac-Cyano-[3-ethyl-4-oxo-5-[1-[3-(2,2,2-trifluoro-1-hydroxy-1-methylethyl)-phenyl-amino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester	(DMSO-d ₆ ; Main Isomer, Selection): δ = 1.21-1.28 (m, 3H); 1.69 (s, 3H); 4.24 (q, 2H); 6.69 (s, 1H); 7.26-7.39 (m, 3H); 7.53 (s, 1H); 8.22 (d, 1H); 10.63 (d, 1H) ppm.	467.470/ 468	INT126/ INT132
108		(DMSO-d ₆ ; Main Isomer): δ = 1.22-1.28 (m, 6H);	414.486/ 415	INT124/ INT132



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	[5-[1-[4-(Acetyl-methyl-amino)-phenyl-amino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester	1.76 (s, 3H); 3.11 (s, 3H); 4.21-4.25 (m, 4H); 7.28-7.38 (dd, 4H) 8.19 (s, 1H); 10.55 (s, 1H) ppm.		
109	 Cyano-[3-ethyl-4-oxo-5-[1-(3-trifluoro-methyl-phenylamino)-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d ₆ ; Main Isomer): $\delta =$ 1.22-1.28 (m, 6H); 4.19-4.25 (m, 4H); 7.36 (d, 1H); 7.53 (t, 1H); 7.59-7.63 (m, 1H); 8.26 (s, 1H); 10.56 (s, 1H) ppm.	411.405/ 412	INT124/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
110	 Cyano-[3-ethyl-4-oxo-5-[1-(4-trifluoro-methyl-phenylamino)-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d₆; Main Isomer): δ = 1.23-1.28 (2t, 6H); 4.21-4.25 (m, 4H); 7.46-7.66 (q, 4 h); 8.22 (s, 1H); 10.68 (s, 1H) ppm.	411.405/ 412	INT124/ INT132
111	 Cyano-[3-ethyl-4-oxo-5-[1-(pyridin-2-ylamino)-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d₆; Main Isomer): δ = 1.22-1.28 (m, 6H); 4.18-4.23 (m, 4H); 7.04-7.07 (m, 2H); 7.71-7.76 (m, 1H); 8.28-8.29 (m, 1H); 8.73 (d, 1H);	344.394/ 345	INT124/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.93 (d,1H) ppm.		
112	 Cyano-[3-ethyl-4-oxo-5-[1-(pyridin-3-yl-amino)-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d₆; Main Isomer): δ = 1.22-1.28 (m, 6H); 4.19-4.24 (m, 4H); 7.32-7.37 (dd, H); 7.73-7.75 (m, 1H); 8.20 (s, 1H); 8.24-8.25 (m, 1H); 8.53 (d, 1H); 10.52 (s, 1H) ppm.	344.394/ 345	INT124/ INT132
113	 Cyano-[5-[1-(4,6-dimethyl-pyridin-2-yl-amino)-meth-(E/Z)-ylidene]-3-ylidene]-acetic acid ethyl ester	(DMSO-d₆; Main Isomer): δ = 1.22-1.28 (m, 6H); 2.24 (s, 3H);	372.449	INT124/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	2.38 (s, 3H); 4.18-4.24 (m, 4H); 6.67 (s, 1H); 6.77 (s, 1H), 8.73 (m, 1H); 10.82 (s, 1H) ppm.		
114	 Cyano-[3-ethyl-5-[1-(4-methylpyridin-2-ylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d ₆ ; Main Isomer): $\delta =$ 1.23-1.26 (2t, 6H); 2.29 (s, 3H); 4.18-4.24 (2q, 4H); 6.65 (d, 1H); 6.89-6.91 (dd, 1H); 8.14 (d, 1H); 8.73 (s, 1H); 10.86 (3, H) ppm.	358.422	INT124/ INT132



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
115	 Cyano-[3-ethyl-5-[1-(6-methylpyridin-2-yl-amino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d₆; Main Isomer): δ = 1.23-1.26 (2t, 6H); 2.41 (s, 3H); 4.17-4.22 (2q, 4H); 6.83 (d, 1H); 6.89 (d, 1H); 7.59 (t, 1H); 8.71 (1H); 10.86 (s, 1H) ppm:	358.422	INT124/ INT132
116	 [5-[1-(3-Chloro-4-fluorophenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	(DMSO-d₆; Main Isomer): δ = 1.22-1.27 (m, 6H); 4.21-4.24 (m, 4H); 7.32 (m, 1H);	395.842	INT124/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ylidene]-cyano-acetic acid ethyl ester	7.37 (m, 1H); 7.58-7.60 (m, 1H); 8.18 (s, 1H); 10.45 (s, 1H) ppm.		
117	 [5-[1-(3-Chloro-4-fluoro-phenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid allyl ester	(DMSO-d₆; Main Isomer, Selection): δ = 1.22-1.25 (m, 6H); 4.21-4.24 (m, 4H); 7.28-7.38 (m, 2H); 7.56-7.58 (m, 1H); 8.16-8.18 (m, 1H); 10.45 (s, 1H) ppm.	407.854	INT126/ INT132
118	 Cyano-[3-ethyl-5-[1-(2-methyl-	(DMSO-d₆; Main Isomer): δ = 1.22-1.28 (2t, 6H);	408.482	INT124/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	quinolin-6-ylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid ethyl ester	2.61 (s, 3H); 4.18-4.24 (2q, 4H); 7.33 (d, 1H); 7.63 (dd, 1H); 7.74 (m, 1H); 7.82 (d, 1H); 8.11 (d, 1H); 8.26 (s, 1H); 10.64 (s, 1H) ppm.		
119	 Cyano-[3-ethyl-5-[1-(2-methyl-quinolin-6-ylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester	(DMSO-d ₆ ; Main Isomer, Selection): δ = 1.25 (t, 3H); 2.60 (s, 3H); 4.22 (q, 2H); 7.33 (d, 1H); 7.61-7.64 (dd, 1H);	420.493	INT126/ INT132

Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.75 (d, 1H); 7.82 (d, 1H); 8.11 (d, 1H); 8.27 (1H); 10.66 (s, 1H) ppm.		
120	 Cyano-[3-ethyl-5-[1-(2-methyl-quinolin-5-ylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z)-ylidene)-acetic acid ethyl ester	(DMSO-d ₆ ; Main Isomer): δ = 1.21-1.26 (m, 6H); 2.66 (s, 3H); 4.17-4.24 (m, 4H); 7.38 (d, 1H); 7.46 (d, 1H); 7.66-7.68 (m, 1H); 7.74 (d, 1H); 8.05 (s, 1H); 8.44 (d, 1H);	408.482	INT124/ INT132


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.65 (s, 1H) ppm.		
121	 Cyano-[3-ethyl-5-[1-(2-methyl-quinolin-5-ylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z)-ylidene)]-acetic acid allyl ester	(DMSO-d₆; Main Isomer, Selection): δ = 1.24 (t, 3H); 2.66 (s, 3H); 4.22 (q, 2H); 7.40 (d, 2H); 7.47 (d, 1H); 7.66-7.70 (m, 1H); 7.75-7.78 (m, 1H); 8.08 (s, 1H); 8.46 (d, 1H); 10.69 (s, 1H) ppm.	420.482	INT126/ INT132


Example No.	Structure and Name	¹ H-NMR	Molecular Weight/MS (ESI) [M+1] ⁺	Educt/Synthesis as in the Case of
122	 [5-[1-(3-Acetyl-phenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-cyano-acetic acid ethyl ester	¹ H-NMR (CDCl ₃ , 400 MHz) (selected peaks) δ = 1.30 (m, 6H); 2.59 (s, 3H); 4.28 (m, 2H); 4.39 (m, 2H); 7.21 (m, 1H); 7.46 (m, 1H); 7.62 (m, 2H); 10.57 (d, 1H).	MW: 385.442 MS (ESI) [M+1] ⁺ : 386	INT12 4/INT1 32
123		¹ H-NMR (CDCl ₃ , 400 MHz) (selected peaks) δ = 1.46	MW: 397.453 MS	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
	[5-[1-(3-Acetyl-phenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-cyano-acetic acid allyl ester	(m, 3H); 2.68 (s, 3H); 4.47 (m, 2H); 4.79 (m, 2H); 5.31 (dd, 1H); 5.42 (d, 1H); 6.02 (m, 1H); 7.32 (m, 1H); 7.53 (m, 1H); 7.74 (m, 2H); 8.25 (d, 1H); 10.70 (d, 1H).	(ESI) [M+1] ⁺ : 398	
124		¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.22 (m, 3H); 2.19 (s,	MW: 519.644 MS (ESI)	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
	Cyano-[5-[1-{4-[(2-dimethylamino-ethyl)-methyl-sulfamoyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid allyl ester	6H); 2.42 (m, 2H); 2.71 (s, 3H); 3.03 (m, 2H); 4.28 (m, 2H); 4.72 (d, 2H); 5.28 (dd, 1H); 5.40 (dd, 1H); 6.00 (m, 1H); 7.51 (d, 2H); 7.73 (d, 2H); 8.28 (s, 1H); 10.70 (s, 1H).	[M+1] ⁺ : 520	
125		¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.24	MW: 505.617 MS	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
	Cyano-[5-[1-[3-(2-dimethylamino-ethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid allyl ester	(m, 3H); 2.10 (s, 6H); 2.30 (m, 2H); 2.88 (m, 2H); 4.25 (m, 2H); 4.71 (d, 2H); 5.28 (dd, 1H); 5.40 (dd, 1H); 6.00 (m, 1H); 7.49 (dd, 1H); 7.60 (m, 3H); 7.75 (s, 1H); 8.29 (s, 1H); 10.71 (s, 1H).	(ESI) [M+1] ⁺ : 506	


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
126	 Cyano-[5-[1-[4-(2-dimethylamino-ethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid allyl ester	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.22 (m, 3H); 2.10 (s, 6H); 2.29 (m, 2H); 2.80 (m, 2H); 4.26 (m, 2H); 4.71 (d, 2H); 5.29 (dd, 1H); 6.00 (m, 1H); 7.48 (s, 1H); 7.49 (d, 2H); 7.74 (d, 2H); 8.30 (s, 1H); 10.70 (s, 1H).	MW: 505.617 MS (ESI) [M+1] ⁺ : 506	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
127	 Cyano-[5-[1-{3-[(2-dimethylamino-ethyl)-methyl-sulfamoyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid allyl ester	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.24 (m, 3H); 2.19 (s, 6H); 2.42 (m, 2H); 2.72 (s, 3H); 3.09 (m, 2H); 4.27 (m, 2H); 4.72 (d, 2H); 5.28 (dd, 1H); 5.39 (dd, 1H); 6.00 (m, 1H); 7.45 (d, 1H); 7.61 (m, 1H); 7.69 (m, 2H); 8.31 (s,	MW: 519.644 MS (ESI) [M+1] ⁺ : 520	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
		1H); 10.62 (s, 1H).		
128	 Cyano-[5-[1-[3-(2-diethylamino-ethylcarbamoyl)-1H-indol-5-ylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid allyl ester	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 0.97 (m, 6H); 1.26 (m, 3H); 4.25 (m, 2H); 4.71 (d, 2H); 5.28 (dd, 1H); 5.38 (dd, 1H); 6.0 (m, 1H); 7.27 (dd, 1H); 7.42 (d, 1H); 7.38 (m, 1H); 8.0 (d, 1H); 8.07 (d, 1H); 8.21 (s,	MW: 536.654 MS (ESI) [M+1] ⁺ : 537	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
		1H); 10.77 (s, 1H); 11.59 (s, 1H).		
129	 Cyano-[5-[1-{3-[(2-dimethylamino-ethyl)-methyl-carbamoyl]-1H-indol-5-ylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid allyl ester	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.28 (m, 3H); 2.15 (s, 6H); 3.11 (s, 3H); 3.59 (m, 2H); 4.26 (m, 2H); 4.72 (d, 2H); 3.27 (dd, 1H); 3.39 (dd, 1H); 6.0 (m, 1H); 7.19 (dd, 1H); 7.42 (d, 1H);	MW: 522.627 MS (ESI) [M+1] ⁺ : 523	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
		7.72 (s, 1H); 7.76 (d, 1H); 8.18 (s, 1H); 10.70 (s, 1H); 11.60 (s, 1H).		
130	 Cyano-[5-[1-[3-(2-dimethylamino-ethylcarbamoyl)-1H-indol-6-ylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid allyl ester	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26 (m, 3H); 2.21 (s, 6H); 2.40 (m, 2H); 4.28 (m, 2H); 4.70 (d, 2H); 5.28 (dd, 1H); 5.40 (dd, 1H); 6.0 (m, 1H); 7.11 (dd, 1H);	MW: 508.600 MS (ESI) [M+1] ⁺ : 509	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
		7.35 (s, 1H); 7.80 (m, 1H); 7.98 (d, 1H); 8.08 (d, 1H); 8.25 (s, 1H); 10.63 (s, 1H); 11.50 (s, 1H).		
131	 6-[[2-[1-Allyloxycarbonyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino]-1H-indazole-3-carboxylic acid methyl ester	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.28 (m, 3H); 3.91 (s, 3H); 4.22 (m, 2H); 4.71 (d, 2H); 5.29 (dd, 1H); 5.40 (dd, 1H); 5.97 (m,	MW: 453.477 MS (ESI) [M+1] ⁺ : 454	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
		1H); 7.32 (dd, 1H); 7.50 (s, 1H); 8.00 (d, 1H); 8.30 (s, 1H); 10.73 (s, 1H).		
132	 [5-[1-(4-Acetyl-phenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-cyano-acetic acid ethyl ester	¹ H-NMR (CDCl ₃ , 400 MHz) (selected peaks) δ = 1.30 (m, 6H); 2.55 (s, 3H); 4.25 (m, 2H); 4.38 (m, 2H); 7.05 (d, 2H); 7.58 (d, 1H); 7.95 (d,	MW: 385.442 MS (ESI) [M+1] ⁺ : 386	INT12 4/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
		2H); 10.60 (d, 1H).		
133	 [5-[1-(4-Acetyl-phenylamino)-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-cyano-acetic acid allyl ester	¹ H-NMR (CDCl ₃ , 400 MHz) (selected peaks) δ = 1.32 (m, 3H); 2.52 (s, 3H); 4.38 (m, 2H); 4.70 (m, 2H); 5.22 (dd, 1H); 5.36 (dd, 1H); 5.90 (m, 1H); 7.08 (d, 2H); 7.60 (d, 1H); 7.92 (d, 2H); 10.61 (d, 1H).	MW: 397.453 MS (ESI) [M+1] ⁺ : 340	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
134	 Cyano-[5-[1-{3-[(2-dimethylamino-ethyl)-methyl-carbamoyl]-1H-indol-5-ylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid ethyl ester	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26 (m, 6H); 2.18 (s, 6H); 3.11 (s, 3H); 3.49 (m, 2H); 4.25 (m, 4H); 7.20 (dd, 1H); 7.42 (d, 1H); 7.71 (s, 1H); 7.78 (d, 1H); 8.16 (s, 1H); 10.70 (s, 1H); 11.60 (s, 1H).	MW: 510.616 MS (ESI) [M+1] ⁺ : 511	INT12 4/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
135	 Cyano-[5-[1-[4-(2-dimethylamino-ethoxy)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid allyl ester	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.23 (m, 3H); 2.21 (s, 6H); 2.62 (m, 2H); 4.03 (m, 2H); 4.23 (m, 2H); 4.71 (d, 2H); 5.27 (dd, 1H); 5.39 (dd, 1H); 5.98 (m, 1H); 6.95 (d, 2H); 7.26 (d, 2H); 8.12 (s, 1H); 10.50 (s, 1H).	MW: 442.537 MS (ESI) [M+1] ⁺ : 443	INT12 6/INT1 32

Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
136	 Cyano-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2Z or E)-ylidene]-acetic acid prop-2-ynyl ester	¹ H-NMR (CDCl ₃ , 300 MHz) (selected peaks) δ = 1.42 (m, 3H); 2.51 (m, 1H); 4.45 (m, 2H); 4.88 (d, 2H); 7.09 (m, 2H); 7.20 (m, 1H); 7.40 (m, 2H); 7.66 (d, 1H); 10.61 (d, 1H).	MW: 353.40 MS (ESI) [M+1] ⁺ : 354	INT13 8

Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
137	 Cyano-[5-[1-[3-(2,2-dimethylpropionylamino)-4-(2-pyrrolidin-1-ylethylcarbamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid allyl ester	¹ H-NMR (CDCl ₃ , 300 MHz) (selected peaks) δ = 1.32 (m, 9H); 1.41 (m, 9H); 1.80 (m, 4H); 2.53 (m, 4H); 2.71 (m, 2H); 3.49 (m, 2H); 4.40 (m, 2H); 4.72 (m, 2H); 5.25 (dd, 1H); 5.38 (dd, 1H); 5.95 (m, 1H); 6.69 (dd, 1H); 7.02 (m, 1H);	MW: 594.733 MS (ESI) [M+1] ⁺ : 595	INT12 6/INT1 32


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
		7.50 (d, 1H); 7.70 (s, 1H); 8.70 (s, 1H); 10.60 (s, 1H); 11.97 (s, 1H).		
138	 Cyano-[5-[1-[3-(2,2-dimethylpropionylamino)-4-(2-pyrrolidin-1-ylethylcarbamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid ethyl ester	¹ H-NMR (CDCl ₃ , 300 MHz) (selected peaks) δ = 1.36 (m, 15H); 1.79 (m, 4H); 2.56 (m, 4H); 2.71 (m, 2H); 3.50 (m, 2H); 4.29 (m, 2H); 4.39 (m, 2H); 6.68 (dd, 1H);	MW: 582.722 MS (ESI) [M+1] ⁺ : 583	INT12 4/INT1 32

Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
		7.06 (m, 1H); 7.48 (d, 1H); 7.68 (s, 1H); 8.70 (d, 1H); 10.56 (s, 1H); 11.97 (s, 1H).		
139	 Cyano-[5-[1-[3-(2,2-dimethyl-propionylamino)-5-(2-pyrrolidin-1-yl-ethylcarbamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid ethyl ester	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 15H); 1.70 (m, 4H); 2.60 (m, 2H); 3.39 (m, 2H); 4.26 (m, 4H); 7.44 (s, 1H); 7.74 (s, 1H); 7.98 (s,	MW: 582.722 MS (ESI) [M+1] ⁺ : 583	INT12 4/INT1 32

Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
		1H); 8.28 (s, 1H); 8.52 (m, 1H); 9.42 (s, 1H); 10.71 (s, 1H).		
140	 Cyano-[5-[1-[3-(2,2-dimethyl-propionylamino)-5-(2-pyrrolidin-1-ylethylcarbamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid allyl ester	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.22 (m, 15H); 1.70 (m, 4H); 2.61 (m, 2H); 3.40 (m, 2H); 4.28 (m, 2H); 4.71 (d, 2H); 5.27 (dd, 1H); 5.39 (dd, 1H);	MW: 594.733 MS (ESI) [M+1] ⁺ : 595	INT12 6/INT1 32

Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthe- sis as in the Case of
		6.00 (m, 1H); 7.42 (s, 1H); 7.77 (s, 1H); 7.97 (s, 1H); 8.28 (s, 1H); 8.52 (m, 1H); 9.42 (s, 1H); 10.76 (s, 1H).		

Example 141[5-[1-[Acetyl-(6-amino-pyridin-3-yl)-amino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid ethyl ester




420 mg of the compound that is described under **Example 82**) and 0.13 ml of triethylamine are dissolved in 5 ml of dichloromethane. 0.02 ml of acetic anhydride is added, and it is stirred for 2 hours at room temperature. The reaction mixture is mixed with dichloromethane and washed three times with semi-saturated sodium bicarbonate solution. The organic phase is dried on sodium sulfate. After purification by chromatography on silica gel, 340 mg of the title compound is obtained.

(DMSO-d₆, stored with K₂CO₃, main isomer): δ = 1.12-1.28 (t, 3H); 2.01 (s, 3H); 4.09-4.27 (m, 4H); 6.51-6.64 (m, 3H); 7.46 (dd, 1H); 7.98 (d, 1H); 8.55 (s, 1H) ppm.

The examples below describe the production of compounds according to the invention without the latter being limited to these examples. These compounds can also be used as intermediate substances in the production of substances of general formula (I) according to the invention.

Example 142

(E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid




2.05 g of potassium-(tert)-butylate is introduced into 50 ml of tetrahydrofuran at 0°C and mixed with 76.4 µl of water. 1.0 g of the compound that is described under Example **INT131**) is added and stirred for 30 minutes at 0°C, and for 20 hours at room temperature. At 0°C, 8.25 ml of 2-molar hydrochloric acid in diethyl ether is added, and it is stirred for one hour at room temperature. The solvent is condensed under high vacuum, and the residue is further reacted without additional purification.

Molar mass = 412.514; MS (ESI): [M+1]⁺ = 413.

Example 143



(E or Z)-Cyano-(3-ethyl-5-(E/Z-({4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene)-acetic acid








4.4 g of the compound that is described under Example 3), 0.91 g of Pd(PPh₃)₄ and 6.9 ml of morpholine are stirred in 150 ml of tetrahydrofuran for 15 minutes. After 45 ml of triethylamine is added, the reaction mixture that is obtained is evaporated to the dry state in a rotary evaporator. The thus obtained crude product is purified by chromatography with a dichloromethane/methanol mixture on silica gel. 3.5 g of the title compound is obtained as a pH-dependent 5-(E/Z)-isomer mixture.



¹H-NMR (DMSO-d₆, main isomer): δ = 1.20 (3H); 2.19 (3H); 2.23-2.55 (10H) 2.61 (2H); 4.20 (2H); 7.18 (2H); 7.52 (2H); 7.87 (1H); ppm.


The compounds below are produced analogously to the above-described process.



Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Educt	Syn-thesis as in the Case of
144	 Cyano-[3-ethyl-4-oxo-5-[1-[4-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid	455.54	456	46	143
145	 Cyano-[3-ethyl-4-oxo-5-[1-{4-[3-(2-pyrrolidin-1-yl-ethyl)-ureido]-phenylamino}-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid	470.55	471	47	143



Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Educt	Synthesis as in the Case of
148	 Cyano-[5-[1-{4-[3-(2-diethylaminoethylcarbamoyl)-propyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid	499.637	500	52	143
149	 Cyano-[3-ethyl-4-oxo-5-[1-[6-(2-pyrrolidin-1-yl-ethylcarbamoyl)-naphthalen-2-ylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid	505.60	506	53	143



Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Educt	Syn-thesis as in the Case of
150	 Cyano-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propylcarbamoyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid	469.57	470	INT13 4	142
151	 Cyano-[5-[1-[3-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid	414.49	415	INT13 5	142
152		456.57	457	INT13 6	142



Example No.	Structure	Molecular Weight	MS (ESI) [M+1] ⁺	Educt	Syn-thesis as in the Case of
	Cyano-[3-ethyl-5-[1-{4-[2-(4-hydroxymethyl-piperidin-1-yl)-ethyl]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid				
153	 Cyano-[3-ethyl-5-[1-{4-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid	441.56	442	INT13 7	142
154	 Cyano-[3-ethyl-5-[1-(3-nitro-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid	360.351	361	8	142



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
155	 [5-[1-[3-Chloro-5-(2,2-dimethylpropionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-cyano-acetic acid	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.12-1.29 (m, 12H); 4.21 (q, 2H); 7.00 (s, 1H); 7.52 (s, 1H); 7.61 (s, 1H); 7.89 (s, 1H); 9.37 (s, 1H); 10.18 (s, 1H); 11.5-12.5 (b, 1H) ppm.	MW: 448.93 MS (ESI) [M+1]⁺: 449	77/ 143

Exam- ple No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis As in the Case of
156	 Cyano-[5-[1-{4-[(2-dimethylamino-ethyl)-methyl-sulfamoyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid	MW: 534.659 MS (ESI) [M+1]⁺: 535	124/ 143
157	 Cyano-[5-[1-[4-(2-dimethylamino-ethoxy)-phenylamino]-meth-(E/ Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid	MW: 402.472 MS (ESI) [M+1]⁺: 403	135/ 143

Exam- ple No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis As in the Case of
158	 Cyano-[5-[1-{3-[(2-dimethylamino-ethyl)-methyl-carbamoyl]-1H-indol-5-ylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid	MW: 482.562 MS (ESI) [M+1]⁺: 483	129/ 143
159	 Cyano-[5-[1-[3-(2-diethylamino-ethylcarbamoyl)-1H-indol-5-ylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid	MW: 496.59 MS (ESI) [M+1]⁺: 497	128/143

Exam- ple No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis As in the Case of
160	 Cyano-[5-[1-[3-(2-dimethylamino-ethylcarbamoyl)-1H-indol-6-ylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid	MW: 468.535 MS (ESI) [M+1]⁺: 469	130/ 143
161	 Cyano-[5-[1-[3-(2,2-dimethyl-propionylamino)-4-(2-pyrrolidin-1-yl-ethylcarbamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid	MW: 554.668 MS (ESI) [M+1]⁺: 555	137/ 143


Exam- ple No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis As in the Case of
162	 Cyano-[5-[1-[3-(2,2-dimethylpropionylamino)-5-(2-pyrrolidin-1-ylethylcarbamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid	MW: 554.668 MS (ESI) [M+1] ⁺ : 555	140/ 143
163	 Cyano-[5-[1-[4-(2-dimethylaminoethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid	MW: 465.552 MS (ESI) [M+1] ⁺ : 466	126/143

Exam- ple No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis As in the Case of
164	 Cyano-[5-[1-{3-[(2-dimethylamino-ethyl)-methyl-sulfamoyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid	MW: 534.659 MS (ESI) [M+1]⁺: 535	127/143
165	 Cyano-[5-[1-[3-(2-dimethylamino-ethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetic acid	MW: 520.632 MS (ESI) [M+1]⁺: 521	125/143

The examples below describe the production of the compounds of general formula (I) according to the invention, without the latter being limited to these examples.

Example 166

2-(E or Z)-Cyano-N-ethyl-2-(3-ethyl-4-oxo-5-(E/Z)-{[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetamide




275 mg of the crude product that is described under Example **142**) (about 0.2 mmol) is dissolved in 10 ml of dimethylformamide, mixed with 139 μ l of triethylamine, 150 μ l of a 2M solution of ethylamine in tetrahydrofuran and 96 mg of TBTU and stirred for 20 hours at room temperature. The reaction mixture is mixed with semi-saturated sodium bicarbonate solution and extracted with dichloromethane. The organic solution is washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, and after purification by chromatography on silica gel, 51 mg of the title compound is obtained as a pH-dependent 5-(E/Z)-isomer mixture.

¹H-NMR (DMSO-d₆, stored with K₂CO₃, main isomer): δ = 1.07 (t, 3H); 1.23 (t, 3H); 1.65 (m, 4H); 2.45 (m, 4H); 2.54-2.62 (m, 2H); 2.62-2.75 (m, 2H); 3.20 (pentuplet, 2H); 4.21 (q, 2H); 7.20 (s, 4H); 7.67 (t, 1H); 8.04 (s, 1H); 10.23 (s, 1H) ppm.

Example 167

2-(E or Z)-{5-(E/Z)-[(3-Amino-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-2-cyano-N-ethyl-acetamide




100 mg of the compound that is described under Example **215**) is dissolved in 20 ml of ethanol, mixed with 291 mg of tin(II) chloride dihydrate and stirred under reflux for 4 hours. Another 145 mg of tin(II) chloride dihydrate is added, and it is stirred under reflux for another 2 hours. The reaction mixture is mixed with saturated sodium bicarbonate solution, stirred for 30 minutes at room temperature, and extracted with a mixture that consists of chloroform, dichloromethane, and methanol (5:5:1). The organic solution is dried on sodium sulfate, concentrated by evaporation, and after purification by chromatography on amino phase silica gel, 50 mg of the title compound is obtained as a pH-dependent 5-(E/Z)-isomer mixture.

¹H-NMR (DMSO-d₆, stored with K₂CO₃, main isomer): δ= 1.07 (t, 3H); 1.26 (t, 3H); 3.21 (q, 2H); 4.22 (q, 2H); 5.23 (s, 2H); 6.29 (d, 1H); 6.39 (d, 1H); 6.45 (s, 1H); 6.97 (t, 1H); 7.68 (t, 1H); 7.95 (d, 1H); 10.18 (d, 1H) ppm.

Example 168



2-(E or Z)-Cyano-N-ethyl-2-[3-ethyl-5-(E/Z)-({3-[2-(2-methoxy-ethoxy)-acetyl-amino]-phenyl-amino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetamide





16.5 μ l of 2-(2-methoxyethoxy)-acetic acid is introduced into 1 ml of tetrahydrofuran at 0°C and mixed with 37 μ l of triethylamine and 18.5 μ l of isobutyl chloroformate. It is stirred for 30 minutes at 0°C, 50 mg of the compound that is described under Example 167), dissolved in 2 ml of tetrahydrofuran, is added, and it is stirred for another 2 hours at room temperature. The reaction mixture is mixed with semi-saturated sodium bicarbonate solution and extracted with dichloromethane. The organic solution is washed with saturated sodium chloride solution, dried on sodium sulfate, concentrated by evaporation, and after purification by chromatography on silica gel, 35 mg of the title compound is obtained as a pH-dependent 5-(E/Z)-isomer mixture.



¹H-NMR (DMSO-d₆, stored with K₂CO₃, main isomer): δ = 1.08 (t, 3H); 1.25 (t, 3H); 3.12-3.25 (m, 2H); 3.30 (s, 3H); 3.54 (t, 2H); 3.68 (t, 2H); 4.09 (s, 2H); 4.22 (q, 2H); 6.97 (s, 1H); 7.20-7.30 (m, 2H); 7.55-7.77 (m, 2H); 8.04 (s, 1H); 9.68 (s, 1H); 10.39 (s, 1H) ppm.


The examples below are produced analogously to the above-described process.


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
169	 3-{[2-((E or Z)-Cyano-ethylcarbamoyl-methylene)-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-(E/Z)-ylidenemethyl]-amino}-N-(3-pyrrolidin-1-yl-propyl)-benzamide	1.07 (t, 3H); 1.27 (t, 3H); 1.67-1.87 (m, 6H); 2.61-2.87 (m, 6H); 3.11-3.31 (m, 4H); 4.23 (q, 2H); 7.16-7.31 (m, 1H); 7.38-7.58 (m, 2H); 7.69-7.71 (m, 2H); 8.19 (s, 1H); 8.68 (s, 1H); 10.42 (s, 1H) ppm.	MW: 496.63 MS (ESI) [M+1]⁺: 497	150/ 166
170		1.25 (t, 3H); 1.58-1.77 (m, 6H); 1.77-1.95 (m, 4H);	MW: 522.671	150/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	3-{{2-[1-(E or Z)-Cyano-2-oxo-2-pyrrolidin-1-yl-ethylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl]-amino}-N-(3-pyrrolidin-1-yl-propyl)-benzamide	2.34-2.48 (m, 6H); 3.19-3.35 (m, 2H); 3.44-3.61 (m, 4H); 4.21 (q, 2H); 7.31-7.52 (m, 3H); 7.69 (s, 1H); 8.20 (s, 1H); 8.61 (t, 1H); 10.36 (s, 1H) ppm.	MS (ESI) [M+1] ⁺ : 523	
171	 3-({2-[1-(E or Z)-Cyano-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-N-(3-pyrrolidin-1-yl-propyl)-benzamide	1.24 (t, 3H); 1.59-1.80 (m, 6H); 1.80-2.03 (m, 4H); 2.30-2.46 (m, 6H); 3.19-3.30 (m, 2H); 3.38-3.49 (m, 1H); 3.49-3.69 (m, 3H); 4.05-4.32 (m, 3H);	MW: 552.696 MS (ESI) [M+1] ⁺ : 553	150/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		4.79 (t, 1H); 7.31-7.55 (m, 3H); 7.71 (s, 1H); 8.20 (s, 1H); 8.62 (t, 1H); 10.32 (s, 1H) ppm.		
172	 3-({2-[(E or Z)-Cyano-(2-hydroxyethyl)carbamoyl]-methylene}-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-N-(3-pyrrolidin-1-yl-propyl)-benzamide	1.27 (t, 3H); 1.58-1.77 (m, 6H); 2.32-2.47 (m, 6H); 3.18-3.32 (m, 4H); 3.48 (q, 2H); 4.24 (q, 2H); 4.75 (t, 1H); 7.34-7.56 (m, 4H); 7.73 (s, 1H); 8.19 (s, 1H); 8.62 (t, 1H);	MW: 512.632 MS (ESI) [M+1] ⁺ : 513	150/166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.40 (s, 1H) ppm.		
173	 3-((2-((E or Z)-Cyano-(N',N'-dimethyl-hydrazinocarbonyl)-methylene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-N-(3-pyrrolidin-1-yl-propyl)-benzamide	1.26 (t, 3H); 1.62-1.77 (m, 6H); 2.38-2.47 (m, 6H); 2.52 (s, 6H); 3.23-3.36 (m, 2H); 4.23 (q, 2H); 7.35-7.42 (m, 2H); 7.50 (m, 1H); 7.71 (s, 1H); 8.20 (s, 1H); 8.58-8.66 (m, 2H); 10.47 (s, b, 1H) ppm.	MW: 511.648 MS (ESI) [M+1]⁺: 512	150/ 166
174	 3-((2-((E or Z)-Cyano-(1-	1.24 (t, 3H); 1.40-1.80 (m, 12H); 1.91 (m, 2H); 2.33-2.48 (m, 6H);	MW: 566.723 MS	150/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	hydroxymethyl- cyclopentylcarbamoyl)-methylene]-3- ethyl-4-oxo-thiazolidin-5-(E/Z)- ylidenemethyl}-amino)-N-(3- pyrrolidin-1-yl-propyl)-benzamide	3.24-3.38 (m, 2H); 3.42 (s, 2H); 4.24 (q, 2H); 5.11 (s, 1H); 6.71 (s, 1H); 7.31-7.42 (m, 2H); 7.49 (m, 1H); 7.70 (s, 1H); 8.20 (s, 1H); 8.61 (t, 1H); 10.35 (s, b, 1H) ppm.	(ESI) [M+1] ⁺ : 567	
175	 3-({2-[(E or Z)-Cyano-(2-hydroxy- 1,1-dimethyl-ethylcarbamoyl)- methylene]-3-ethyl-4-oxo-thiazolidin-	1.25 (t, 3H); 1.30 (s, 6H); 1.60-1.78 (m, 6H); 2.36-2.48 (m, 6H); 3.21-3.45 (m, 4H); 4.21 (q, 2H);	MW: 540.685 MS (ESI) [M+1] ⁺ :	150/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	5-(E/Z)-ylidenemethyl}-amino)-N-(3-pyrrolidin-1-yl-propyl)-benzamide	5.20 (s, 1H); 6.68 (s, 1H); 7.33-7.42 (m, 2H); 7.50 (m, 1H); 7.72 (s, 1H); 8.20 (s, 1H); 8.61 (t, 1H); 10.37 (s, b, 1H) ppm.	541	
176	 3-({2-[(E or Z)-(1-Benzyl-2-hydroxy-ethylcarbamoyl)-cyano-methylene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-N-(3-pyrrolidin-1-yl-propyl)-benzamide	1.25 (t, 3H); 1.60-1.78 (m, 6H); 2.35-2.50 (m, 6H); 2.74-2.92 (m, 2H); 3.20-3.51 (m, 4H); 4.05 (m, 1H); 4.23 (q, 2H); 4.94 (s, 1H); 7.05-7.34 (m, 6H);	MW: 602.756 MS (ESI) [M+1] ⁺ : 603	150/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.34-7.45 (m, 2H); 7.49 (m, 1H); 7.72 (s, 1H); 8.19 (s, 1H); 8.61 (s, 1H); 10.35 (s, b, 1H) ppm.		
177	 3-({2-[(E or Z)-Cyano-(2-hydroxy-1-phenyl-ethylcarbamoyl)-methylene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-N-(3-pyrrolidin-1-yl-propyl)-benzamide	1.26 (t, 3H); 1.60-1.77 (m, 6H); 2.35-2.48 (m, 6H); 3.21-3.40 (m, 2H); 3.62-3.79 (m, 2H); 4.23 (q, 2H); 4.89 (q, 1H); 5.06 (s, 1H); 7.18-7.43 (m, 8H); 7.49 (m, 1H); 7.71 (s, 1H);	MW: 588.729 MS (EI) [M+1] ⁺ : 589	150/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		8.19 (s, 1H); 8.60 (s, 1H); 10.35 (s, b, 1H) ppm.		
178	 2-[2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-{[3-(3-pyrrolidin-1-yl-propylcarbamoyl)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetyl-amino]-3-hydroxy-propionic acid methyl ester	1.26 (t, 3H); 1.60-1.79 (m, 6H); 2.35-2.48 (m, 6H); 3.19-3.48 (m, 2H); 3.68 (s, 3H); 3.70-3.89 (m, 2H); 4.27 (q, 2H); 4.45 (m, 1H); 5.26 (s, 1H); 7.32-7.46 (m, 3H); 7.50 (m, 1H); 7.72 (s, 1H); 8.22 (s, 1H); 8.61 (t, 1H);	MW: 570.668 MS (ESI) [M+1] ⁺ : 571	150/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.49 (s, 1H) ppm.		
179	 3-({2-[(E or Z)-Cyano-(1-hydroxymethyl-3-methylsulfanyl-propylcarbamoyl)-methylene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-N-(3-pyrrolidin-1-yl-propyl)-benzamide	1.25 (t, 3H); 1.60-1.90 (m, 8H); 2.04 (s, 3H); 2.32-2.48 (m, 8H); 3.20-3.51 (m, 4H); 3.98 (m, 1H); 4.25 (q, 2H); 4.85 (s, 1H); 7.14 (d, 1H); 7.33-7.46 (m, 2H); 7.50 (m, 1H); 7.71 (s, 1H); 8.20 (s, 1H); 8.62 (t, 1H); 10.32 (s, b, 1H) ppm.	MW: 586.778 MS (ESI) [M+1]⁺: 587	150/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
180	 3-({2-[(E or Z)-Cyano-(1-hydroxymethyl-butylcarbamoyl)-methylene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-N-(3-pyrrolidin-1-yl-propyl)-benzamide	0.89 (t, 3H); 1.18-1.39 (m, 5H); 1.39-1.60 (m, 2H); 1.60-1.79 (m, 6H); 2.35-2.48 (m, 6H); 3.20-3.50 (m, 4H); 3.80-3.94 (m, 1H); 4.23 (q, 2H); 4.79 (s, 1H); 6.99 (d, 1H); 7.31-7.45 (m, 2H); 7.49 (d, 1H); 7.70 (s, 1H); 8.20 (s, 1H); 8.61 (s, 1H); 10.39 (s, b. 1H) ppm.	MW: 554.712 MS (ESI) [M+1]⁺: 555	150/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
181	 3-([2-((E or Z)-Cyano-prop-2-ynylcarbamoyl-methylene)-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl]-amino)-N-(3-pyrrolidin-1-yl-propyl)-benzamide	1.25 (t, 3H); 1.62-1.75 (m, 6H); 2.38-2.49 (m, 6H); 3.07 (t, 1H); 3.22-3.35 (m, 2H); 3.92 (m, 2H); 4.23 (q, 2H); 7.36-7.44 (m, 2H); 7.50 (m, 1H); 7.72 (s, 1H); 8.09 (t, 1H); 8.21 (s, 1H); 8.62 (t, 1H); 10.46 (s, b, 1H) ppm.	MW: 506.628 MS (ESI) [M+1]⁺: 507	150/ 166
182		1.15-1.31 (m, 12H); 1.31-1.45 (m, 2H); 1.72-1.85 (m, 2H);	MW: 497.617	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	N-[3-({2-[1-(E or Z)-Cyano-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-phenyl]-2,2-dimethyl-propionamide	3.14-3.28 (m, 2H); 3.68-3.80 (m, 1H); 3.80-3.93 (m, 2H); 4.10-4.27 (m, 2H); 4.80 (d, 1H); 6.90 (d, 1H); 7.23 (t, 1H); 7.35 (d, 1H); 7.69 (s, 1H); 8.04 (s, 1H); 9.23 (s, 1H); 10.20 (s, 1H) ppm.	MS (ESI) [M+1] ⁺ : 498	
183	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-	1.12-1.30 (m, 15H); 3.21 (pent., 2H); 4.24 (q, 2H); 6.93 (d, 1H); 7.23 (t, 1H);	MW: 441.553 MS (ESI)	151/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-ethyl-acetamide	7.35 (d, 1H); 7.63-7.75 (m, 2H); 8.00 (d, 1H); 9.23 (s, 1H); 10.38 (d, 1H) ppm.	[M+1] ⁺ : 442	
184	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-methyl-acetamide	1.16-1.29 (m, 12H); 2.72 (d, 3H); 4.23 (q, 2H); 6.92 (d, 1H); 7.23 (t, 1H); 7.35 (d, 1H); 7.61 (s, 1H); 7.70 (s, 1H); 8.01 (s, 1H); 9.23 (s, 1H); 10.40 (s, 1H) ppm.	MW: 427.526 MS (ESI) [M+1] ⁺ : 428	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
185	 N-[3-({2-[1-(E or Z)-Cyano-2-(2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-phenyl]-2,2-dimethyl-propionamide	1.15-1.32 (m, 12H); 1.65-2.03 (m, 4H); 3.35-3.48 (m, 1H); 3.50-3.70 (m, 3H); 4.05-4.32 (m, 3H); 4.79 (t, 1H); 6.91 (d, 1H); 7.23 (t, 1H); 7.35 (d, 1H); 7.69 (s, 1H); 8.02 (s, 1H); 9.23 (s, 1H); 10.32 (s, 1H) ppm.	MW: 497.617 MS (EESI) [M+1] ⁺ : 498	151/ 166
186	 N-[3-({2-[1-(E or Z)-Cyano-2-(2-hydroxymethyl-piperidin-1-yl)-2-oxo-ethylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-phenyl]-2,2-dimethyl-propionamide	1.10-1.30 (m, 13H); 1.31-1.73 (m, 4H); 1.73-1.89 (m, 1H); 2.87-3.05 (m, 1H);	MW: 511.644 MS	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	hydroxymethyl-piperidin-1-yl)-2-oxo-ethylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-ylidenemethyl}-amino)-phenyl]-2,2-dimethyl-propionamide	3.45-3.65 (m, 2H); 3.89-4.01 (m, 1H); 4.10-4.35 (m, 3H); 4.75 (t, 1H); 6.90 (d, 1H); 7.22 (t, 1H); 7.34 (d, 1H); 7.70 (s, 1H); 8.00 (s, 1H); 9.23 (s, 1H); 10.20 (s, 1H) ppm.	(ESI) [M+1] ⁺ : 512	
187	 N-(3-([2-(1-(E or Z)-Cyano-2-oxo-2-pyrrolidin-1-yl-ethylidene)-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-	1.15-1.29 (m, 12H); 1.83 (m, 4H); 3.49 (m, 4H); 4.21 (q, 2H); 6.80 (d, 1H); 7.17 (t, 1H);	MW: 467.591 MS (ESI) [M+1] ⁺ :	151/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ylidenemethyl]-amino}-phenyl)-2,2- dimethyl-propionamide	7.31 (d, 1H); 7.50 (s, 1H); 8.14 (s, 1H); 9.13 (s, 1H); 10.34 (s, 1H) ppm.	468	
188	 N-[3-({2-[(E or Z)-Cyano-(N',N'- dimethyl-hydrazinocarbonyl)- methylene]-3-ethyl-4-oxo-thiazolidin- 5-(E/Z)-ylidenemethyl}-amino)- phenyl]-2,2-dimethyl-propionamide	1.17-1.28 (m, 12H); 2.54 (s, 6H); 4.23 (q, 2H); 6.91 (d, 1H); 7.22 (t, 1H); 7.36 (d, 1H); 7.68 (s, 1H); 8.02 (s, 1H); 8.58 (s, 1H); 9.22 (s, 1H); 10.40 (s, 1H) ppm.	MW: 456.568 MS (ESI) [M+1] ⁺ : 457	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
189	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-(1-hydroxymethyl-3-methylsulfanyl-propyl)-acetamide	1.15-1.30 (m, 12H); 1.65-1.91 (m, 2H); 2.05 (s, 3H); 2.40-2.52 (m, 2H); 3.38-3.55 (m, 2H); 3.90-4.05 (m, 1H); 4.23 (q, 2H); 4.84 (t, 1H); 6.91 (d,b, 1H); 7.09 (s, b, 1H); 7.23 (t, 1H); 7.35 (d, 1H); 7.69 (s, 1H); 8.04 (s, 1H); 9.21 (s, 1H); 10.39 (s, b, 1H) ppm.	MW: 531.699 MS (ESI) [M+1]⁺: 532	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
190	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N,N-dimethyl-acetamide	1.15-1.32 (m, 12H); 3.01 (s, 6H); 4.20 (q, 2H); 6.90 (d, 1H); 7.22 (t, 1H); 7.35 (d, 1H); 7.69 (s, 1H); 8.02 (s, 1H); 9.22 (s, 1H); 10.29 (s, 1H) ppm.	MW: 441.553 MS (ESI) [M+1] ⁺ : 442	151/166
191	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-(2-hydroxyethyl)-acetamide	1.16-1.30 (m, 12H); 3.28 (q, 2H); 3.48 (q, 2H); 4.24 (q, 2H); 4.75 (t, 1H); 6.91 (d, 1H); 7.21 (t, 1H);	MW: 457.552 MS (ESI) [M+1] ⁺ : 458	151/166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	hydroxy-ethyl)-acetamide	7.34 (d, 1H); 7.40 (s, 1H); 7.68 (s, 1H); 8.03 (s, 1H); 9.21 (s, 1H); 10.48 (s, 1H) ppm.		
192	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-(1-hydroxymethyl-cyclopentyl)-acetamide	1.17-1.30 (m, 12H); 1.44-1.59 (m, 2H); 1.59-1.84 (m, 4H); 1.84-2.00 (m, 2H); 3.42 (d, 2H); 4.21 (q, 2H); 5.10 (t, 1H); 6.70 (s, 1H); 6.91 (d, 1H); 7.22 (t, 1H); 7.35 (d, 1H);	MW: 511.644 MS (ESI) [M+1] ⁺ : 512	151/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.69 (s, 1H); 8.04 (s, 1H); 9.21 (s, 1H); 10.38 (s, 1H) ppm.		
193	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-(2-hydroxy-1,1-dimethyl-ethyl)-acetamide	1.17-1.28 (m, 12H); 1.30 (s, 6H); 3.38 (d, 2H); 4.20 (q, 2H); 5.19 (t, 1H); 6.68 (s, 1H); 6.94 (d, 1H); 7.23 (t, 1H); 7.37 (d, 1H); 7.70 (s, 1H); 8.01 (d, 1H); 9.23 (s, 1H); 10.38 (d, 1H) ppm.	MW: 485.606 MS (ESI) [M+1] ⁺ : 486	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
194	 N-(1-Benzyl-2-hydroxy-ethyl)-2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-acetamide	1.13-1.30 (m, 12H); 2.72-2.93 (m, 2H); 3.44 (m, 2H); 3.98-4.08 (m, 1H); 4.21 (q, 2H); 4.94 (t, 1H); 6.93 (d, 1H); 7.08-7.39 (m, 8H); 7.70 (s, 1H); 8.02 (s, 1H); 9.23 (s, 1H); 10.40 (s, 1H) ppm.	MW: 547.677 MS (EESI) [M+1] ⁺ : 548	151/ 166
195	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-acetamide	1.19-1.32 (m, 12H); 3.71 (m, 2H); 4.24 (q, 2H); 4.90 (q, 1H); 5.05 (t, 1H);	MW: 533.65 MS (EESI)	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	dimethyl-propionylamino)- phenylamino]-methylene}-3-ethyl-4- oxo-thiazolidin-2-ylidene)-N-(2- hydroxy-1-phenyl-ethyl)-acetamide	6.91 (d, 1H); 7.17-7.27 (m, 2H); 7.27-7.40 (m, 5H); 7.69 (s, 2H); 8.00 (s, 1H); 9.21 (s, 1H); 10.36 (s, 1H) ppm.	[M+1] ⁺ : 534	
196	 2-[2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-acetyl-amino]-3-hydroxy-propionic acid methyl ester	1.19-1.31 (m, 12H); 3.67 (s, 3H); 3.69-3.88 (m, 2H); 4.25 (q, 2H); 4.43 (m, 1H); 5.25 (t, 1H); 6.93 (d, 1H); 7.23 (t, 1H); 7.30-7.41 (m, 2H); 7.71 (s, 1H);	MW: 515.588 MS (ESI) [M+1] ⁺ : 516	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		8.07 (s, 1H); 9.24 (s, 1H); 10.48 (s, 1H) ppm.		
197	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-(1-hydroxymethyl-butyl)-acetamide	0.89 (t, 3H); 1.15-1.35 (m, 14H); 1.40-1.55 (m, 2H); 3.35-3.50 (m, 2H); 3.87 (m, 1H); 4.24 (q, 2H); 4.78 (t, 1H); 6.95 (d, 1H); 6.99 (d, 1H); 7.25 (t, 1H); 7.36 (d, 1H); 7.70 (s, 1H); 8.01 (d, 1H); 9.24 (s, 1H);	MW: 499.633 MS (EI) [M+1] ⁺ : 500	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.38 (d, 1H) ppm.		
198	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-(1-hydroxymethyl-3-methyl-butyl)-acetamide	0.83-0.94 (m, 6H); 1.18-1.65 (m, 15H); 3.41 (m, 2H); 3.97 (m, 1H); 4.21 (q, 2H); 4.78 (t, 1H); 6.54 (d, 1H); 7.00 (d, 1H); 7.23 (t, 1H); 7.35 (d, 1H); 7.71 (s, 1H); 8.00 (d, 1H); 9.24 (s, 1H); 10.39 (d, 1H) ppm.	MW: 513.659 MS (EI) [M+1] ⁺ : 514	151/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
199	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-(1-hydroxymethyl-2,2-dimethyl-propyl)-acetamide	0.91 (s, 9H); 1.20-1.32 (m, 12H); 3.58 (t, 2H); 3.73 (m, 1H); 4.25 (q, 2H); 4.68 (t, 1H); 6.75 (d, 1H); 6.95 (d, 1H); 7.24 (t, 1H); 7.36 (d, 1H); 7.72 (s, 1H); 8.02 (d, 1H); 9.24 (s, 1H); 10.40 (d, 1H) ppm.	MW: 513.659 MS (ESI) [M+1]⁺: 514	151/ 166
200		0.85 (d, 3H); 0.90 (d, 3H); 1.17-1.30 (m, 12H);	MW: 499.633	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-(1-hydroxymethyl-2-methyl-propyl)-acetamide	1.90 (octet, 1H); 3.41-3.60 (m, 2H); 3.68 (m, 1H); 4.23 (q, 2H); 4.75 (t, 1H); 6.88 (d, 1H); 6.94 (d, 1H); 7.25 (t, 1H); 7.37 (d, 1H); 7.72 (d, 1H); 8.02 (d, 1H); 9.24 (s, 1H); 10.40 (d, 1H) ppm.	MS (ESI) [M+1] ⁺ : 500	
201	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-	0.85 (t, 3H); 1.20-1.31 (m, 12H); 1.40-1.68 (m, 2H); 3.45 (m, 2H);	MW: 485.606 MS	151/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	dimethyl-propionylamino)- phenylamino]-methylene}-3-ethyl-4- oxo-thiazolidin-2-ylidene)-N-(1- hydroxymethyl-propyl)-acetamide	3.76 (m, 1H); 4.23 (q, 2H); 4.28 (t, 1H); 6.94 (d, 1H); 7.00 (d, 1H); 7.24 (t, 1H); 7.36 (d, 1H); 7.72 (s, 1H); 8.02 (d, 1H); 9.24 (s, 1H); 10.38 (d, 1H) ppm.	(ESI) [M+1] ⁺ : 486	
202	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2- dimethyl-propionylamino)- phenylamino]-methylene}-3-ethyl-4-	1.11 (d, 2H); 1.19-1.30 (m, 12H); 3.41 (m, 2H); 3.91 (m, 1H); 4.23 (q, 2H); 4.83 (t, 1H);	MW: 471.579 MS (ESI) [M+1] ⁺ :	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	oxo-thiazolidin-2-ylidene)-N-(2-hydroxy-1-methyl-ethyl)-acetamide	6.94 (d, 1H); 7.06 (d, 1H); 7.24 (t, 1H); 7.36 (d, 1H); 7.71 (s, 1H); 8.02 (d, 1H); 9.25 (s, 1H); 10.40 (d, 1H) ppm.	472	
203	 2-(E or Z)-Cyano-2-(5-(E/Z)-{[3-(2,2-dimethyl-propionylamino)-phenylamino]-methylene}-3-ethyl-4-oxo-thiazolidin-2-ylidene)-N-prop-2-ynyl-acetamide	1.15-1.29 (m, 12H); 3.05 (t, 1H); 3.91 (m, 2H); 4.23 (q, 2H); 6.90 (d, 1H); 7.21 (t, 1H); 7.34 (d, 1H); 7.63 (s, 1H); 7.98 (s, 1H);	MW: 451.548 MS (ESI) [M+1] ⁺ : 452	151/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		8.09 (s, 1H); 9.20 (s, 1H); 10.45 (s, 1H) ppm.		
204	 [2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-{[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetylamino]-acetic acid ethyl ester	1.12-1.30 (m, 6H); 1.65 (m, 4H); 2.39-2.48 (m, 2H); 2.52-2.61 (m, 2H); 2.61-2.72 (m, 2H); 3.88 (d, 2H); 4.11 (q, 2H); 4.22 (q, 2H); 6.96-7.19 (m, 4H); 7.69 (s, b, 1H); 8.15 (s, 1H); 10.30 (s, b, 1H) ppm.	MW: 497.617 MS (ESI) [M+1] ⁺ : 498	142/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
205	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-{[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-methylene}-thiazolidin-2-ylidene)-N-(2-hydroxy-ethyl)-acetamide	1.21 (t, 3H); 1.68 (m, 4H); 2.35-2.49 (m, 2H); 2.54-2.62 (m, 2H); 2.62-2.72 (m, 2H); 3.24 (q, 2H); 3.45 (q, 2H); 4.20 (q, 2H); 4.74 (t, 1H); 7.06-7.19 (m, 3H); 7.86-7.06 (m, 2H); 8.20 (s, 1H); 10.30 (s, 1H) ppm.	MW: 455.58 MS (ESI) [M+1]⁺: 456	142/ 166
206	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-{[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-methylene}-thiazolidin-2-ylidene)-N-(2-ethynyl-ethyl)-acetamide	1.25 (t, 3H); 1.66 (m, 4H); 2.38-2.48 (m, 4H); 2.54-2.61 (m, 2H);	MW: 449.576 MS	142/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	(E/Z)-{[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-methylene}-thiazolidin-2-ylidene)-N-prop-2-ynyl-acetamide	2.61-2.76 (m, 2H); 3.07 (t, 1H); 3.93 (m, 2H); 4.24 (q, 2H); 7.10-7.28 (m, 4H); 8.40 (s, 1H); 8.90 (s, 1H); 10.31 (s, 1H) ppm.	(ESI) [M+1] ⁺ : 450	
207	 2-(E or Z)-Cyano-2-[3-ethyl-5-(E/Z)-({4-[2-(4-hydroxymethyl)-piperidin-1-yl]-ethyl}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene]-N-prop-2-ynyl-acetamide	1.00-1.45 (m, 6H); 1.57-1.73 (m, 2H); 1.88-2.12 (m, 2H); 2.38-2.55 (m, 2H); 2.62-2.78 (m, 2H); 2.89-3.05 (m, 2H); 3.06 (t, 1H); 3.24 (t, 2H); 3.90 (m, 2H);	MW: 493.629 MS (ESI) [M+1] ⁺ : 494	152/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		4.24 (q, 2H); 4.44 (m, 1H); 7.10-7.30 (m, 5H); 8.09 (t, 1H); 10.32 (d, 1H) ppm.		
208	 2-(E or Z)-(3-Ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-3-(4-methyl-piperazin-1-yl)-3-oxo-propionitrile	1.25 (t, 3H); 2.20 (s, 3H); 2.35 (m, 4H); 3.55 (m, 4H); 4.20 (q, 2H); 7.17 (t, 1H); 7.24-7.40 (m, 4H); 8.10 (s, 1H); 10.20 (s, 1H) ppm.	MW: 397.501 MS (ESI) [M+1] ⁺ : 398	INT13 8/166
209		1.24 (t, 3H); 1.50 (m, 2H); 1.78 (m, 2H);	MW: 425.511	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	1-[2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-acetyl]-piperidine-4-carboxylic acid amide	2.40 (t, 1H); 2.97 (t, 2H); 4.05-4.29 (m, 4H); 6.81 (s, 1H); 7.05 (t, 1H); 7.20-7.40 (m, 5H); 8.10 (s, 1H); 10.15 (s, 1H) ppm.	MS (ESI) [M+1] ⁺ : 426	
210	 2-(E or Z)-(3-Ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-3-oxo-3-pyrrolidin-1-yl-propionitrile	1.27 (t, 3H); 1.87 (m, b, 4H); 3.51 (m, b, 4H); 4.23 (q, 2H); 7.05 (t, 1H); 7.25-7.39 (m, 4H); 8.20 (s, 1H); 10.23 (s, 1H) ppm.	MW: 368.459 MS (ESI) [M+1] ⁺ : 369	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
211	 2-(E or Z)-(3-Ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-3-(2-hydroxymethyl-piperidin-1-yl)-3-oxo-propionitrile	1.15-1.90 (m, 8H); 2.85-3.05 (m, 1H); 3.24-3.40 (m, 1H); 3.56 (m, 2H); 3.95 (d, 1H); 4.18 (q, 2H); 4.30 (s, b, 1H); 4.74 (t, 1H); 7.05 (t, 1H); 7.20-7.38 (m, 4H); 8.18 (s, 1H); 10.20 (s, 1H) ppm.	MW: 412.512 MS (ESI) [M+1] ⁺ : 413	INT13 8/166
212	 disclosed, but not claimed 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-	1.25 (t, 3H); 3.02 (s, 6H); 4.20 (q, 2H); 7.06 (t, 1H); 7.23-7.40 (m, 4H);	MW: 342.421 MS (ESI)	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	(E/Z)-phenylaminomethylene- thiazolidin-2-ylidene)-N,N-dimethyl- acetamide	8.09 (d, 1H); 10.18 (d, 1H) ppm.	[M+1] ⁺ : 343	
213	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5- (E/Z)-phenylaminomethylene- thiazolidin-2-ylidene)-N-methyl- acetamide	1.26 (t, 3H); 2.71 (d, 3H); 4.21 (q, 2H); 7.06 (t, 1H); 7.23-7.39 (m, 4H); 7.63 (q, 1H); 8.08 (s, 1H); 10.30 (s, 1H) ppm.	MW: 328.394 MS (ESI) [M+1] ⁺ : 329	INT13 8/166
214	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5- (E/Z)-phenylaminomethylene- thiazolidin-2-ylidene)-N-isopropyl-	1.15 (d, 6H); 1.25 (t, 3H); 3.99 (octet, 1H); 4.22 (q, 2H); 7.05 (t, 1H); 7.23-7.40 (m, 4H);	MW: 356.448 MS (ESI) [M+1] ⁺ :	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	acetamide	8.09 (d, 1H); 10.28 (d, 1H) ppm.	357	
215	 2-(E or Z)-Cyano-N-ethyl-2-{3-ethyl-5-(E/Z)-[(3-nitro-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetamide	1.08 (t, 3H); 1.25 (t, 3H); 3.24 (q, 2H); 4.24 (q, 2H); 7.61 (t, 1H); 7.71-7.81 (m, 2H); 7.86 (d, 1H); 8.10 (s, 1H); 8.20 (s, 1H); 10.50 (s, 1H) ppm.	MW: 387.420 MS (EI) [M+1] ⁺ : 388	89/166
216	 (2-(E or Z)-Cyano-2-{3-ethyl-5-(E/Z)-[(3-nitro-phenylamino)-methylene]-4-	1.22 (t, 3H); 1.28 (t, 3H); 3.90 (d, 2H); 4.14 (q, 2H); 4.25 (q, 2H);	MW: 445.454 MS (EI)	89/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	oxo-thiazolidin-2-ylidene}- acetylamino)-acetic acid ethyl ester	7.60 (t, 1H); 7.79 (d, 1H); 7.86 (d, 1H); 8.01-8.15 (m, 2H); 8.23 (s, 1H); 10.55 (s, 1H) ppm.	[M+1] ⁺ : 446	
217	 2-(E or Z)-Cyano-N-cyanomethyl-2- (3-ethyl-4-oxo-5-(E/Z)- phenylaminomethylene-thiazolidin-2- ylidene)-acetamide	1.25 (t, 3H); 4.16 (d, 2H); 4.23 (q, 2H); 7.08 (t, 1H); 7.18-7.43 (m, 4H); 8.17 (s, 1H); 8.30 (s, 1H); 10.40 (s, 1H) ppm.	MW: 353.405 MS (ESI) [M+1] ⁺ : 354	INT13 8/166
218		1.27 (m, 3H), 3.45 (m, 1H), 3.53 (m, 1H), 4.21 (m, 2H),	MW: 360.411	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-N-(2-fluoro-ethyl)-acetamide	4.40 (m, 1H), 4.53 (m, 1H), 7.05 (m, 1H), 7.30 (m, 4H), 7.70 (s, 1H), 8.10 (s, 1H), 10.31 (s, 1H).	MS (ESI) [M+1] ⁺ : 361	
219	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)- N-phenethyl-acetamide	1.22 (m, 3H), 2.78 (m, 2H), 3.32 (m, 2H), 4.20 (m, 2H), 7.00 (m, 1H), 7.20 (m, 4H), 7.31 (m, 5H), 7.97 (s, 1H), 8.12 (s, 1H), 10.30 (s, 1H).	MW: 418.519 MS (ESI) [M+1] ⁺ : 419	INT13 8/166
220	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)- N-phenethyl-acetamide	0.89 (m, 3H), 1.28 (m, 5H), 1.46 (m, 2H), 3.19 (m, 2H), 4.21 (m, 2H), 7.08	MW: 370.475 MS	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	N-Butyl-2-(E or Z)-cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-acetamide	(m, 1H), 7.32 (m, 4H), 7.63 (m, 1H), 8.08 (m, 1H), 10.27 (d, 1H).	(ESI) [M+1] ⁺ : 371	
221	 N-Biphenyl-4-ylmethyl-2-(E or Z)-cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-acetamide	1.25 (m, 3H), 4.26 (m, 2H), 4.39 (d, 2H), 7.06 (m, 1H), 7.45 (m, 8H), 7.61 (m, 5H), 8.10 (d, 1H), 8.32 (m, 1H), 10.30 (d, 1H).	MW: 480.59 MS (ESI) [M+1] ⁺ : 481	INT13 8/166
222	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-acetamide	1.25 (m, 3H), 4.20 (m, 2H), 4.50 (m, 2H), 6.96 (m, 2H), 7.08 (m, 1H), 7.35 (m, 4H), 7.97 (s, 1H).	MW: 410.52 MS (ESI)	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)- N-thiophen-2-ylmethyl-acetamide	8.10 (s, 1H), 8.33 (m, 1H), 10.31 (s, 1H).	[M+1] ⁺ : 411	
223	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)- N-furan-2-ylmethyl-acetamide	1.25 (m, 3H), 4.20 (m, 2H), 4.35 (m, 2H), 6.21 (m, 1H), 6.40 (m, 1H), 7.08 (m, 1H), 7.31 (m, 4H), 7.55 (s, 1H), 8.13 (m, 2H), 10.31 (s, 1H).	MW: 394.453 MS (ESI) [M+1] ⁺ : 395	INT13 8/166
224	 2-(E or Z)-Cyano-N-cyclopropyl-2-(3-ethyl-4-oxo-5-(E/Z)-	0.60 (m, 4H), 1.21 (m, 3H), 3.30 (m, 1H), 4.20 (m, 2H), 7.07 (m, 1H), 7.30 (m, 4H), 7.65 (m, 1H), 8.08 (s, 1H),	MW: 354.432 MS (ESI) [M+1] ⁺ :	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	phenylaminomethylene-thiazolidin-2-ylidene)-acetamide	10.30 (s, 1H).	355	
225	 2-(3-Ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-(E or Z)-ylidene)-3-oxo-3-(4-phenyl-piperazin-1-yl)-propionitrile	1.25 (m, 3H), 3.71 (m, 4H), 4.22 (m, 2H), 6.81 (m, 1H), 6.97 (m, 2H), 7.07 (m, 1H), 7.30 (m, 6H), 8.11 (d, 1H), 10.21 (d, 1H).	MW: 459.572 MS (ESI) [M+1] ⁺ : 460	INT13 8/166
226	 N-Biphenyl-2-ylmethyl-2-(E or Z)-cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-3-oxo-3-(4-phenyl-piperazin-1-yl)-propionitrile	1.23 (m, 3H), 4.21 (m, 2H), 4.31 (d, 2H), 7.05 (m, 1H), 7.19 (m, 1H), 7.35 (m, 12H), 8.08 (d, 1H), 8.16 (m, 1H), 10.29 (d, 1H).	MW: 480.59 MS (ESI) [M+1] ⁺ : 481	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ylidene)-acetamide			
227	 N-Biphenyl-3-ylmethyl-2-(E or Z)- cyano-2-(3-ethyl-4-oxo-5-(E/Z)- phenylaminomethylene-thiazolidin-2- ylidene)-acetamide	1.23 (m, 3H), 4.20 (m, 2H), 4.42 (d, 2H), 7.06 (m, 1H), 7.35 (m, 13H), 8.08 (d, 1H), 8.36 (m, 1H), 10.28 (d, 1H).	MW: 480.59 MS (ESI) [M+1]⁺: 481	INT13 8/166
228	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5- (E/Z)-phenylaminomethylene- thiazolidin-2-ylidene)- N-methyl-N- prop-2-ynyl-acetamide	1.26 (m, 3H), 3.28 (m, 1H), 4.21 (m, 4H), 7.06 (m, 1H), 7.31 (m, 4H), 8.10 (d, 1H), 10.26 (d, 1H).	MW: 366.443 MS (ESI) [M+1]⁺: 367	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
229	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-N-(3-phenyl-prop-2-ynyl)-acetamide	1.25 (m, 3H), 4.21 (m, 4H), 7.08 (m, 1H), 7.49 (m, 9H), 8.10 (d, 1H), 8.20 (m, 1H), 10.38 (d, 1H).	MW: 428.514 MS (ESI) [M+1] ⁺ : 429	INT13 8/166
230	 N-tert-Butyl-2-(E or Z)-cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-acetamide	1.22 (m, 3H), 1.36 (s, 9H), 4.22 (m, 2H), 6.11 (s, 1H), 7.08 (m, 1H), 7.32 (m, 4H), 8.11 (d, 1H), 10.27 (d, 1H).	MW: 370.475 MS (ESI) [M+1] ⁺ : 371	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
231	 (E or Z)-N-But-2-ynyl-2-cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)- N-methyl-acetamide	1.36 (m, 3H), 1.81 (m, 3H), 3.20 (s, 3H), 4.35 (m, 2H), 7.03 (m, 3H), 7.36 (m, 2H), 8.08 (d, 1H), 10.47 (d, 1H).	MW: 380.47 MS (ESI) [M+1] ⁺ : 381	INT13 8/166
232	 1-[2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-acetyl]-aziridine-2-carboxylic acid methyl ester	1.23 (m, 3H), 2.52 (d, 1H), 2.71 (d, 1H), 3.40 (m, 1H), 3.70 (s, 3H), 4.25 (m, 2H), 7.10 (m, 1H), 7.38 (m, 4H), 8.22 (s, 1H), 10.61 (s, 1H).	MW: 398.441 MS (ESI) [M+1] ⁺ : 399	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
233	 3-(E or Z)-Azetidin-1-yl-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-3-oxo-propionitrile	1.25 (m, 3H), 2.22 (m, 2H), 4.21 (m, 6H), 7.06 (m, 1H), 7.31 (m, 4H), 8.10 (s, 1H), 10.37 (s, 1H).	MW: 354.432 MS (ESI) [M+1] ⁺ : 355	INT13 8/166
234	 N-Butyl-2-(E or Z)-cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)- N-methyl-acetamide	0.91 (m, 3H), 1.22 (m, 5H), 1.54 (m, 2H), 3.00 (s, 3H), 3.41 (m, 2H), 4.20 (m, 2H), 7.08 (m, 1H), 7.31 (m, 4H), 8.07 (d, 1H), 10.16 (d, 1H).	MW: 384.502 MS (ESI) [M+1] ⁺ : 385	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
235	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)- N-methyl-N-phenethyl-acetamide	1.21 (m, 3H), 2.88 (m, 2H), 3.03 (s, 3H), 3.61 (m, 2H), 4.19 (m, 2H), 7.08 (m, 1H), 7.20 (m, 1H), 7.35 (m, 8H), 8.07 (s, 1H), 10.10 (s, 1H).	MW: 432.546 MS (ESI) [M+1]⁺: 433	INT13 8/166
236	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)- N-(2,2,2-trifluorethyl)-acetamide	1.28 (m, 3H), 3.95 (m, 2H), 4.22 (m, 2H), 7.09 (m, 1H), 7.33 (m, 4H), 7.96 (s, 1H), 8.12 (d, 1H), 10.39 (d, 1H).	MW: 396.392 MS (ESI) [M+1]⁺: 397	INT13 8/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
237	 2-(E or Z)-Cyano-2-(3-ethyl-4-oxo-5-(E/Z)-phenylaminomethylene-thiazolidin-2-ylidene)-N-prop-2-ynyl-acetamide	1.26 (m, 3H), 3.08 (m, 1H), 3.92 (m, 2H), 4.20 (m, 2H), 7.08 (m, 1H), 7.31 (m, 4H), 8.10 (m, 2H), 10.35 (d, 1H).	MW: 352.42 MS (ESI) [M+1] ⁺ : 353	INT13 8/166
238			MW: 528.67 MS (ESI) [M+1] ⁺ : 529	153/166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
239			MW: 510.66 MS (ESI) [M+1] ⁺ : 511	153/ 166
240			MW: 494.66 MS (ESI) [M+1] ⁺ : 495	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
241			MW: 493.63 MS (ESI) [M+1] ⁺ : 494	153/ 166
242	 (E or Z)-2-Cyano-N-cyclopropyl-2-[3-ethyl-5-(E/Z)-({4-[2-(4-methylpiperazin-1-yl)-ethyl]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetamide		MW: 480.63 MS (ESI) [M+1] ⁺ : 481	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
243			MW: 494.66 MS (ESI) [M+1] ⁺ : 495	153/ 166
244			MW: 522.71 MS (ESI) [M+1] ⁺ : 523	153/ 166




Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
245			MW: 496.68 MS (ESI) [M+1] ⁺ : 497	153/ 166
246			MW: 548.68 MS (ESI) [M+1] ⁺ : 549	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
247			MW: 560.72 MS (ESI) [M+1] ⁺ : 561	153/ 166
248			MW: 496.68 MS (ESI) [M+1] ⁺ : 497	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
249	 (E or Z)-2-Cyano-N-cyclopropylmethyl-2-[3-ethyl-5-(E/Z)-({4-[2-(4-methyl-piperazin-1-yl)-ethyl]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetamide		MW: 494.66 MS (ESI) [M+1] ⁺ : 495	153/ 166
250			MW: 562.71 MS (ESI) [M+1] ⁺ : 563	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
251	 (E or Z)-2-Cyano-2-[3-ethyl-5-(E/Z)- ({4-[2-(4-methyl-piperazin-1-yl)- ethyl]-phenylamino}-methylene)-4- oxo-thiazolidin-2-ylidene]-N- (2,2,3,3,3-pentafluoro-propyl)- acetamide		MW: 572.60 MS (ESI) [M+1] ⁺ : 573	153/ 166
252			MW: 494.66 MS (ESI) [M+1] ⁺ : 495	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
253			MW: 531.68 MS (ESI) [M+1] ⁺ : 532	153/ 166
254			MW: 512.68 MS (ESI) [M+1] ⁺ : 513	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
255			MW: 510.70 MS (ESI) [M+1] ⁺ : 511	153/ 166
256			MW: 560.72 MS (ESI) [M+1] ⁺ : 561	153/ 166
257			MW: 553.77	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
			MS (ESI) [M+1] ⁺ : 554	
258			MW: 514.72 MS (ESI) [M+1] ⁺ : 515	153/ 166
259			MW: 565.78 MS (ESI) [M+1] ⁺ :	153/ 166




Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
			566	
260			MW: 537.73 MS (ESI) [M+1] ⁺ : 538	153/ 166
261			MW: 526.70 MS (ESI) [M+1] ⁺ : 527	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
262			MW: 526.70 MS (ESI) [M+1] ⁺ : 527	153/ 166
263			MW: 545.71 MS (ESI) [M+1] ⁺ : 546	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
264			MW: 482.65 MS (ESI) [M+1] ⁺ : 483	153/ 166
265			MW: 494.66 MS (ESI) [M+1] ⁺ : 495	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
266			MW: 496.68 MS (ESI) [M+1] ⁺ : 497	153/ 166
267			MW: 496.68 MS (ESI) [M+1] ⁺ : 497	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
268			MW: 498.65 MS (ESI) [M+1] ⁺ : 499	153/ 166
269			MW: 498.65 MS (ESI) [M+1] ⁺ : 499	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
270			MW: 510.70 MS (ESI) [M+1] ⁺ : 511	153/ 166
271			MW: 510.70 MS (ESI) [M+1] ⁺ : 511	153/ 166
272			MW: 510.70	153/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
			MS (ESI) [M+1] ⁺ : 511	
273			MW: 525.72 MS (ESI) [M+1] ⁺ : 526	153/ 166
274			MW: 525.72 MS (ESI) [M+1] ⁺ :	153/ 166




Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
			526	
275			MW: 526.70 MS (ESI) [M+1] ⁺ : 527	153/ 166
276			MW: 531.68 MS (ESI) [M+1] ⁺ : 532	153/ 166

Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
277			MW: 532.67 MS (ESI) [M+1] ⁺ : 533	153/ 166
278			MW: 558.75 MS (ESI) [M+1] ⁺ : 559	153/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
279			MW: 558.75 MS (ESI) [M+1] ⁺ : 559	153/ 166
280			MW: 561.75 MS (ESI) [M+1] ⁺ : 562	153/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
281			MW: 562.71 MS (ESI) [M+1] ⁺ : 563	153/ 166
282			MW: 570.76 MS (ESI) [M+1] ⁺ : 571	153/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
283			MW: 480.63 MS (ESI) [M+1] ⁺ : 481	153/ 166
284			MW: 550.724 MS (ESI) [M+1] ⁺ : 551	150/ 166

Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
285			MW: 524.686 MS (ESI) [M+1] ⁺ : 525	150/ 166
286			MW: 550.603 MS (ESI) [M+1] ⁺ : 551	150/ 166
287		(DMSO-d6, Stored with K ₂ CO ₃ , Main Isomer):	MW: 482.61	146/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide	$\delta =$ 1.08 (t, 3H); 1.24 (t, 3H); 1.70 (m, 4H); 2.39-2.60 (m, 6H); 2.73 (t, 2H); 3.20 (pentuplet, 2H); 4.23 (q, 2H); 6.96 (d, 1H); 7.16 (d, 1H); 7.25 (t, 1H); 7.65-7.77 (m, 2H); 7.99 (d, 1H); 10.14 (s, 1H); 10.39 (d, 1H) ppm.	MS (ESI) [M+1] ⁺ : 483	



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
288	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-((S)-1-hydroxymethyl-propyl)-acetamide	(CDCl₃, Stored with K₂CO₃, Main Isomer): δ = 1.00 (t, 3H); 1.27 (t, 3H); 1.47-1.73 (m, 2H); 1.81 (m, 4H); 2.57 (m, 2H); 2.67 (m, 2H); 2.80 (m, 2H); 3.60-3.79 (m, 2H); 3.97 (m, 1H); 4.38 (q, 2H); 6.22 (d, 1H); 7.00 (d, 2H); 7.21 (d, 2H);	MW: 483.63 MS (ESI) [M+1]⁺: 484	142/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.54 (d, 1H); 10.47 (d, 1H) ppm.		
289	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-((S)-2-hydroxy-1-methyl-ethyl)-acetamide	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.11 (d, 3H); 1.25 (t, 3H); 1.68 (m, 4H); 2.47 (m, 4H); 2.59 (m, 2H); 2.70 (m, 2H); 3.41 (m, 1H); 3.91 (m, 1H); 4.21 (q, 2H); 4.83 (t, 1H); 7.03 (d, 1H);	MW: 469.61 MS (ESI) [M+1]⁺: 470	142/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.13-7.24 (m, 4H); 8.08 (s, 1H); 10.28 (s, 1H) ppm.		
290	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-((S)-1-hydroxymethyl-2-methyl-propyl)-acetamide	(CDCl₃, Stored with K₂CO₃, Main Isomer): δ = 0.90-1.03 (m, 6H); 1.40 (t, 3H); 1.80 (m, 4H); 1.96 (m, 1H); 2.57 (m, 4H); 2.67 (m, 2H); 2.80 (m, 2H); 3.63-3.90 (m, 3H); 4.38 (q, 2H); 6.30 (d, 2H);	MW: 497.67 MS (ESI) [M+1]⁺: 498	142/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		6.99 (d, 2H); 7.20 (d, 2H); 7.52 (d, 1H); 10.47 (d, 1H) ppm.		



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
291	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(2-hydroxy-1,1-dimethyl-ethyl)-acetamide	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.22 (t, 3H); 1.29 (s, 6H); 1.68 (m, 4H); 2.45 (m, 4H); 2.58 (m, 2H); 2.69 (m, 2H); 3.38 (d, 2H); 4.20 (q, 2H); 5.20 (t, 1H); 6.66 (s, 1H); 7.15-7.25 (m, 4H); 8.08 (s, 1H); 10.25 (s, 1H) ppm.	MW: 483.63 MS (ESI) [M+1]⁺: 484	142/166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
292	 N-((1S,2S)-2-Amino-cyclohexyl)-2-cyano-2-[5-[1-[3-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide	(DMSO-d6, Stored with K₂CO₃, Main Isomer): δ = 1.07-1.32 (m, 16H); 1.63 (s, b, 2H); 1.84 (d, 2H); 2.59-2.75 (m, 1H); 3.35 (m, b, 3H); 4.22 (q, 2H); 6.90 (d, 1H); 7.04-7.28 (m, 2H); 7.34 (d, 1H); 7.67 (d, 1H); 8.03 (s, 1H); 9.21 (s, 1H) ppm.	MW: 510.66 MS (ESI) [M+1]⁺: 511	151/ 166
293		(DMSO-d6, Stored with K₂CO₃, Main Isomer):	MW: 545.66	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	2-Cyano-2-[5-[1-[3-(2,2-dimethyl- propionylamino)-phenylamino]-meth- (E/Z)-ylidene]-3-ethyl-4-oxo- thiazolidin-(2-(E or Z))-ylidene]-N- ((1S,2R)-2-hydroxy-indan-1-yl)- acetamide	$\delta =$ 1.24 (s, 9H); 1.28 (t, 3H); 2.85 (d, 1H); 3.13 (dd, 1H); 4.25 (q, 2H); 4.50 (m, 1H); 5.27 (m, 1H); 5.56 (d, 1H); 6.94 (d, 1H); 7.15-7.30 (m, 6H); 7.36 (d, 1H); 7.72 (s, 1H); 8.08 (s, 1H); 9.23 (s, 1H); 10.50 (s, 1H) ppm.	MS (ESI) [M+1] ⁺ : 546	
294		(DMSO-d ₆ , Stored with K ₂ CO ₃ , Main Isomer):	MW: 413.50	151/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	2-Cyano-2-[5-[1-[3-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetamide	$\delta =$ 1.10-1.30 (m, 12H); 4.24 (q, 2H); 6.94 (d, 1H); 7.10-7.41 (m, 4H); 7.71 (s, 1H); 8.01 (d, 1H); 9.23 (s, 1H); 10.41 (d, 1H) ppm.	MS (ESI) [M+1] ⁺ : 414	
295	 2-[5-[1-[3-Chloro-5-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-(2-hydroxy-1,1-dimethylethyl)-acetamide	(DMSO-d ₆ , Stored with K ₂ CO ₃ , Main Isomer): $\delta =$ 1.13-1.28 (m, 12H); 1.30 (s, 6H); 3.36 (d, 2H); 4.20 (q, 2H); 5.16 (s, b, 1H); 6.35-6.70 (s, b, 1H);	MW: 520.05 MS (ESI) [M+1] ⁺ : 521	155/ 166

Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		6.70-6.98 (s, b, 1H); 7.48 (s, 2H); 8.13 (s, 1H); 9.27 (s, 1H); 10.37 (s, 1H) ppm.		
296	 2-[5-[1-[3-Chloro-5-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-ethyl-acetamide	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.06 (t, 3H); 1.15-1.32 (m, 12H); 3.21 (pentuplet, 2H); 4.23 (q, 2H); 7.01 (s, 1H); 7.51 (s, 1H); 7.64 (s, 1H); 7.72 (s, 1H); 7.99 (s, 1H); 9.35 (s, 1H);	MW: 476.00 MS (ESI) [M+1]⁺: 477	155/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		10.36 (s, 1H) ppm.		
297	 2-[5-[1-[3-Chloro-5-(2,2-dimethylpropionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-prop-2-ynyl-acetamide	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.14-1.32 (m, 12H); 3.06 (s, b, 1H); 3.94 (m, 2H); 4.23 (q, 2H); 7.03 (s, 1H); 7.52 (s, 1H); 7.65 (s, 1H); 8.03 (s, 1H); 8.12 (s, 1H); 9.37 (s, 1H); 10.42 (s, 1H) ppm.	MW: 485.99 MS (ESI) [M+1]⁺: 486	155/ 166
298		(DMSO-d₆, Stored with K₂CO₃, Main Isomer):	MW: 486.98	155/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	2-[5-[1-[3-Chloro-5-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-cyanomethyl-acetamide	$\delta =$ 1.13-1.34 (m, 12H); 4.17 (d, 2H); 4.22 (q, 2H); 7.00 (s, 1H); 7.51 (s, 1H); 7.63 (s, 1H); 8.09 (s, 1H); 8.32 (s, 1H); 9.35 (s, 1H); 10.50 (s, 1H) ppm.	MS (ESI) [M+1] ⁺ : 487	
299	 2-[5-[1-[3-Chloro-5-(2,2-dimethyl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-	(DMSO-d ₆ , Stored with K ₂ CO ₃ , Main Isomer): $\delta =$ 1.12-1.34 (m, 12H); 3.95 (m, 2H); 4.24 (q, 2H); 7.00 (s, 1H);	MW: 529.97 MS (ESI) [M+1] ⁺ : 530	155/ 166



Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	cyano-N-(2,2,2-trifluoro-ethyl)- acetamide	7.51 (s, 1H); 7.62 (s, 1H); 8.09 (s, 1H); 8.18 (s, 1H); 9.33 (s, 1H); 10.48 (s, 1H) ppm.		
300	 2-[5-[1-[3-Chloro-5-(2,2-dimethylpropionylamino)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-2-cyano-N-((1S,2S)-2-hydroxy-cyclopentyl)-acetamide	(DMSO-d₆, Stored with K₂CO₃, Main Isomer): δ = 1.17-1.31 (m, 12H); 1.39-1.52 (m, 2H); 1.62 (m, 2H); 1.77-2.01 (m, 2H); 3.85 (m, 1H); 4.00 (m, 1H); 4.23 (q, 2H); 4.78 (d, 1H); 7.02 (s, 1H);	MW: 532.06 MS (ESI) [M+1]⁺: 533	155/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.39 (s, 1H); 7.51 (s, 1H); 7.65 (s, 1H); 8.01 (s, 1H); 9.34 (s, 1H); 10.37 (s, 1H) ppm.		
301	 {2-Cyano-2-[3-ethyl-5-[1-(3-nitro-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetylamino}-acetic acid ethyl ester	(DMSO-d ₆ , Stored with K ₂ CO ₃ , Main Isomer): δ = 1.22 (t, 3H); 1.28 (t, 3H); 3.91 (d, 2H); 4.12 (q, 2H); 4.25 (q, 2H); 7.61 (t, 1H); 7.79 (d, 1H); 7.86 (d, 1H); 8.02-8.15 (m, 2H);	MW: 445.45 MS (ESI) [M+1] ⁺ : 446	155/ 166


Exam- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		8.22 (s, 1H); 10.56 (s, 1H) ppm.		



Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
302	 N-But-2-ynyl-2-cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E or Z)-ylidene]-thiazolidin-(2Z/E)-ylidene]-acetamide	¹ H-NMR (CDCl ₃ , 300 MHz) (selected peaks) δ = 1.38 (m, 3H); 1.83 (s, 3H); 4.09 (m, 2H); 4.36 (m, 2H); 6.40 (m, 1H); 7.09 (m, 3H); 7.38 (m, 2H); 8.10 (d,	MW: 366.443 MS (ESI) [M+1] ⁺ : 367	INT138 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H); 10.50 (d, 1H).		
303	 2-Cyano-2-[5-[1-[4-(2-dimethylaminoethoxy)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-(2-fluoro-ethyl)-acetamide	¹ H-NMR (DSMO-d6, 300 MHz) (selected peaks) δ = 1.24 (m, 3H); 2.21 (s, 6H); 2.61 (m, 2H); 3.45 (m, 1H); 3.52 (m, 1H); 4.03 (m, 2H); 4.22 (m, 2H); 4.40 (m, 1H); 4.58 (m, 1H); 6.95 (d, 2H); 7.23 (d, 2H); 7.77 (m, 1H); 8.01 (m, 1H); 10.28 (s, 1H).	MW: 447.532 MS (ESI) [M+1] ⁺ : 448	157 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
304	 2-Cyano-N-cyanomethyl-2-[5-[1-[4-(2-dimethylamino-ethoxy)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 3H); 2.20 (s, 6H); 2.60 (m, 2H); 4.02 (m, 2H); 4.15 (d, 2H); 4.25 (m, 2H); 6.91 (d, 2H); 7.26 (d, 2H); 8.08 (s, 1H); 8.30 (m, 1H); 10.39 (s, 1H).	MW: 440.525 MS (ESI) [M+1] ⁺ : 441	157/ 166
305	 N-Allyl-2-cyano-2-[5-[1-[4-(2-dimethylamino-ethoxy)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetamide	¹ H-NMR (CDCl ₃ , 300 MHz) δ = 1.40 (m, 3H); 2.32 (s, 6H); 2.72 (m, 2H); 4.02 (m, 2H); 4.15 (d, 2H); 4.25 (m, 2H); 6.91 (d, 2H); 7.26 (d, 2H); 8.08 (s, 1H); 8.30 (m, 1H); 10.39 (s, 1H).	MW: 441.553 MS (ESI) [M+1] ⁺ : 442	157/ 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethoxy)-phenylamino]-meth- (E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetamide	(m, 2H); 4.00 (m, 4H); 4.39 (m, 2H); 5.18 (dd, 1H); 5.25 (dd, 1H); 5.90 (m, 1H); 6.27 (m, 1H); 6.92 (d, 2H); 7.01 (d, 2H); 7.47 (d, 1H); 10.48 (d, 1H).	442	
306	 2-Cyano-N-cyclopropylmethyl-2-[5-[1-[4-(2- dimethylamino-ethoxy)-phenylamino]-meth- (E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 0.22 (m, 2H); 0.40 (m, 2H); 1.01 (m, 1H); 1.22 (m, 3H); 2.19 (s, 6H); 2.60 (m, 2H); 3.02 (m,	MW: 455.580 MS (ESI) [M+1] ⁺ : 456	157/ 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		2H); 4.00 (m, 2H); 4.22 (m, 2H); 6.91 (d, 2H); 7.20 (d, 2H); 7.70 (m, 1H); 8.00 (s, 1H); 10.19 (s, 1H).		
307	 2-Cyano-2-[5-[1-[4-(2-dimethylaminoethoxy)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-prop-2-ynyl-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.23 (m, 3H); 2.19 (s, 6H); 2.58 (m, 2H); 3.05 (m, 1H); 3.90 (m, 2H); 4.01 (m, 2H); 4.22 (m, 2H); 6.92 (d, 2H); 7.22 (d, 2H); 8.03 (m, 	MW: 439.537 MS (ESI) [M+1] ⁺ : 440	157 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		2H); 10.27 (s, 1H).		
308	 2-Cyano-2-[5-[1-[4-(2-dimethylaminoethoxy)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-(2,2,2-trifluoro-ethyl)-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.25 (m, 3H); 2.19 (s, 6H); 2.59 (m, 2H); 3.98 (m, 4H); 4.22 (m, 2H); 6.91 (d, 2H); 7.22 (d, 2H); 8.06 (s, 1H); 8.16 (m, 1H); 10.31 (s, 1H).	MW: 483.512 MS (ESI) [M+1] ⁺ : 484	157 / 166
309	 2-Cyano-2-[5-[1-[4-(2-dimethylaminoethoxy)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-(2,2,2-trifluoro-ethyl)-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.05 (m, 3H); 1.22 (m, 3H);	MW: 429.542 MS (ESI) [M+1] ⁺ :	157 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethoxy)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-ethyl-acetamide	2.21 (s, 6H); 2.60 (m, 2H); 3.20 (m, 2H); 4.00 (m, 2H); 4.21 (m, 2H); 6.92 (d, 2H); 7.22 (d, 2H); 7.63 (m, 1H); 7.99 (s, 1H); 10.20 (s, 1H).	430	
310	 2-Cyano-N-(2,2-difluoro-ethyl)-2-[5-[1-[4-(2-dimethylamino-ethoxy)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.20 (m, 3H); 2.20 (s, 6H); 2.49 (m, 2H); 3.52 (m, 2H); 4.00 (m, 2H); 4.20 (m, 2H); 6.03 (tt, 1H);	MW: 465.522 MS (ESI) [M+1] ⁺ : 466	157 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		6.82 (d, 1H); 6.97 (m, 1H); 7.33 (s, 1H); 8.20 (s, 1H).		
311	 3-{[2-[1-Cyano-1-(2,2-difluoroethyl)carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethylpropionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.24 (m, 12H); 1.69 (m, 4H); 2.58 (m, 2H); 3.60 (m, 2H); 4.23 (m, 2H); 6.09 (tt, 1H); 7.41 (s, 1H); 7.71 (s, 1H); 7.93 (m, 2H); 8.19 (m, 1H); 8.50 (m, 1H); 9.41 (s, 1H); 10.60 (s,	MW: 617.718 MS (ESI) [M+1] ⁺ : 618	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H).		
312	 3-{[2-[1-Cyano-1-(2-fluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26 (m, 12H); 1.68 (m, 4H); 2.58 (m, 2H); 3.46 (m, 1H); 3.53 (m, 1H); 4.23 (m, 2H); 4.40 (m, 1H); 4.59 (m, 1H); 7.41 (s, 1H); 7.71 (s, 1H); 7.82 (m, 1H); 7.92 (s, 1H); 8.18 (m, 1H); 8.50 (m, 1H); 9.41 (s, 1H); 10.57 (d,	MW: 599.728 MS (ESI) [M+1] ⁺ : 600	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H).		
313	 3-{[2-[1-Cyano-1-(cyclopropylmethyl)-carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 0.21 (m, 2H); 0.40 (m, 2H); 1.02 (m, 1H); 1.69 (m, 4H); 2.57 (m, 2H); 3.03 (m, 2H); 4.22 (m, 2H); 7.38 (s, 1H); 7.70 (s, 2H); 7.90 (m, 1H); 8.16 (s, 1H); 8.49 (m, 1H); 9.40 (s, 1H); 10.51 (s, 1H).	MW: 607.775 MS (ESI) [M+1] ⁺ : 608	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
314	 4-{[2-[1-Cyano-1-(2,2-difluoroethyl)carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethylpropionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.24 (m, 12H); 1.67 (m, 4H); 2.59 (m, 2H); 3.60 (m, 2H); 4.23 (m, 2H); 6.08 (tt, 1H); 7.08 (dd, 1H); 7.78 (d, 1H); 8.00 (m, 1H); 8.08 (s, 1H); 8.52 (d, 1H); 8.69 (m, 1H); 10.68 (s, 1H); 12.13 (s, 1H).	MW: 617.718 MS (ESI) [M+1] ⁺ : 618	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
315	 4-([2-[1-Cyano-1-ethylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino)-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.07 (m, 3H); 1.26 (m, 12H); 1.67 (m, 4H); 2.58 (m, 2H); 3.21 (m, 2H); 3.39 (m, 2H); 4.23 (m, 2H); 7.08 (dd, 1H); 7.77 (m, 2H); 8.04 (s, 1H); 8.53 (d, 1H); 8.65 (m, 1H); 10.58 (s, 1H); 12.13 (s, 1H).	MW: 581.738 MS (ESI) [M+1] ⁺ : 582	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
316	 4-{{[2-[1-Allylcarbamoyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 12H); 1.69 (m, 4H); 2.59 (m, 2H); 3.39 (m, 2H); 3.80 (m, 2H); 4.22 (m, 2H); 5.07 (dd, 1H); 5.12 (dd, 1H); 5.83 (m, 1H); 7.07 (dd, 1H); 7.77 (d, 1H); 7.88 (m, 1H); 8.06 (s, 1H); 8.52 (d, 1H); 8.68 (m, 1H); 10.58 (s, 1H); 12.12 (s,	MW: 593.749 MS (ESI) [M+1] ⁺ : 594	161 / 166



Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H).		
317	 4-[[2-[1-Cyano-1-(cyanomethyl-carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26 (m, 12H); 1.69 (m, 4H); 2.59 (m, 2H); 3.38 (m, 2H); 4.15 (m, 2H); 4.22 (m, 2H); 7.10 (dd, 1H); 7.77 (d, 1H); 8.12 (s, 1H); 8.39 (m, 1H); 8.57 (d, 1H); 8.69 (m, 1H); 10.70 (s, 1H); 12.15 (s, 1H).	MW: 592.721 MS (ESI) [M+1] ⁺ : 593	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
318	 4-{{[2-[[1-cyano-1-(2-fluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.22 (m, 12H); 1.68 (m, 4H); 2.60 (m, 2H); 3.45 (m, 1H); 3.52 (m, 1H); 4.21 (m, 2H); 4.41 (m, 1H); 4.57 (m, 1H); 7.08 (dd, 1H); 7.77 (d, 1H); 7.83 (m, 1H); 8.08 (s, 1H); 8.55 (d, 1H); 8.67 (m, 1H); 10.60 (s, 1H); 12.16 (s, 1H).	MW: 599.728 MS (ESI) [M+1] ⁺ : 600	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
319	 4-[[2-[1-Cyano-1-(cyclopropylmethyl)-carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 0.21 (m, 2H); 0.41 (m, 2H); 1.02 (m, 1H); 10.22 (m, 12H); 1.65 (m, 4H); 2.59 (m, 2H); 3.05 (m, 2H); 4.22 (m, 2H); 7.07 (dd, 1H); 7.77 (m, 2H); 8.04 (s, 1H); 8.56 (d, 1H); 8.68 (m, 1H); 10.58 (s, 1H); 12.11 (s, 1H).	MW: 607.775 MS (ESI) [M+1] ⁺ : 608	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
320	 3-{{2-[[1-Cyano-1-prop-2-ynylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.23 (m, 12H); 1.68 (m, 4H); 2.57 (m, 2H); 3.08 (m, 1H); 3.92 (m, 2H); 4.26 (m, 2H); 7.41 (s, 1H); 7.71 (s, 1H); 7.93 (s, 1H); 8.15 (m, 2H); 8.52 (m, 1H); 9.42 (s, 1H); 10.58 (d, 1H).	MW: 591.733 MS (ESI) [M+1] ⁺ : 592	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
321	 3-{[2-[1-Cyano-1-ethylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.06 (m, 3H); 1.22 (m, 12H); 1.68 (m, 4H); 2.59 (m, 2H); 3.20 (m, 2H); 4.22 (m, 2H); 7.40 (s, 1H); 7.72 (m, 2H); 7.93 (s, 1H); 8.12 (m, 1H); 8.51 (m, 1H); 9.42 (s, 1H); 10.50 (d, 1H).	MW: 581.738 MS (ESI) [M+1] ⁺ : 582	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
322	 3-{[2-[1-Cyano-1-(2,2,2-trifluoroethyl)carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethylpropionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.28 (m, 12H); 1.69 (m, 4H); 2.58 (m, 2H); 3.92 (m, 2H); 4.24 (m, 2H); 7.41 (s, 1H); 7.72 (s, 1H); 7.93 (s, 1H); 8.21 (m, 2H); 8.51 (m, 1H); 9.42 (s, 1H); 10.62 (s, 1H).	MW: 635.708 MS (ESI) [M+1] ⁺ : 636	162 / 166
323		¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ =	MW: 591.733 MS (ESI)	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	4-{[2-[1-Cyano-1-prop-2-ynylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	1.24 (m, 12H); 1.68 (m, 4H); 2.58 (m, 2H); 3.09 (m, 1H); 3.93 (m, 2H); 4.22 (m, 2H); 7.09 (dd, 1H); 7.78 (d, 1H); 8.12 (m, 2H); 8.53 (d, 1H); 8.68 (m, 1H); 10.62 (s, 1H); 12.12 (s, 1H).	[M+1] ⁺ : 592	
324	 3-{[2-[1-Cyano-1-(cyanomethyl-carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 12H); 1.70 (m, 4H); 2.60 (m, 2H);	MW: 592.721 MS (ESI) [M+1] ⁺ : 593	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	4.15 (m, 2H); 4.25 (m, 2H); 7.41 (s, 1H); 7.76 (s, 1H); 7.98 (s, 1H); 8.21 (s, 1H); 8.37 (s, 1H); 8.52 (m, 1H); 9.45 (s, 1H); 10.64 (s, 1H).		
325	 3-{[2-[1-Allylcarbamoyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-5-(2,2-dimethyl-propionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 12H); 1.70 (m, 4H); 2.58 (m, 2H); 3.80 (m, 2H); 4.25 (m, 2H); 5.08 (dd, 1H);	MW: 593.749 MS (ESI) [M+1] ⁺ : 594	162 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		5.12 (dd, 1H); 5.83 (m, 1H); 7.41 (s, 1H); 7.71 (s, 1H); 7.88 (m, 1H); 7.98 (s, 1H); 8.52 (m, 1H); 9.42 (s, 1H); 10.51 (d, 1H).		
326	 4-{[2-[1-Cyano-1-(2,2,2-trifluoroethyl)carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-2-(2,2-dimethylpropionylamino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.22 (m, 12H); 1.68 (m, 4H); 2.61 (m, 2H); 3.40 (m, 2H); 3.95 (m, 2H); 4.23 (m, 2H); 7.09 (dd, 1H);	MW: 635.708 MS (ESI) [M+1] ⁺ : 636	161 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.77 (d, 1H); 8.11 (s, 1H); 8.25 (m, 1H); 8.56 (s, 1H); 8.67 (m, 1H); 10.67 (s, 1H); 12.12 (s, 1H).		
327	 5-([2-[1-Cyano-1-prop-2-ynylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino)-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 0.97 (m, 6H); 1.28 (m, 3H); 3.07 (s, 1H); 3.93 (m, 2H); 4.25 (m, 2H); 7.15 (dd, 1H); 7.41 (d, 1H); 7.86 (m, 1H); 8.05 (m, 4H); 10.52 (d, 1H); 11.59 (s,	MW: 533.654 MS (ESI) [M+1] ⁺ : 534	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H).		
328	 5-{{[2-[1-Cyano-1-(cyclopropylmethyl)-carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ , 300 MHz) δ = 0.26 (m, 2H); 0.57 (m, 2H); 1.10 (m, 7H); 1.41 (m, 3H); 2.62 (m, 4H); 2.72 (m, 2H); 3.22 (m, 2H); 3.55 (m, 2H); 4.40 (m, 2H); 6.29 (m, 1H); 6.90 (m, 1H); 6.98 (dd, 1H); 7.40 (d, 1H); 7.68 (d, 1H); 7.80 (s, 1H); 7.90 (d, 1H); 8.90 (s,	MW: 549.696 MS (ESI) [M+1] ⁺ : 550	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H); 10.66 (d, 1H).		
329	 5-{[2-[1-Allylcarbamoyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ , 300 MHz) (selected peaks) δ = 1.10 (m, 6H); 1.42 (m, 3H); 2.66 (m, 4H); 2.75 (m, 2H); 3.56 (m, 2H); 4.0 (m, 2H); 4.40 (m, 2H); 5.19 (dd, 1H); 5.26 (dd, 1H); 5.90 (m, 1H); 6.28 (m, 1H); 6.90 (s, 1H); 6.98 (dd, 1H); 7.40 (d, 1H); 7.65 (m,	MW: 535.67 MS (ESI) [M+1] ⁺ : 536	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H); 7.77 (s, 1H); 7.88 (m, 1H); 9.17 (s, 1H); 10.65 (s, 1H).		
330	 5-{[2-[1-Cyano-1-(2,2,2-trifluoroethyl)carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ , 300 MHz) (selected peaks) δ = 1.0 (m, 6H); 1.29 (m, 3H); 3.97 (m, 2H); 4.25 (m, 2H); 7.13 (dd, 1H); 7.42 (d, 1H); 7.85 (m, 1H); 8.01 (dd, 1H); 8.16 (m, 1H); 10.58 (s, 1H); 11.59 (d, 1H).	MW: 577.629 MS (ESI) [M+1] ⁺ : 578	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		1H).		
332	 5-{{2-[[1-cyano-1-isopropylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ and DMSO-d ₆ , 300 MHz) δ = 1.06 (m, 6H); 1.18 (m, 6H); 1.36 (m, 3H); 2.57 (m, 4H); 2.69 (m, 2H); 3.50 (m, 2H); 4.10 (m, 1H); 4.31 (m, 2H); 5.92 (m, 1H); 6.81 (s, 1H); 6.90 (dd, 1H); 7.35 (d, 1H); 7.72 (s, 1H); 7.88 (d, 1H); 10.42 (s, 1H); 10.61 (d, 1H).	MW: 537.685 MS (ESI) [M+1] ⁺ : 538	159 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
333	 6-{{[2-[1-Cyano-1-(cyanomethyl-carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26 (m, 3H); 2.20 (s, 6H); 2.38 (m, 2H); 4.14 (d, 2H); 4.22 (m, 2H); 7.11 (d, 1H); 7.30 (s, 1H); 7.80 (m, 1H); 7.97 (d, 1H); 8.08 (d, 1H); 8.18 (s, 1H); 8.30 (m, 1H); 10.50 (s, 1H); 11.49 (s, 1H).	MW: 506.588 MS (ESI) [M+1] ⁺ : 507	160 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
334	 6-{[2-[1-Cyano-1-prop-2-ynylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 3H); 2.20 (s, 6H); 2.39 (m, 2H); 2.90 (m, 2H); 3.08 (m, 1H); 3.92 (m, 2H); 4.25 (m, 2H); 7.10 (dd, 1H); 7.30 (s, 1H); 7.80 (m, 1H); 7.95 (d, 1H); 8.05 (m, 2H); 8.13 (s, 1H); 10.40 (s, broad, 1H); 11.48 (s, 1H).	MW: 505.600 MS (ESI) [M+1] ⁺ : 506	160 / 166



Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
335	 6-{[2-[1-Cyano-1-(cyclopropylmethyl)-carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 0.22 (m, 2H); 0.40 (m, 2H); 1.02 (m, 1H); 1.25 (m, 3H); 2.20 (s, 6H); 2.39 (m, 2H); 3.03 (m, 2H); 4.22 (m, 2H); 7.11 (d, 1H); 7.30 (s, 1H); 7.71 (m, 1H); 7.80 (m, 1H); 7.97 (d, 1H); 8.09 (m, 2H); 10.48 (s, 1H); 11.48 (s, 1H).	MW: 521.642 MS (ESI) [M+1] ⁺ : 522	160 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
336	 6-{[2-[1-Cyano-1-(2,2-difluoroethyl)carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.23 (m, 3H); 2.18 (s, 6H); 2.39 (m, 2H); 3.60 (m, 2H); 4.25 (m, 2H); 6.08 (tt, 1H); 7.11 (dd, 1H); 7.31 (s, 1H); 7.80 (m, 1H); 7.95 (m, 2H); 8.09 (d, 1H); 8.12 (s, 1H); 10.48 (s, 1H); 11.48 (s, 1H).	MW: 531.585 MS (ESI) [M+1] ⁺ : 532	160/ 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
337	 6-{{[2-[[1-cyano-1-(2-fluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino]}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 3H); 2.19 (s, 6H); 2.40 (m, 2H); 3.50 (dq, 2H); 4.25 (m, 2H); 4.40 (m, 1H); 4.58 (m, 1H); 7.10 (dd, 1H); 7.30 (s, 1H); 7.79 (m, 1H); 7.95 (d, 1H); 8.05 (d, 1H); 8.12 (s, 1H); 10.41 (s, 1H); 11.49 (s, 1H).	MW: 513.595 MS (ESI) [M+1] ⁺ : 514	160 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
338	 6-([2-[1-Allylcarbamoyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino)-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 3H); 2.18 (s, 6H); 2.39 (m, 2H); 3.80 (m, 2H); 4.25 (m, 2H); 5.08 (dd, 1H); 5.12 (dd, 1H); 5.81 (m, 1H); 7.10 (dd, 1H); 7.30 (s, 1H); 7.80 (m, 1H); 7.95 (d, 1H); 8.08 (d, 1H); 8.10 (s, 1H); 10.38 (s, 1H); 11.48 (s, 1H).	MW: 507.616 MS (ESI) [M+1] ⁺ : 508	160 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
339	 6-{[2-[1-Cyano-1-ethylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.05 (m, 3H); 1.25 (m, 3H); 2.20 (s, 6H); 2.40 (m, 2H); 3.20 (m, 2H); 4.22 (m, 2H); 7.11 (dd, 1H); 7.30 (s, 1H); 7.67 (m, 1H); 7.80 (m, 1H); 7.93 (d, 1H); 8.06 (d, 1H); 8.12 (s, 1H); 10.48 (d, 1H); 11.48 (s, 1H).	MW: 495.605 MS (ESI) [M+1] ⁺ : 496	160 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
340	 6-{[2-[1-Cyano-1-(2,2,2-trifluoroethyl)carbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.25 (m, 3H); 2.19 (s, 6H); 2.40 (m, 2H); 3.96 (m, 2H); 4.25 (m, 2H); 7.12 (dd, 1H); 7.33 (s, 1H); 7.80 (m, 1H); 7.97 (d, 1H); 8.08 (d, 1H); 8.16 (m, 2H); 10.49 (s, 1H); 11.49 (s, 1H).	MW: 549.575 MS (ESI) [M+1] ⁺ : 550	160 / 166
341		¹ H-NMR (DMSO-d ₆ , 300 MHz) δ =	MW: 563.602	158 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	5-{[2-[1-Cyano-1-(2,2,2-trifluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	1.25 (m, 3H); 2.18 (s, 6H); 2.48 (m, 2H); 3.11 (s, 3H); 3.60 (m, 2H); 3.95 (m, 2H); 4.26 (m, 2H); 7.14 (dd, 1H); 7.41 (d, 1H); 7.70 (s, 1H); 7.78 (d, 1H); 8.12 (m, 2H); 10.50 (s, 1H); 11.60 (s, 1H).	MS (ESI) [M+1] ⁺ : 564	
342	 5-{[2-[1-Cyano-1-(2,2-difluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.24 (m, 3H); 2.18 (s, 6H); 2.48 (m, 2H);	MW: 545.612 MS (ESI) [M+1] ⁺ : 546	158/ 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethyl-4-oxo-thiazolidin-(5E/Z)-ylidene-methyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	3.12 (s, 3H); 3.57 (m, 4H); 4.22 (m, 2H); 6.08 (tt, 1H); 7.11 (dd, 1H); 7.40 (d, 1H); 7.61 (s, 1H); 7.71 (s, 1H); 7.79 (m, 1H); 8.11 (s, 1H); 10.0 (s, broad, 1H); 11.58 (s, 1H).		
343	 5-{{[2-[1-Cyano-1-ethylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.07 (m, 3H); 1.29 (m, 3H); 2.18 (s, 6H); 2.45 (m, 2H); 3.11 (s, 3H);	MW: 509.631 MS (ESI) [M+1] ⁺ : 510	158 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	methyl-amide	3.21 (m, 2H); 3.60 (m, 2H); 4.22 (m, 2H); 7.15 (dd, 1H); 7.42 (d, 1H); 7.62 (m, 1H); 7.69 (s, 1H); 7.75 (d, 1H); 8.05 (d, 1H); 10.40 (d, 1H); 11.60 (d, 1H).		
344	 5-[[2-[1-Allylcarbamoyl-1-cyano-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.25 (m, 3H); 2.17 (s, 6H); 2.42 (m, 2H); 3.11 (s, 3H); 3.58 (m, 2H); 3.79 (m, 2H);	MW: 521.642 MS (ESI) [M+1] ⁺ : 522	158/ 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		4.26 (m, 2H); 5.06 (dd, 1H); 5.12 (dd, 1H); 5.88 (m, 1H); 7.13 (dd, 1H); 7.41 (d, 1H); 7.69 (s, 1H); 7.73 (d, 1H); 7.80 (m, 1H); 8.06 (s, 1H); 10.39 (s, 1H); 11.60 (s, 1H).		
345	 5-([2-[1-Cyano-1-(2-fluoro-ethylcarbamoyl)-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino)-1H-indole-3-carboxylic acid (2-dimethylamino-	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26 (m, 3H); 2.18 (s, 6H); 3.11 (s, 3H); 3.49 (dd, 2H);	MW: 527.622 MS (ESI) [M+1] ⁺ : 528	158 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	ethyl)-methyl-amide	3.60 (m, 2H); 4.24 (m, 2H); 4.50 (dt, 2H); 7.18 (dd, 1H); 7.41 (d, 1H); 7.69 (s, 1H); 7.77 (d, 1H); 8.08 (d, 1H); 10.47 (d, 1H); 11.60 (s, 1H).		
346	 5-{[2-[1-Cyano-1-(cyclopropylmethyl)-carbamoyl]-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 0.21 (m, 2H); 0.40 (m, 2H); 1.02 (m, 1H); 1.25 (m, 3H); 2.16 (s, 6H); 2.48 (m, 2H); 3.07 (m, 2H);	MW: 535.669 MS (ESI) [M+1] ⁺ : 536	158 / 166


Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		3.10 (s, 3H); 3.60 (m, 2H); 4.27 (m, 2H); 7.12 (dd, 1H); 7.42 (d, 1H); 7.70 (s, 1H); 7.78 (d, 1H); 8.05 (s, 1H); 10.40 (s, 1H); 11.60 (s, 1H).		
347	 5-([2-[1-Cyano-1-prop-2-ynylcarbamoyl-meth-(Z or E)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino)-1H-indole-3-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide	¹ H-NMR (DMSO-d ₆ , 300 MHz) δ = 1.22 (m, 3H); 2.15 (s, 6H); 2.47 (m, 2H); 3.08 (m, 1H); 3.12 (s, 3H); 3.58 (m, 2H); 3.92 (m, 2H);	MW: 519.627 MS (ESI) [M+1] ⁺ : 520	158 / 166



Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		4.22 (m, 2H); 7.11 (dd, 1H); 7.41 (d, 1H); 7.69 (s, 1H); 7.75 (s, 1H); 8.0 (s, 1H); 8.08 (s, 1H); 10.40 (s, broad, 1H); 11.58 (s, 1H).		
348	 5-{[2-[1-Cyano-2-morpholin-4-yl]-2-oxo-ethylidene]-3-ethyl-4-oxo-thiazolidin-(5E/Z)-ylidenemethyl]-amino}-1H-indole-3-carboxylic acid (2-diethylamino-ethyl)-amide	¹ H-NMR (CDCl ₃ , 300 MHz) δ = 1.09 (m, 6H); 1.42 (m, 3H); 2.68 (m, 4H); 2.75 (m, 3H); 3.59 (m, 2H); 3.70 (m, 4H); 7.76 (m, 4H); 4.40 (m, 2H);	MW: 565.695 MS (ESI) [M+1] ⁺ : 566	159 / 166

Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		6.94 (m, 2H); 7.48 (d, 1H); 7.61 (d, 1H); 7.78 (s, 1H); 7.88 (d, 1H); 9.32 (s, 1H); 10.63 (d, 1H).		
349	 2-Cyano-2-[5-[1-{4-[(2-dimethylamino-ethyl)-methyl-sulfamoyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-prop-2-ynyl-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.28 (m, 3H); 2.12 (s, 6H); 2.40 (m, 2H); 2.69 (s, 3H); 3.02 (m, 2H); 3.09 (m, 1H); 3.93 (m, 2H); 4.24 (m, 2H); 7.50 (d, 2H);	MW: 516.644 MS (ESI) [M+1] ⁺ : 517	156 / 166



Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
		7.71 (d, 2H); 8.19 (s, 1H); 10.58 (s, 1H).		
350	 2-Cyano-2-[5-[1-{3-[(2-dimethylamino-ethyl)-methyl-sulfamoyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-prop-2-ynyl-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.24 (m, 3H); 2.19 (s, 6H); 2.42 (m, 2H); 2.72 (s, 3H); 3.08 (m, 2H); 3.92 (m, 2H); 4.23 (m, 2H); 7.42 (d, 1H); 7.60 (m, 1H); 7.68 (m, 2H); 8.19 (m, 2H); 10.50 (s, 1H).	MW: 516.644 MS (ESI) [M+1] ⁺ : 517	164 / 166




Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
351	 2-Cyano-2-[5-[1-[3-(2-dimethylamino-ethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-prop-2-ynyl-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.24 (m, 3H); 2.06 (s, 6H); 2.27 (m, 2H); 2.82 (m, 2H); 2.91 (s, 3H); 3.08 (m, 1H); 3.92 (m, 2H); 4.22 (m, 2H); 7.44 (m, 1H); 7.54 (m, 2H); 7.71 (s, 1H); 8.16 (m, 2H); 10.55 (s, 1H).	MW: 502.617 MS (ESI) [M+1] ⁺ : 503	165 / 166




Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
352	 N-Allyl-2-cyano-2-[5-[1-[4-(2-dimethylaminoethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.28 (m, 3H); 2.08 (s, 6H); 2.25 (m, 2H); 2.80 (m, 2H); 3.80 (m, 2H); 4.22 (m, 2H); 5.05 (dd, 1H); 5.13 (dd, 1H); 5.82 (m, 1H); 7.41 (s, 1H); 7.46 (d, 2H); 7.73 (d, 2H); 7.92 (m, 1H); 8.17 (m, 1H); 10.50 (d, 1H).	MW: 504.633 MS (ESI) [M+1] ⁺ : 505	163 / 166




Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
353	 2-Cyano-2-[5-[1-[4-(2-dimethylamino-ethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-(2,2,2-trifluoroethyl)-acetamide	¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.28 (m, 3H); 2.07 (s, 6H); 2.25 (m, 2H); 2.80 (m, 2H); 3.96 (m, 2H); 4.25 (m, 2H); 7.41 (s, 1H); 7.48 (d, 2H); 7.73 (d, 2H); 8.20 (s, 1H); 8.29 (m, 1H); 10.59 (s, 1H).	MW: 546.592 MS (ESI) [M+1] ⁺ : 547	163 / 166
354		¹ H-NMR (DMSO-d ₆ , 300 MHz) (selected peaks) δ = 1.26	MW: 502.617 MS (ESI)	163 / 166




Ex- am- ple No.	Structure and Name	¹ H-NMR	Molecu- lar Weight/ MS (ESI) [M+1] ⁺	Educt/ Syn- thesis as in the Case of
	2-Cyano-2-[5-[1-[4-(2-dimethylamino-ethylsulfamoyl)-phenylamino]-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2Z or E)-ylidene]-N-prop-2-ynyl-acetamide	(m, 3H); 2.08 (s, 6H); 2.28 (m, 2H); 2.80 (m, 2H); 3.08 (m, 1H); 3.93 (m, 2H); 4.22 (m, 2H); 7.41 (s, 1H); 7.47 (d, 2H); 7.72 (d, 2H); 8.18 (m, 2H); 10.52 (s, 1H).	[M+1] ⁺ : 503	




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
355		MW: 612.70 MS (ESI) $[M+1]^+$: 613	149 / 166
356		MW: 586.60 MS (ESI) $[M+1]^+$: 587	149 / 166

Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
357		MW: 532.66 MS (ESI) $[M+1]^+$: 533	149 / 166
358	 6-{{2-[1-Cyano-1-prop-2-ynylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-naphthalene-2-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide	MW: 542.66 MS (ESI) $[M+1]^+$: 543	149 / 166
359		MW: 595.72 MS (ESI) $[M+1]^+$: 596	149 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
360		MW: 578.76 MS (ESI) $[M+1]^+$: 579	149 / 166
361		MW: 574.75 MS (ESI) $[M+1]^+$: 575	149 / 166
362		MW: 542.66 MS (ESI) $[M+1]^+$: 543	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
363		MW: 574.70 MS (ESI) [M+1] ⁺ : 575	146 / 166
364		MW: 539.66 MS (ESI) [M+1] ⁺ : 540	146 / 166
365	 N-tert-Butyl-2-cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin[2-(E or Z)]-ylidene]-N-methyl-acetamide	MW: 524.69 MS (ESI) [M+1] ⁺ : 525	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
366		MW: 581.74 MS (ESI) $[M+1]^+$: 582	146 / 166
367		MW: 507.62 MS (ESI) $[M+1]^+$: 508	146 / 166
368		MW: 540.69 MS (ESI) $[M+1]^+$: 541	146 / 166

Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
369		MW: 508.64 MS (ESI) [M+1] ⁺ : 509	146 / 166
370		MW: 536.70 MS (ESI) [M+1] ⁺ : 537	146 / 166
371		MW: 510.66 MS (ESI) [M+1] ⁺ : 511	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
372	 <chem>CN(CC)C(=O)[C@H](NC(=O)c1ccc(F)cc1)[C@@H](NC(=O)CCN2CCCC2)c3sc(C#N)c3n2C(=O)</chem>	MW: 562.67 MS (ESI) [M+1] ⁺ : 563	146 / 166
373	 <chem>CN(CC)C(=O)[C@H](NC(=O)Cc1ccc(OC)cc1)[C@@H](NC(=O)CCN2CCCC2)c3sc(C#N)c3n2C(=O)</chem>	MW: 574.70 MS (ESI) [M+1] ⁺ : 575	146 / 166
374	 <chem>CN(CC)C(=O)[C@H](NC(=O)CCF(F)F)[C@@H](NC(=O)CCN2CCCC2)c3sc(C#N)c3n2C(=O)</chem>	MW: 536.58 MS (ESI) [M+1] ⁺ : 537	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
375		MW: 494.62 MS (ESI) [M+1] ⁺ : 495	146 / 166
376	 2-Cyano-N-cyclopropylmethyl-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl)propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)-ylidene]-acetamide	MW: 508.64 MS (ESI) [M+1] ⁺ : 5098	146 / 166
377		MW: 576.69 MS (ESI) [M+1] ⁺ : 577	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
378		MW: 492.60 MS (ESI) [M+1] ⁺ : 493	146 / 166
379		MW: 574.66 MS (ESI) [M+1] ⁺ : 575	146 / 166
380		MW: 508.64 MS (ESI) [M+1] ⁺ : 509	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
381		MW: 570.70 MS (ESI) $[M+1]^+$: 575	146 / 166
382	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-N-(2-pyridin-2-yl-ethyl)-acetamide	MW: 559.69 MS (ESI) $[M+1]^+$: 560	146 / 166
383		MW: 545.67 MS (ESI) $[M+1]^+$: 546	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
384	 <chem>CN(CC(=O)c1cc(NC(=O)CCN2CCCC2)ccc1NC(=O)CC(C)OC#N)c1sc(C(=O)NCC)nc1=O</chem>	MW: 526.66 MS (ESI) [M+1] ⁺ : 527	146 / 166
385	 <chem>CC(C)CN(CC(=O)c1cc(NC(=O)CCN2CCCC2)ccc1NC(=O)CC(C)C#N)c1sc(C(=O)NCC)nc1=O</chem>	MW: 524.69 MS (ESI) [M+1] ⁺ : 525	146 / 166
386	 <chem>CCN(CC(=O)c1cc(NC(=O)CCN2CCCC2)ccc1NC(=O)COc1ccccc1C#N)c1sc(C(=O)NCC)nc1=O</chem>	MW: 574.70 MS (ESI) [M+1] ⁺ : 575	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
387		MW: 528.70 MS (ESI) $[M+1]^+$: 529	146 / 166
388		MW: 579.77 MS (ESI) $[M+1]^+$: 580	146 / 166
389		MW: 551.71 MS (ESI) $[M+1]^+$: 552	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
390		MW: 540.69 MS (ESI) $[M+1]^+$: 541	146 / 166
391		MW: 559.69 MS (ESI) $[M+1]^+$: 560	146 / 166
392		MW: 524.69 MS (ESI) $[M+1]^+$: 525	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
393		MW: 524.69 MS (ESI) $[M+1]^+$: 525	146 / 166
394	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin- [2-(E or Z)]-ylidene]-N-phenyl-acetamide	MW: 530.65 MS (ESI) $[M+1]^+$: 531	146 / 166
395		MW: 534.68 MS (ESI) $[M+1]^+$: 535	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
396		MW: 539.70 MS (ESI) [M+1] ⁺ : 540	146 / 166
397		MW: 540.69 MS (ESI) [M+1] ⁺ : 541	146 / 166
398		MW: 572.73 MS (ESI) [M+1] ⁺ : 573	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
399		MW: 572.73 MS (ESI) $[M+1]^+$: 573	146 / 166
400		MW: 575.73 MS (ESI) $[M+1]^+$: 576	146 / 166
401	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-2-(E or Z)-ylidene]-N-[2-(4-fluoro-phenyl)-ethyl]-acetamide	MW: 576.69 MS (ESI) $[M+1]^+$: 577	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
402		MW: 560.72 MS (ESI) [M+1] ⁺ : 561	146 / 166
403		MW: 584.74 MS (ESI) [M+1] ⁺ : 585	146 / 166
404		MW: 586.76 MS (ESI) [M+1] ⁺ : 587	146 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
405		MW: 557.67 MS (ESI) $[M+1]^+$: 558	145 / 166
406		MW: 589.72 MS (ESI) $[M+1]^+$: 590	145 / 166
407		MW: 555.70 MS (ESI) $[M+1]^+$: 556	145 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
408	 1-(4-{[2-[1-Cyano-2-(3-hydroxy-pyrrolidin-1-yl)-2-oxo-eth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-3-(2-pyrrolidin-1-yl-ethyl)-urea	MW: 539.66 MS (ESI) $[M+1]^+$: 540	145 / 166
409		MW: 554.67 MS (ESI) $[M+1]^+$: 555	145 / 166
410		MW: 596.75 MS (ESI) $[M+1]^+$: 597	145 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
411		MW: 522.63 MS (ESI) [M+1] ⁺ : 523	145 / 166
412	 2-Cyano-N-cyclohexyl-2-[3-ethyl-4-oxo-5-[1-{4-[3-(2-pyrrolidin-1-yl-ethyl)-ureido]-phenylamino}-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-acetamide	MW: 551.71 MS (ESI) [M+1] ⁺ : 552	145 / 166
413		MW: 525.67 MS (ESI) [M+1] ⁺ : 526	145 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
414		MW: 577.68 MS (ESI) [M+1] ⁺ : 578	145 / 166
415		MW: 589.72 MS (ESI) [M+1] ⁺ : 590	145 / 166
416		MW: 551.59 MS (ESI) [M+1] ⁺ : 552	145 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
417		MW: 591.71 MS (ESI) $[M+1]^+$: 592	145 / 166
418		MW: 507.62 MS (ESI) $[M+1]^+$: 508	145 / 166
419		MW: 589.68 MS (ESI) $[M+1]^+$: 590	145 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
422		MW: 574.71 MS (ESI) $[M+1]^+$: 575	145 / 166
423		MW: 560.68 MS (ESI) $[M+1]^+$: 561	145 / 166
424		MW: 541.67 MS (ESI) $[M+1]^+$: 542	145 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
425		MW: 539.70 MS (ESI) $[M+1]^+$: 540	145 / 166
426		MW: 589.72 MS (ESI) $[M+1]^+$: 590	145 / 166
427		MW: 582.77 MS (ESI) $[M+1]^+$: 583	145 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
428		MW: 543.71 MS (ESI) $[M+1]^+$: 544	145 / 166
429		MW: 566.73 MS (ESI) $[M+1]^+$: 567	145 / 166
430		MW: 555.70 MS (ESI) $[M+1]^+$: 556	145 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
431		MW: 539.70 MS (ESI) [M+1] ⁺ : 540	145 / 166
432		MW: 539.70 MS (ESI) [M+1] ⁺ : 540	145 / 166
433		MW: 542.66 MS (ESI) [M+1] ⁺ : 543	145 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
434		MW: 574.70 MS (ESI) $[M+1]^+$: 575	147 / 166
435	 4-{{2-[1-Cyano-1-[(2-hydroxy-ethyl)-propyl-carbamoyl]-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 540.69 MS (ESI) $[M+1]^+$: 541	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
436		MW: 524.64 MS (ESI) [M+1] ⁺ : 525	147 / 166
437		MW: 508.64 MS (ESI) [M+1] ⁺ : 509	147 / 166
438		MW: 556.71 MS (ESI) [M+1] ⁺ : 557	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
439		MW: 581.74 MS (ESI) $[M+1]^+$: 582	147 / 166
440		MW: 507.62 MS (ESI) $[M+1]^+$: 508	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI)	Educt/ Synthe- sis as in the Case of
441	 4-{{[2-[1-Cyano-1-[ethyl-(2-methoxy-ethyl)-carbamoyl]-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidene-methyl]-amino}}-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 540.69 MS (ESI) [M+1] ⁺ : 541	147 / 166
442		MW: 536.70 MS (ESI) [M+1] ⁺ : 537	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
446	 4-([2-[1-Cyano-1-(2,2,2-trifluoroethylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 536.58 MS (ESI) $[M+1]^+$: 537	147 / 166
447		MW: 492.60 MS (ESI) $[M+1]^+$: 493	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
448		MW: 508.64 MS (ESI) $[M+1]^+$: 509	147 / 166
449		MW: 574.70 MS (ESI) $[M+1]^+$: 575	147 / 166
450		MW: 559.69 MS (ESI) $[M+1]^+$: 560	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
451		MW: 545.67 MS (ESI) $[M+1]^+$: 546	147 / 166
452		MW: 526.66 MS (ESI) $[M+1]^+$: 527	147 / 166
453		MW: 524.69 MS (ESI) $[M+1]^+$: 525	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
454		MW: 574.70 MS (ESI) [M+1] ⁺ : 575	147 / 166
455		MW: 567.76 MS (ESI) [M+1] ⁺ : 568	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
456	 4-{{[2-[1-Cyano-1-(2-methylsulfonyl-ethylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}}-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 528.70 MS (ESI) $[M+1]^+$: 529	147 / 166
457		MW: 579.77 MS (ESI) $[M+1]^+$: 580	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI)	Educt/ Synthe- sis as in the Case of
458		MW: 551.71 MS (ESI) [M+1] ⁺ : 552	147 / 166
459		MW: 540.69 MS (ESI) [M+1] ⁺ : 541	147 / 166
460		MW: 540.69 MS (ESI) [M+1] ⁺ : 541	147 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
461	 4-{[2-[1-Cyano-1-(pyrrol-1-ylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/Z))-ylidenemethyl]-amino}-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 519.63 MS (ESI) [M+1] ⁺ : 520	147 / 166
462		MW: 548.71 MS (ESI) [M+1] ⁺ : 549	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI)	Educt/ Synthe- sis as in the Case of
463		MW: 530.65 MS (ESI) [M+1] ⁺ : 531	147 / 166
464		MW: 539.70 MS (ESI) [M+1] ⁺ : 540	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
465	 4-([2-[1-Cyano-1-(2-dimethylamino-1-methyl-ethylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino)-N-(2-pyrrolidin-1-yl-ethyl)-benzamide	MW: 539.70 MS (ESI) $[M+1]^+$: 540	147 / 166
466		MW: 572.73 MS (ESI) $[M+1]^+$: 573	147 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
467		MW: 572.73 MS (ESI) $[M+1]^+$: 573	147 / 166
468		MW: 573.68 MS (ESI) $[M+1]^+$: 574	147 / 166
469		MW: 571.70 MS (ESI) $[M+1]^+$: 572	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
470		MW: 603.74 MS (ESI) [M+1] ⁺ : 604	143/166
471		MW: 553.69 MS (ESI) [M+1] ⁺ : 554	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
472	 N-(2-Acetylamino-ethyl)-2-cyano-2-[3-ethyl-5-[1-{4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-[2-(E or Z)]-ylidene]-acetamide	MW: 568.70 MS (ESI) $[M+1]^+$: 569	143/166
473		MW: 537.69 MS (ESI) $[M+1]^+$: 538	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
474		MW: 585.76 MS (ESI) $[M+1]^+$: 586	143/166
475		MW: 565.74 MS (ESI) $[M+1]^+$: 566	143/166
476		MW: 539.70 MS (ESI) $[M+1]^+$: 540	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
477		MW: 591.71 MS (ESI) [M+1] ⁺ : 592	143/166
478		MW: 603.74 MS (ESI) [M+1] ⁺ : 604	143/166
479		MW: 565.62 MS (ESI) [M+1] ⁺ : 566	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
480		MW: 511.65 MS (ESI) $[M+1]^+$: 512	143/166
481		MW: 523.66 MS (ESI) $[M+1]^+$: 524	143/166
482		MW: 537.69 MS (ESI) $[M+1]^+$: 538	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
483		MW: 605.74 MS (ESI) $[M+1]^+$: 606	143/166
484	 2-Cyano-2-[3-ethyl-5-[1-{4-[3-(4-methylpiperazin-1-yl)-propionylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N-prop-2-ynyl-acetamide	MW: 521.64 MS (ESI) $[M+1]^+$: 522	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
485		MW: 541.67 MS (ESI) $[M+1]^+$: 542	143/166
486		MW: 537.69 MS (ESI) $[M+1]^+$: 538	143/166
487		MW: 603.74 MS (ESI) $[M+1]^+$: 604	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
488		MW: 588.73 MS (ESI) $[M+1]^+$: 589	143/166
489		MW: 574.71 MS (ESI) $[M+1]^+$: 575	143/166
490		MW: 555.70 MS (ESI) $[M+1]^+$: 556	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
491		MW: 553.73 MS (ESI) $[M+1]^+$: 554	143/166
492		MW: 603.74 MS (ESI) $[M+1]^+$: 604	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
493	 2-Cyano-2-[3-ethyl-5-[1-{4-[3-(4-methylpiperazin-1-yl)-propionylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-[2-(E or Z)]-ylidene]-N-(2-methylsulfanyl-ethyl)-acetamide	MW: 557.74 MS (ESI) $[M+1]^+$: 558	143/166
494		MW: 608.81 MS (ESI) $[M+1]^+$: 609	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
495		MW: 580.75 MS (ESI) $[M+1]^+$: 581	143/166
496		MW: 569.73 MS (ESI) $[M+1]^+$: 570	143/166
497		MW: 569.73 MS (ESI) $[M+1]^+$: 570	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
498		MW: 548.67 MS (ESI) $[M+1]^+$: 549	143/166
499		MW: 525.67 MS (ESI) $[M+1]^+$: 526	143/166
500		MW: 539.70 MS (ESI) $[M+1]^+$: 540	143/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
501		MW: 541.67 MS (ESI) $[M+1]^+$: 542	143/166
502		MW: 541.67 MS (ESI) $[M+1]^+$: 542	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
503	 2-Cyano-N-(1,1-diethyl-prop-2-ynyl)-2-[3-ethyl-5-[1-{4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-2-(E or Z)]-ylidene]-acetamide	MW: 577.75 MS (ESI) $[M+1]^+$: 578	143/166
504		MW: 553.73 MS (ESI) $[M+1]^+$: 554	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
505		MW: 553.73 MS (ESI) $[M+1]^+$: 554	143/166
506		MW: 553.73 MS (ESI) $[M+1]^+$: 554	143/166
507		MW: 559.69 MS (ESI) $[M+1]^+$: 560	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
508		MW: 569.73 MS (ESI) $[M+1]^+$: 570	143/166
509		MW: 601.77 MS (ESI) $[M+1]^+$: 602	143/166
510		MW: 601.77 MS (ESI) $[M+1]^+$: 602	143/166

Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
511		MW: 604.78 MS (ESI) $[M+1]^+$: 605	143/166
512		MW: 589.76 MS (ESI) $[M+1]^+$: 590	143/166
513		MW: 613.78 MS (ESI) $[M+1]^+$: 614	143/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
514		MW: 615.80 MS (ESI) $[M+1]^+$: 616	143/166
515	 2-Cyano-N-(2,3-dihydroxy-propyl)-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-N-methyl-acetamide	MW: 499.63 MS (ESI) $[M+1]^+$: 500	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
516		MW: 531.68 MS (ESI) $[M+1]^+$: 532	142/166
517		MW: 497.66 MS (ESI) $[M+1]^+$: 498	142/166
518		MW: 481.62 MS (ESI) $[M+1]^+$: 482	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
519		MW: 496.63 MS (ESI) $[M+1]^+$: 497	142/166
520		MW: 464.59 MS (ESI) $[M+1]^+$: 465	142/166
521		MW: 497.66 MS (ESI) $[M+1]^+$: 498	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
522		MW: 493.67 MS (ESI) $[M+1]^+$: 494	142/166
523		MW: 523.61 MS (ESI) $[M+1]^+$: 524	142/166
524		MW: 467.64 MS (ESI) $[M+1]^+$: 468	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
525		MW: 519.64 MS (ESI) [M+1] ⁺ : 520	142/166
526		MW: 531.68 MS (ESI) [M+1] ⁺ : 532	142/166
527		MW: 493.55 MS (ESI) [M+1] ⁺ : 494	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
528		MW: 533.67 MS (ESI) $[M+1]^+$: 534	142/166
529		MW: 449.58 MS (ESI) $[M+1]^+$: 450	142/166
530		MW: 531.64 MS (ESI) $[M+1]^+$: 532	142/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
531		MW: 513.69 MS (ESI) $[M+1]^+$: 514	142/166
532	 2-Cyano-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-N-(2-methyl-allyl)-acetamide	MW: 465.62 MS (ESI) $[M+1]^+$: 466	142/166
533		MW: 483.63 MS (ESI) $[M+1]^+$: 484	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
534		MW: 481.66 MS (ESI) $[M+1]^+$: 482	142/166
535		MW: 531.68 MS (ESI) $[M+1]^+$: 532	142/166
536		MW: 497.66 MS (ESI) $[M+1]^+$: 498	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
537		MW: 476.60 MS (ESI) $[M+1]^+$: 477	142/166
538		MW: 517.65 MS (ESI) $[M+1]^+$: 518	142/166
539		MW: 469.61 MS (ESI) $[M+1]^+$: 470	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
540	 2-Cyano-N-(cyano-dimethyl-methyl)-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-acetamide	MW: 478.62 MS (ESI) $[M+1]^+$: 479	142/166
541		MW: 505.68 MS (ESI) $[M+1]^+$: 506	142/166
542		MW: 481.66 MS (ESI) $[M+1]^+$: 482	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
543		MW: 481.66 MS (ESI) $[M+1]^+$: 482	142/166
544		MW: 487.63 MS (ESI) $[M+1]^+$: 488	142/166
545		MW: 491.66 MS (ESI) $[M+1]^+$: 492	142/166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
546	 2-Cyano-N-(2-dimethylamino-ethyl)-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-N-methyl-acetamide	MW: 496.68 MS (ESI) [M+1]⁺: 497	142/166
547		MW: 497.66 MS (ESI) [M+1]⁺: 498	142/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
548		MW: 503.62 MS (ESI) $[M+1]^+$: 504	142/166
549		MW: 529.71 MS (ESI) $[M+1]^+$: 530	142/166
550		MW: 529.71 MS (ESI) $[M+1]^+$: 530	142/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
551		MW: 532.71 MS (ESI) $[M+1]^+$: 533	142/166
552		MW: 533.67 MS (ESI) $[M+1]^+$: 534	142/166
553		MW: 517.70 MS (ESI) $[M+1]^+$: 518	142/166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
554		MW: 541.72 MS (ESI) $[M+1]^+$: 542	142/166
555	 2-Cyano-N-(1,1-dimethyl-2-phenyl-ethyl)-2-[3-ethyl-4-oxo-5-[1-[4-(2-pyrrolidin-1-yl-ethyl)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-[2-(E or Z)]-ylidene]-acetamide	MW: 543.73 MS (ESI) $[M+1]^+$: 544	142/166
556		MW: 540.73 MS (ESI) $[M+1]^+$: 541	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
557		MW: 554.76 MS (ESI) $[M+1]^+$: 555	148 / 166
558		MW: 568.78 MS (ESI) $[M+1]^+$: 569	148 / 166
559		MW: 594.82 MS (ESI) $[M+1]^+$: 595	148 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
560		MW: 589.76 MS (ESI) $[M+1]^+$: 590	148 / 166
561		MW: 604.77 MS (ESI) $[M+1]^+$: 605	148 / 166
562		MW: 596.79 MS (ESI) $[M+1]^+$: 597	148 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
563	 4-(4-{[2-[1-Cyano-1-(2,3-dimethylcyclohexylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 608.85 MS (ESI) $[M+1]^+$: 609	148 / 166
564		MW: 568.78 MS (ESI) $[M+1]^+$: 569	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
565		MW: 614.77 MS (ESI) $[M+1]^+$: 615	148 / 166
566		MW: 616.83 MS (ESI) $[M+1]^+$: 617	148 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) [M+1] ⁺	Educt/ Synthesis as in the Case of
567	 4-(4-{[2-[1-Cyano-2-oxo-2-(4-pyridin-2-yl-piperazin-1-yl)-eth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 644.84 MS (ESI) [M+1] ⁺ : 645	 148 / 166
568		MW: 673.88 MS (ESI) [M+1] ⁺ : 674	 148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
569		MW: 583.80 MS (ESI) $[M+1]^+$: 584	148 / 166
570		MW: 614.81 MS (ESI) $[M+1]^+$: 615	148 / 166
571		MW: 638.83 MS (ESI) $[M+1]^+$: 639	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
572	 4-(4-{[2-[1-Cyano-1-(4-propylphenylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 616.83 MS (ESI) $[M+1]^+$: 617	148 / 166
573		MW: 617.82 MS (ESI) $[M+1]^+$: 618	148 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
574		MW: 628.84 MS (ESI) $[M+1]^+$: 629	148 / 166
575	 4-(4-{[2-[1-Cyano-1-[3-(2-methylpiperidin-1-yl)-propylcarbamoyl]-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 637.89 MS (ESI) $[M+1]^+$: 638	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
576		MW: 672.77 MS (ESI) $[M+1]^+$: 673	148 / 166
577		MW: 566.77 MS (ESI) $[M+1]^+$: 567	148 / 166
578		MW: 692.32 MS (ESI) $[M+1]^+$: 693	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
579		MW: 616.83 MS (ESI) $[M+1]^+$: 617	148 / 166
580	 4-(4-{[2-[2-[4-(4-Bromo-phenyl)-4-hydroxy-piperidin-1-yl]-1-cyano-2-oxo-eth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 737.76 MS (ESI) $[M+1]^+$: 738	148 / 166



Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
581		MW: 592.76 MS (ESI) $[M+1]^+$: 593	148 / 166
582		MW: 619.83 MS (ESI) $[M+1]^+$: 620	148 / 166
583		MW: 620.79 MS (ESI) $[M+1]^+$: 621	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
584		MW: 617.77 MS (ESI) $[M+1]^+$: 618	148 / 166
585		MW: 700.95 MS (ESI) $[M+1]^+$: 701	148 / 166
586		MW: 653.93 MS (ESI) $[M+1]^+$: 654	148 / 166




Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
587		MW: 666.84 MS (ESI) $[M+1]^+$: 667	148 / 166
588	 4-(4-{[2-[1-Cyano-1-[(tetrahydro-furan-2-ylmethyl)-carbamoyl]-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 582.77 MS (ESI) $[M+1]^+$: 583	148 / 166

Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
589		MW: 569.77 MS (ESI) $[M+1]^+$: 570	148 / 166
590		MW: 609.84 MS (ESI) $[M+1]^+$: 610	148 / 166
591		MW: 595.81 MS (ESI) $[M+1]^+$: 596	148 / 166






Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
592		MW: 625.83 MS (ESI) $[M+1]^+$: 626	148 / 166
593		MW: 638.88 MS (ESI) $[M+1]^+$: 639	148 / 166
594		MW: 639.91 MS (ESI) $[M+1]^+$: 640	148 / 166

Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
595		MW: 638.87 MS (ESI) $[M+1]^+$: 639	148 / 166
596	 4-(4-{[2-[1-Cyano-1-(2-morpholin-4-ylethylcarbamoyl)-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-phenyl)-N-(2-diethylamino-ethyl)-butyramide	MW: 611.81 MS (ESI) $[M+1]^+$: 612	148 / 166







Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
597		MW: 611.85 MS (ESI) $[M+1]^+$: 612	148 / 166
598		MW: 637.89 MS (ESI) $[M+1]^+$: 638	148 / 166
599		MW: 645.87 MS (ESI) $[M+1]^+$: 646	148 / 166

Example No.	Structure and Name	Molecular Weight/ MS (ESI) $[M+1]^+$	Educt/ Synthesis as in the Case of
600		MW: 597.82 MS (ESI) $[M+1]^+$: 598	148 / 166
601		MW: 642.79 MS (ESI) $[M+1]^+$: 643	148 / 166
602		MW: 659.85 MS (ESI) $[M+1]^+$: 660	148 / 166

The following compounds can also be produced analogously to the synthesis of Example 166.

Example	Structure
603	
604	
605	
606	
607	

Example	Structure
608	
609	
610	
611	
612	
613	

Example	Structure
614	
615	
616	
617	
618	
619	







[illegible]

Example	Structure
626	 <chem>CC1=C(C#N)C(=C(C(=O)NCC2CC2)C1=CN2C(=O)NC3=CC=CC=C3C(=O)NCC4CCCN4)C5=CC=CC=C6C(=C5)C(=O)NCC7CCCN7</chem>
627	 <chem>CC1=C(C#N)C(=C(C(=O)NCC2=CC=C(C=C2)F)C1=CN2C(=O)NC3=CC=CC=C3C(=O)NCC4CCCN4)C5=CC=CC=C6C(=C5)C(=O)NCC7CCCN7</chem>
628	 <chem>CC1=C(C#N)C(=C(C(=O)NCC2CCNCC2)C1=CN2C(=O)NC3=CC=CC=C3C(=O)NCC4CCCN4)C5=CC=CC=C6C(=C5)C(=O)NCC7CCCN7</chem>
629	 <chem>CC1=C(C#N)C(=C(C(=O)NCC2CCN(C)CC2)C1=CN2C(=O)NC3=CC=CC=C3C(=O)NCC4CCCN4)C5=CC=CC=C6C(=C5)C(=O)NCC7CCCN7</chem>
630	 <chem>CC1=C(C#N)C(=C(C(=O)NCC2CCN(CCCO)CC2)C1=CN2C(=O)NC3=CC=CC=C3C(=O)NCC4CCCN4)C5=CC=CC=C6C(=C5)C(=O)NCC7CCCN7</chem>
631	 <chem>CC1=C(C#N)C(=C(C(=O)NCC2CCOCC2)C1=CN2C(=O)NC3=CC=CC=C3C(=O)NCC4CCCN4)C5=CC=CC=C6C(=C5)C(=O)NCC7CCCN7</chem>

Example	Structure
632	 <chem>CCN1C(=O)NC(S1)C(=C(C#N)C(=O)NC(=O)Nc2ccncc2)CNC(=O)c3ccc4ccccc4c3CN5CCCC5</chem>
633	 <chem>CCN1C(=O)NC(S1)C(=C(C#N)C(=O)NC(=O)NCO)CNC(=O)c2ccc3ccccc3c2CN4CCCC4</chem>
634	 <chem>CCN1C(=O)NC(S1)C(=C(C#N)C(=O)NC(=O)NC(C)S)CNC(=O)c2ccc3ccccc3c2CN4CCCC4</chem>
635	 <chem>CCN1C(=O)NC(S1)C(=C(C#N)C(=O)NC(=O)NC(C)C)CNC(=O)c2ccc3ccccc3c2CN4CCCC4</chem>
636	 <chem>CCN1C(=O)NC(S1)C(=C(C#N)C(=O)NC(=O)NC(C1=CC=CC=C1)O)CNC(=O)c2ccc3ccccc3c2CN4CCCC4</chem>
637	 <chem>CCN1C(=O)NC(S1)C(=C(C#N)C(=O)NC(=O)Nc2ccncc2)CNC(=O)c3ccc4ccccc4c3CN5CCCC5</chem>

Example	Structure
644	 <chem>COCCNC(=O)C1=C(C#N)SC(=O)N1Cc2ccc3cc(NC(=O)OCCN4CCCC4)ccc3cc2</chem>
645	 <chem>CC(C)(CO)NC(=O)C1=C(C#N)SC(=O)N1Cc2ccc3cc(NC(=O)OCCN4CCCC4)ccc3cc2</chem>
646	 <chem>CCN1CCCC1CCNC(=O)C1=C(C#N)SC(=O)N1Cc2ccc3cc(NC(=O)OCCN4CCCC4)ccc3cc2</chem>
647	 <chem>CCN1CCCC1CCNC(=O)C1=C(C#N)SC(=O)N1Cc2ccc3cc(NC(=O)OCCN4CCCC4)ccc3cc2</chem>
648	 <chem>CCCNCCNC(=O)C1=C(C#N)SC(=O)N1Cc2ccc3cc(NC(=O)OCCN4CCCC4)ccc3cc2</chem>
649	 <chem>C1CCNC(=O)N1C(=O)C1=C(C#N)SC(=O)N1Cc2ccc3cc(NC(=O)OCCN4CCCC4)ccc3cc2</chem>

[illegible]

Example	Structure
656	
657	
658	
659	
660	
661	









Example	Structure
662	 <chem>CN(C)C(=O)N[C@@H]1C(=O)N(CC)C(=N1)Nc2ccc3cc(NC(=O)NCC4CCCC4)ccc3cc2</chem>
663	 <chem>CN(C)C(=O)N[C@@H]1C(=O)N(CC)C(=N1)Nc2ccc3cc(NC(=O)NCC4CCCC4)ccc3cc2</chem>
664	 <chem>CC(C)C(O)C(=O)N[C@@H]1C(=O)N(CC)C(=N1)Nc2ccc3cc(NC(=O)NCC4CCCC4)ccc3cc2</chem>
665	 <chem>CN1CCCC1C(=O)Nc2ccc3cc(NC(=O)NCC4CCCC4)ccc3cc2</chem>
666	 <chem>Oc1ccccc1NC(=O)[C@@H]2C(=O)N(CC)C(=N2)Nc3ccc4cc(NC(=O)NCC5CCCC5)ccc4cc3</chem>
667	 <chem>N#Cc1ccc(NC(=O)[C@@H]2C(=O)N(CC)C(=N2)Nc3ccc4cc(NC(=O)NCC5CCCC5)ccc4cc3)cc1</chem>








[illegible]

Example	Structure
681	
682	
683	
684	
685	
686	
687	








Example	Structure
688	
689	
690	
691	
692	
693	
694	
695	








Example	Structure
696	
697	
698	
699	
700	
701	
702	
703	

Example	Structure
704	
705	
706	
707	
708	
709	
710	
711	

Example	Structure
712	
713	
714	
715	
716	
717	
718	

Example	Structure
719	
720	
721	
722	
723	
724	
725	








Example	Structure
726	
727	
728	
729	
730	
731	
732	







Example	Structure
733	
734	
735	
736	
737	
738	
739	

Example	Structure
740	
741	
742	
743	
744	
745	
746	

Example	Structure
747	
748	
749	
750	
751	
752	
753	

[illegible]







Example	Structure
761	
762	
763	
764	
765	
766	
767	







Example	Structure
768	
769	
770	
771	
772	
773	







Example	Structure
774	
775	
776	
777	
778	
779	







Example	Structure
780	
781	
782	
783	
784	
785	







Example	Structure
786	 <chem>CCN1C(=O)C(S1)C(=C(C#N)C(=O)NCCCN2CCCC2)NC(=O)C3=CC=C(NC(=O)NCCCN4CCCC4)C=C3</chem>
787	 <chem>CCN1C(=O)C(S1)C(=C(C#N)C(=O)N2CCCC2)NC(=O)C3=CC=C(NC(=O)NCCCN4CCCC4)C=C3</chem>
788	 <chem>CCN1C(=O)C(S1)C(=C(C#N)C(=O)NCCCN2CCCC2)NC(=O)C3=CC=C(NC(=O)NCCCN4CCCC4)C=C3</chem>
789	 <chem>CCN1C(=O)C(S1)C(=C(C#N)C(=O)NCCCC)NC(=O)C2=CC=C(NC(=O)NCCCN3CCCC3)C=C2</chem>
790	 <chem>CCN1C(=O)C(S1)C(=C(C#N)C(=O)Nc2cc(O)ccc2)NC(=O)C3=CC=C(NC(=O)NCCCN4CCCC4)C=C3</chem>
791	 <chem>CCN1C(=O)C(S1)C(=C(C#N)C(=O)NCC(O)C)NC(=O)C2=CC=C(NC(=O)NCCCN3CCCC3)C=C2</chem>







Example	Structure
792	
793	
794	
795	
796	
797	







Example	Structure
798	
799	
800	
801	
802	
803	







Example	Structure
804	
805	
806	
807	
808	
809	







Example	Structure
810	
811	
812	
813	
814	
815	






Example	Structure
816	
817	
818	
819	
820	
821	






Example	Structure
822	
823	
824	
825	
826	
827	






Example	Structure
828	
829	
830	
831	
832	
833	

Example	Structure
834	
835	
836	
837	
838	
839	

Example	Structure
840	
841	
842	
843	
844	
845	






Example	Structure
846	
847	
848	
849	
850	

Example	Structure
851	
852	
853	
854	
855	






Example	Structure
856	
857	
858	
859	
860	






[illegible]

Example	Structure
866	
867	
868	
869	
870	






Example	Structure
871	 Chemical structure of compound 871: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with an ethyl group at the 2-position and a 4-((4-(4-(2-(2-(2-methoxyethyl)amino)ethyl)amino)phenyl)amino)phenyl)amino group at the 4-position. The 3-position of the thiazolidine ring is substituted with a 4-((4-(4-(2-(2-(2-methoxyethyl)amino)ethyl)amino)phenyl)amino)phenyl)amino group.
872	 Chemical structure of compound 872: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with an ethyl group at the 2-position and a 4-((4-(4-(2-(2-(2-methoxyethyl)amino)ethyl)amino)phenyl)amino)phenyl)amino group at the 4-position. The 3-position of the thiazolidine ring is substituted with a 4-((4-(4-(2-(2-(2-methoxyethyl)amino)ethyl)amino)phenyl)amino)phenyl)amino group.
873	 Chemical structure of compound 873: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with an ethyl group at the 2-position and a 4-((4-(4-(2-(2-(2-methoxyethyl)amino)ethyl)amino)phenyl)amino)phenyl)amino group at the 4-position. The 3-position of the thiazolidine ring is substituted with a 4-((4-(4-(2-(2-(2-methoxyethyl)amino)ethyl)amino)phenyl)amino)phenyl)amino group.
874	 Chemical structure of compound 874: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with an ethyl group at the 2-position and a 4-((4-(4-(2-(2-(2-methoxyethyl)amino)ethyl)amino)phenyl)amino)phenyl)amino group at the 4-position. The 3-position of the thiazolidine ring is substituted with a 4-((4-(4-(2-(2-(2-methoxyethyl)amino)ethyl)amino)phenyl)amino)phenyl)amino group.
875	 Chemical structure of compound 875: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with an ethyl group at the 2-position and a 4-((4-(4-(2-(2-(2-methoxyethyl)amino)ethyl)amino)phenyl)amino)phenyl)amino group at the 4-position. The 3-position of the thiazolidine ring is substituted with a 4-((4-(4-(2-(2-(2-methoxyethyl)amino)ethyl)amino)phenyl)amino)phenyl)amino group.

Example	Structure
876	
877	
878	
879	
880	






Example	Structure
881	 Chemical structure of compound 881: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with a 4-(4-(2-(pyrrolidin-1-yl)ethyl)benzoylamino)phenyl group at the 2-position and a 2-cyano-2-oxo-1-ethyl-1H-thiazolidine-4-carboxamide group at the 4-position. The amide group is further substituted with a 1-phenylethanol moiety.
882	 Chemical structure of compound 882: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with a 4-(4-(2-(pyrrolidin-1-yl)ethyl)benzoylamino)phenyl group at the 2-position and a 2-cyano-2-oxo-1-ethyl-1H-thiazolidine-4-carboxamide group at the 4-position. The amide group is further substituted with a 2-(dimethylamino)-2-methylpropyl moiety.
883	 Chemical structure of compound 883: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with a 4-(4-(2-(pyrrolidin-1-yl)ethyl)benzoylamino)phenyl group at the 2-position and a 2-cyano-2-oxo-1-ethyl-1H-thiazolidine-4-carboxamide group at the 4-position. The amide group is further substituted with a 2-(methylthio)ethyl moiety.
884	 Chemical structure of compound 884: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with a 4-(4-(2-(pyrrolidin-1-yl)ethyl)benzoylamino)phenyl group at the 2-position and a 2-cyano-2-oxo-1-ethyl-1H-thiazolidine-4-carboxamide group at the 4-position. The amide group is further substituted with a 2-(piperidin-1-yl)ethyl moiety.
885	 Chemical structure of compound 885: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with a 4-(4-(2-(pyrrolidin-1-yl)ethyl)benzoylamino)phenyl group at the 2-position and a 2-cyano-2-oxo-1-ethyl-1H-thiazolidine-4-carboxamide group at the 4-position. The amide group is further substituted with a 2-(4-methylpiperidin-1-yl)ethyl moiety.

Example	Structure
886	
887	
888	
889	
890	







Example	Structure
891	 <chem>CCN1C(=O)C(S1)C(=N2C(=O)N(CC)C2=CC(=O)NCCN3CCCC3)C(=O)N4CCCC4</chem>
892	 <chem>CCN1C(=O)C(S1)C(=N2C(=O)N(CC)C2=CC(=O)NCCN3CCCC3)C(=O)N4CCCC4</chem>
893	 <chem>CCN1C(=O)C(S1)C(=N2C(=O)N(CC)C2=CC(=O)NCCN3CCCC3)C(=O)N4CCCC4</chem>
894	 <chem>CCN1C(=O)C(S1)C(=N2C(=O)N(CC)C2=CC(=O)NCCN3CCCC3)C(=O)N4CCCC4</chem>
895	 <chem>CCN1C(=O)C(S1)C(=N2C(=O)N(CC)C2=CC(=O)NCCN3CCCC3)C(=O)N4CCCC4</chem>








Example	Structure
896	
897	
898	
899	
900	

[illegible]

Example	Structure
906	 Chemical structure of Example 906: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with a 4-(4-(2-(2-(dimethylamino)ethyl)carbamoyl)phenyl)amino group at the 2-position and a 2-cyano-2-(dimethylamino)ethyl group at the 4-position. The thiazolidine ring also has a carbonyl group at the 3-position and a methyl group at the 5-position.
907	 Chemical structure of Example 907: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with a 4-(4-(2-(2-(dimethylamino)ethyl)carbamoyl)phenyl)amino group at the 2-position and a 2-cyano-2-(dimethylamino)ethyl group at the 4-position. The thiazolidine ring also has a carbonyl group at the 3-position and a methyl group at the 5-position.
908	 Chemical structure of Example 908: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with a 4-(4-(2-(2-(dimethylamino)ethyl)carbamoyl)phenyl)amino group at the 2-position and a 2-cyano-2-(dimethylamino)ethyl group at the 4-position. The thiazolidine ring also has a carbonyl group at the 3-position and a methyl group at the 5-position.
909	 Chemical structure of Example 909: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with a 4-(4-(2-(2-(dimethylamino)ethyl)carbamoyl)phenyl)amino group at the 2-position and a 2-cyano-2-(dimethylamino)ethyl group at the 4-position. The thiazolidine ring also has a carbonyl group at the 3-position and a methyl group at the 5-position.
910	 Chemical structure of Example 910: A thiazolidine-4-carboxamide derivative. The thiazolidine ring is substituted with a 4-(4-(2-(2-(dimethylamino)ethyl)carbamoyl)phenyl)amino group at the 2-position and a 2-cyano-2-(dimethylamino)ethyl group at the 4-position. The thiazolidine ring also has a carbonyl group at the 3-position and a methyl group at the 5-position.








Example	Structure
911	 <chem>CCN1C(=O)C(S1C(=O)N2C(=O)N(C2)C3=CC=C(C=C3)NC(=O)N4CCCN4C5=CC=CC=C5C#N)C(=O)N6=CC=CC=C6C#N</chem>
912	 <chem>CCN1C(=O)C(S1C(=O)N2C(=O)N(C2)C3=CC=C(C=C3)NC(=O)N4CCCN4C5=CC=CC=C5C#N)C(=O)N6=CC=CC=C6C#N</chem>
913	 <chem>CCN1C(=O)C(S1C(=O)N2C(=O)N(C2)C3=CC=C(C=C3)NC(=O)N4CCCN4C5=CC=CC=C5C#N)C(=O)N6=CC=CC=C6C#N</chem>
914	 <chem>CCN1C(=O)C(S1C(=O)N2C(=O)N(C2)C3=CC=C(C=C3)NC(=O)N4CCCN4C5=CC=CC=C5C#N)C(=O)N6=CC=CC=C6C#N</chem>
915	 <chem>CCN1C(=O)C(S1C(=O)N2C(=O)N(C2)C3=CC=C(C=C3)NC(=O)N4CCCN4C5=CC=CC=C5C#N)C(=O)N6=CC=CC=C6C#N</chem>








Example	Structure
916	
917	
918	
919	
920	
921	







Example	Structure
922	
923	
924	
925	
926	
927	
928	

Example	Structure
929	 <chem>CC1CN(C(=O)N1C#N)C(=O)NCCc2ccc(NCCN3CCCC3)cc2C(=O)NCC(C)C</chem>
930	 <chem>CC1CN(C(=O)N1C#N)C(=O)NCCc2ccc(NCCN3CCCC3)cc2C(=O)NCC</chem>
931	 <chem>CC1CN(C(=O)N1C#N)C(=O)NCCc2ccc(NCCN3CCCC3)cc2C(=O)NCC=C</chem>
932	 <chem>CC1CN(C(=O)N1C#N)C(=O)NCCc2ccc(NCCN3CCCC3)cc2C(=O)NCC1CC1</chem>
933	 <chem>CC1CN(C(=O)N1C#N)C(=O)NCCc2ccc(NCCN3CCCC3)cc2C(=O)NCCN4CCCCC4</chem>
934	 <chem>CC1CN(C(=O)N1C#N)C(=O)NCCc2ccc(NCCN3CCCC3)cc2C(=O)NCCN4CCNCC4</chem>
935	 <chem>CC1CN(C(=O)N1C#N)C(=O)NCCc2ccc(NCCN3CCCC3)cc2C(=O)NCCN4CCNCC4CO</chem>






Example	Structure
936	<chem>CCN1C(=O)C(S1C(=O)N1CCc2ccc(cc2)N3CCCC3)C(=O)N1CCc2ccc(cc2)N3CCCC3</chem>
937	<chem>CCN1C(=O)C(S1C(=O)N1CCc2ccc(cc2)N3CCCC3)C(=O)N1CCc2ccc(cc2)N3CCCC3</chem>
938	<chem>CCN1C(=O)C(S1C(=O)N1CCc2ccc(cc2)N3CCCC3)C(=O)N1CCc2ccc(cc2)N3CCCC3</chem>
939	<chem>CCN1C(=O)C(S1C(=O)N1CCc2ccc(cc2)N3CCCC3)C(=O)N1CCc2ccc(cc2)N3CCCC3</chem>
940	<chem>CCN1C(=O)C(S1C(=O)N1CCc2ccc(cc2)N3CCCC3)C(=O)N1CCc2ccc(cc2)N3CCCC3</chem>
941	<chem>CCN1C(=O)C(S1C(=O)N1CCc2ccc(cc2)N3CCCC3)C(=O)N1CCc2ccc(cc2)N3CCCC3</chem>
942	<chem>CCN1C(=O)C(S1C(=O)N1CCc2ccc(cc2)N3CCCC3)C(=O)N1CCc2ccc(cc2)N3CCCC3</chem>

Example	Structure
943	
944	
945	
946	
947	
948	
949	

Example	Structure
950	
951	
952	
953	
954	
955	
956	

Example	Structure
957	
958	
959	
960	
961	
962	

Example	Structure
963	
964	
965	
966	
967	
968	
969	
970	
971	
972	
973	

Example	Structure
974	
975	
976	
977	
978	

Example 1

The following examples describe the biological action of the compounds according to the invention:

PLK Enzyme Assay

Recombinant human Plk-1 (6xHis) was purified from baculovirus-infected insect cells (Hi5).

10 ng of (produced in a recombinant manner and purified) PLK enzyme is incubated for 90 minutes at room temperature with biotinylated casein and 33P- γ -ATP as a substrate in a volume of 15 μ l in 384-well Greiner small-volume microtiter plates (final concentrations in the buffer: 660 ng/ml of PLK; 0.7 μ mol of casein, 0.5 μ mol of ATP incl. 400 nCi/ml of 33P- γ -ATP; 10 mmol of MgCl₂, 1 mmol of MnCl₂; 0.01% NP40; 1 mmol of DTT, protease inhibitors; 0.1 mmol of Na₂VO₃ in 50 mmol of HEPES, pH 7.5). To complete the reaction, 5 μ l of stop solution (500 μ mol of ATP; 500 mmol of EDTA; 1% Triton X100; 100 mg/ml of streptavidin-coated SPA beads in PBS) is added. After the microtiter plate is sealed by film, the beads are sedimented by centrifuging (10 minutes, 1500 rpm). The incorporation of 33P- γ -ATP in casein is intended as a measurement of enzyme activity by β -counting. The extent of the inhibitor activity is referenced against a solvent control (= uninhibited enzyme activity = 0% inhibition) and the mean value of several batches that contained 300 μ mol of wortmannin (= completely inhibited enzyme activity = 100% inhibition).







Test substances are used in various concentrations (0 μ mol, as well as in the range of 0.01 - 30 μ mol). The final concentration of the solvent dimethyl sulfoxide is 1.5% in all batches.


Proliferation Assay

Cultivated human MaTu breast tumor cells were flattened out at a density of 5000 cells/measuring point in a 96-well multititer plate in 200 μ l of the corresponding growth medium. After 24 hours, the cells of one plate (zero-point plate) were colored with crystal violet (see below), while the medium of the other plates was replaced by fresh culture medium (200 μ l), to which the test substances were added in various concentrations (0 μ M, as well as in the range of 0.01-30 μ M; the final concentration of the solvent dimethyl sulfoxide was 0.5%). The cells were incubated for 4 days in the presence of test substances. The cell proliferation was determined by coloring the cells with crystal violet: the cells were fixed by adding 20 μ l/measuring point of an 11% glutaric aldehyde solution for 15 minutes at room temperature. After three washing cycles of the fixed cells with water, the plates were dried at room temperature. The cells were colored by adding 100 μ l/measuring point of a 0.1% crystal violet solution (pH was set at 3 by adding acetic acid). After three washing cycles of the colored cells with water, the plates were dried at room temperature. The dye was dissolved by adding 100 μ l/measuring point of a 10% acetic acid solution. The extinction was determined by photometry at a wavelength of 595 nm. The change of cell growth, in percent, was calculated by standardization of the measured values to the extinction values of the zero-point plate (=0%) and the extinction of the untreated (0 μ M) cells (=100%).

The results of the PLK enzyme assay are presented in Table 1 below:




Table 1:

Example No.	Structure	PLK IC ₅₀ [nM]
25		36
7		46
36		160
19		500
56		810
234		950

Example No.	Structure	PLK IC50 [nM]
223		3100

The results of other PLK enzyme assays and the proliferation assay are presented in Tables 2 and 3 below:

Table 2: Amides

Example No.	Structure	Inhibition of Plk-1 IC50 [nM]	Inhibition of Tumor Cell Proliferation (MaTu) IC50 [μM]
527		100	2.8
310		74	5.6
307		71	1.7









Example No.	Structure	Inhibition of Plk-1 IC ₅₀ [nM]	Inhibition of Tumor Cell Proliferation (MaTu) IC ₅₀ [μM]
330		41	1.2
169		345	3.55
192		190	9.7
210		270	4.5

Table 3: Esters

Example No.	Structure	Inhibition of Plk-1 IC ₅₀ [nM]	Inhibition of Tumor Cell Proliferation (MaTu) IC ₅₀ [μM]
133		34	1.4

Example No.	Structure	Inhibition of Plk-1 IC50 [nM]	Inhibition of Tumor Cell Proliferation (MaTu) IC50 [μ M]
132		81	3.1
47		23	1.1
74		37	3.3

Tables 1 to 3 show that the compounds according to the invention inhibit PLK in the nanomolar range.

Description of the Figure

Fig. 1 shows the function of Plk-1

Here:

1. Entry into mitosis: Plk-1 activates CDC25 C. This results in the activation of the CDK/cyclin B complex and converts the cell from G2 to M-status.
2. Triggering of mitosis: Plk 1 plays an important role during the cytokinesis, especially in the formation of the bipolar spindle apparatus and the chromosome separation during the late mitosis phase. Plk-1 is also required during centrosome maturation and binds to so-called 'kinesin motors.'
3. Completion of mitosis: Plk-1 activates the APC/C complex (anaphase promoting complex/cyclosome; Kotani et al. 1998;). APC/C catalyzes as E3-enzyme the polyubiquitylation of specific substrates, such as, e.g., cyclin B. Such an ubiquitylation of proteins ultimately results in their degradation into proteasomes. This in turn leads to a reduction of cell-cycle regulators below a critical value and in the exit from the mitosis phase in the so-called G1-status of the cell (M→G1 transition).

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

In the foregoing and in the examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.


The entire disclosures of all applications, patents and publications, cited herein and of corresponding Germany Application No. 10351744.8-44, filed October 31, 2003, and U.S. Provisional Application Serial No. 60/517,061, filed November 5, 2003 are incorporated by reference herein.

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims

1. Compounds of general formula I



(I),

in which

Q stands for aryl or heteroaryl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro,

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-

heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the

heterocycloalkyl itself optionally can be interrupted by one or more nitrogen,

oxygen and/or sulfur atoms and/or optionally can be interrupted by one or

more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double

bonds can be contained in the ring, and/or the ring itself optionally can be

substituted in one or more more places, in the same way or differently, with

C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for $-\text{NR}^3(\text{CO})-\text{L}$, $-\text{NR}^3(\text{CO})-\text{NR}^3-\text{L}$, $-\text{COR}^6$, $-\text{CO}(\text{NR}^3)-\text{M}$, $-\text{NR}^3(\text{CS})\text{NR}^3\text{R}^4$,
 $-\text{NR}^3\text{SO}_2-\text{M}$, $-\text{SO}_2-\text{NR}^3\text{R}^4$ or $-\text{SO}_2(\text{NR}^3)-\text{M}$,

- L** stands for C_1 - C_6 -alkyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with C_1 - C_6 -hydroxyalkoxy, C_1 - C_6 -alkoxyalkoxy, C_3 - C_6 -heterocycloalkyl or with the group $-\text{NR}^3\text{R}^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(\text{CO})-$ or $-\text{SO}_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_1 - C_6 -hydroxyalkyl or with the group $-\text{NR}^3\text{R}^4$,
- M** stands for C_1 - C_6 -alkyl that is optionally substituted in one or more places, in the same way or differently, with the group $-\text{NR}^3\text{R}^4$ or C_3 - C_6 -heterocycloalkyl,
- X** stands for $-\text{NH}-$ or $-\text{NR}^5-$,
- R¹** stands for C_1 - C_4 -alkyl, C_3 -cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,
- R²** stands for hydrogen or for C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, C_1 - C_6 -alkenyl, C_1 - C_6 -alkinyl, C_3 - C_6 -cycloalkyl, C_3 - C_6 -heterocycloalkyl, aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, C_1 - C_6 -hydroxyalkyl, C_3 - C_6 -cycloalkyl, C_3 - C_6 -heterocycloalkyl, C_1 - C_6 -alkinyl, aryl, aryloxy, heteroaryl or with the group $-\text{S}-\text{C}_1$ - C_6 -alkyl, $-\text{COR}^6$, $-\text{NR}^3\text{R}^4$, $-\text{NR}^3(\text{CO})-\text{L}$ or $-\text{NR}^3\text{COOR}^7$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(\text{CO})-$ or $-\text{SO}_2-$ groups in the ring, and/or

optionally one or more double bonds can be contained in the ring, and whereby aryl, heteroaryl, C₃-C₆-cycloalkyl- and/or the C₃-C₆-heterocycloalkyl ring in each case itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl or C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl, benzyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen,

or

for the group -NR³R⁴, -NR³(CO)-L, or -NR³(CS)NR³R⁴,

or

R² and R⁵ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted at least one time by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more-(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl or with the group -NR³R⁴ or -COR⁶, and/or can be substituted with aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, C₁-C₆-alkoxy or with the group -COR⁶,

R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, -CO-C₁-C₆-alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or

more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C_3 - C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C_1 - C_6 -alkyl, C_1 - C_6 -hydroxyalkyl, C_1 - C_6 -alkoxy, C_3 - C_6 -cycloalkyl, or with the group $-NR^3R^4$ or $-CO-NR^3R^4$,

or

R^3 and R^4 together form a C_3 - C_6 -heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_1 - C_6 -hydroxyalkyl, C_1 - C_6 -alkoxyalkyl, cyano, hydroxy or with the group $-NR^3R^4$,

R^5 stands for C_1 - C_6 -alkyl, C_1 - C_6 -alkenyl, or C_1 - C_6 -alkinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C_1 - C_6 -alkoxy, C_3 - C_6 -cycloalkyl, C_3 - C_6 -heterocycloalkyl, or with the group $-NR^3R^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C_3 - C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with

cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

R⁶ stands for hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy or the group -NR³R⁴,

R⁷ stands for -(CH₂)_n-aryl or -(CH₂)_n-heteroaryl and

n stands for 1 - 6,

as well as their stereoisomers, diastereomers, enantiomers and salts,

with the stipulation that the following compounds do not fall under general formula (I):

{2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetyl-amino}-acetic acid methyl ester,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-pyridin-3-ylmethyl-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(3-imidazol-1-yl-propyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(4-fluoro-benzyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(3-morpholin-4-yl-propyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(2-morpholin-4-yl-ethyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-[3-(2-oxo-pyrrolidin-1-yl)-propyl]-acetamide,

2-Cyano-N-cyclohexyl-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

4-{2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetyl-amino}-piperidine-1-carboxylic acid ethyl ester,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(3-hydroxy-propyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(4-methoxy-benzyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-[2-(4-hydroxy-phenyl)-ethyl]-acetamide,

N-Allyl-2-cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(2-hydroxy-ethyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(4-hydroxy-butyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N-(6-hydroxy-hexyl)-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

2-Cyano-N-ethyl-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetamide,

2-Cyano-2-[3-ethyl-5-[1-(4-methoxy-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide,

2-Cyano-2-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide,

6-{[2-[1-Cyano-1-dimethylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-naphthalene-2-carboxylic acid,

4-{[2-[1-Cyano-1-dimethylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-benzoic acid,

2-Cyano-2-[3-ethyl-5-[1-(4-hydroxy-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide,

4-{[2-[1-Cyano-1-dimethylcarbamoyl-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(5-(E/Z))-ylidenemethyl]-amino}-benzamide,

2-Cyano-2-[3-ethyl-5-[1-(4-hydroxymethyl-phenylamino)-meth-(E/Z)-ylidene]-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-N,N-dimethyl-acetamide.

2. Compounds of general formula I, according to claim 1, in which

Q stands for phenyl, naphthyl, quinoliny, benzimidazolyl, indolyl, indazolyl, thiazolyl, imidazolyl or pyridyl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for -NR³(CO)-L, -NR³(CO)-NR³-L, -COR⁶, -CO(NR³)-M, -NR³(CS)NR³R⁴, -NR³SO₂-M, -SO₂-NR³R⁴ or -SO₂(NR³)-M,

L stands for C₁-C₆-alkyl or heteroaryl that is optionally substituted in one or

more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-C₆-alkoxyalkoxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -NR³R⁴ or C₃-C₆-heterocycloalkyl,

X stands for -NH- or -NR⁵-,

R¹ stands for C₁-C₄-alkyl, C₃-cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,

R² stands for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-alkenyl, C₁-C₆-alkinyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-hydroxyalkyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, C₁-C₆-alkinyl, aryl, aryloxy, heteroaryl or with the group -S-C₁-C₆-alkyl, -COR⁶, -NR³R⁴, -NR³(CO)-L or -NR³COOR⁷, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby aryl, heteroaryl, C₃-C₆-cycloalkyl- and/or the C₃-C₆-heterocycloalkyl ring in each case itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-

C₆-alkyl, C₁-C₆-hydroxyalkyl, or C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl, benzyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen,

or

for the group -NR³R⁴, -NR³(CO)-L, or -NR³(CS)NR³R⁴,

or

R² and R⁵ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl or with the group -NR³R⁴ or -COR⁶, and/or with aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, C₁-C₆-alkoxy or with the group -COR⁶,

R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, -CO-C₁-C₆-alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in

the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

or

R³ and R⁴ together form a C₃-C₆-heterocycloalkyl ring, which is interrupted by nitrogen at least once and optionally can be interrupted in one or more places by oxygen or sulfur, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxyalkyl, cyano, hydroxy or with the group -NR³R⁴,

R⁵ stands for C₁-C₆-alkyl, C₁-C₆-alkenyl, or C₁-C₆-alkinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

R⁶ stands for hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy or the group -NR³R⁴,

R⁷ stands for -(CH₂)_n-aryl or -(CH₂)_n-heteroaryl and

n stands for 1 - 6,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

3. Compounds of general formula I, according to claim 1 or 2, in which

Q stands for phenyl, naphthyl or indolyl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-

heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen,

oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double

bonds can be contained in the ring, and/or the ring itself optionally can be

substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for -NR³(CO)-L, -NR³(CO)-NR³-L, -COR⁶, -CO(NR³)-M, -NR³(CS)NR³R⁴, -NR³SO₂-M, -SO₂-NR³R⁴ or -SO₂(NR³)-M,

L stands for C₁-C₆-alkyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-C₆-alkoxyalkoxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be

substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -NR³R⁴ or C₃-C₆-heterocycloalkyl,

X stands for -NH- or -NR⁵-,

R¹ stands for C₁-C₄-alkyl, C₃-cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,

R² stands for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-alkenyl, C₁-C₆-alkinyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-hydroxyalkyl, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, C₁-C₆-alkinyl, aryl, aryloxy, heteroaryl or with the group -S-C₁-C₆-alkyl, -COR⁶, -NR³R⁴, -NR³(CO)-L or -NR³COOR⁷,

whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring,

and whereby aryl, heteroaryl, C₃-C₆-cycloalkyl- and/or the C₃-C₆-heterocycloalkyl ring in each case itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, or C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, C₃-C₆-heterocycloalkyl, aryl, benzyl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen,

or

for the group -NR³R⁴, -NR³(CO)-L, or -NR³(CS)NR³R⁴,

or

R^2 and R^5 together form a C_3 – C_6 -heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, C_1 – C_6 -alkyl, C_3 – C_6 -cycloalkyl, C_1 – C_6 -hydroxyalkyl, C_1 – C_6 -alkoxyalkyl or with the group $-NR^3R^4$ or $-COR^6$, and/or can be substituted with aryl or heteroaryl that is optionally substituted in one or more places, in the same way or differently, with halogen, C_1 – C_6 -alkoxy or with the group $-COR^6$,

R^3 and R^4 , independently of one another, stand for hydrogen or for C_1 – C_6 -alkyl, C_1 – C_6 -alkoxy, $-CO$ – C_1 – C_6 -alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C_3 – C_6 -heterocycloalkyl, C_1 – C_6 -hydroxyalkoxy or with the group $-NR^3R^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C_3 – C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C_1 – C_6 -alkyl, C_1 – C_6 -hydroxyalkyl, C_1 – C_6 -alkoxy, C_3 – C_6 -cycloalkyl, or with the group $-NR^3R^4$ or $-CO-NR^3R^4$,

or

R^3 and R^4 together form a C_3 – C_6 -heterocycloalkyl ring, which is interrupted at least

once by nitrogen, and optionally can be interrupted in one or more places by oxygen or sulfur, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring,

and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C_1-C_6 -alkyl, C_3-C_6 -cycloalkyl, C_1-C_6 -hydroxyalkyl, C_1-C_6 -alkoxyalkyl, cyano, hydroxy or with the group $-NR^3R^4$,

R^5 stands for C_1-C_6 -alkyl, C_1-C_6 -alkenyl, or C_1-C_6 -alkinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C_1-C_6 -alkoxy, C_3-C_6 -cycloalkyl, C_3-C_6 -heterocycloalkyl, or with the group $-NR^3R^4$, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C_3-C_6 -heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C_1-C_6 -alkyl, C_1-C_6 -hydroxyalkyl, C_1-C_6 -alkoxy, C_3-C_6 -cycloalkyl, or with the group $-NR^3R^4$ or $-CO-NR^3R^4$,

R^6 stands for hydroxy, C_1-C_6 -alkyl, C_1-C_6 -alkoxy or the group $-NR^3R^4$,

R^7 stands for $-(CH_2)_n$ -aryl or $-(CH_2)_n$ -heteroaryl and

n stands for 1 - 6,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

4. Compounds of general formula I, according to one of the above-mentioned claims, in which

Q stands for phenyl, naphthyl or indolyl,

- A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro
- or
- for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with pyrrolidinyl, piperidinyl, piperazinyl or with the group -N(C₁-C₆-alkyl)₂, whereby pyrrolidinyl, piperidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl or C₁-C₆-hydroxyalkyl,
- or
- for -CO(NH)-M, -CO(NCH₃)-M, -NH(CO)-L, -NH(CO)-NH-L, -SO₂(NH)-M or -SO₂(NCH₃)-M,
- L stands for C₁-C₆-alkyl or pyridyl that is optionally substituted in one or more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-C₆-alkoxyalkoxy, pyrrolidinyl, piperazinyl or with the group -N(C₁-C₆-alkyl)₂, whereby the pyrrolidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl,
- M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -N(C₁-C₆-alkyl)₂ or pyrrolidinyl,
- X stands for -NH- or -NR⁵-,
- R¹ stands for C₁-C₄-alkyl that is optionally substituted in one or more places, in the same way or differently, with halogen,
- R² stands for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkenyl, C₁-C₆-alkinyl, C₃-C₆-cycloalkyl, pyrrolidinyl, piperidinyl, phenyl, tetralinyl or indolyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₁-C₆-hydroxyalkyl, C₃-C₆-cycloalkyl, tetrahydrofuranyl, pyrrolidinyl, piperazinyl, morpholinyl,

phenyl, phenoxy, biphenyl, naphthyl, thienyl, furanyl, tetrazolyl, pyridyl or with the group $-S-C_1-C_6\text{-alkyl}$, $-\text{CONH}_2$, $-\text{COO}-C_1-C_6\text{-alkyl}$, $-\text{N}(C_1-C_6\text{-alkyl})_2$, $-\text{N}(C_1-C_6\text{-alkyl})\text{phenyl}$, or $-\text{NH}(\text{CO})-\text{L}$,

whereby phenyl, furanyl, $C_3-C_6\text{-cycloalkyl}$, piperidinyl or piperazinyl in each case itself optionally can be substituted in one or more places, in the same way or differently, with $C_1-C_6\text{-alkyl}$, $C_1-C_6\text{-alkoxy}$, cyano, halogen, hydroxy, phenyl, benzyl, or morpholinyl, and the $C_1-C_6\text{-alkyl}$ or $C_1-C_6\text{-alkoxy}$ itself optionally can be substituted in one or more places, in the same way or differently, with halogen,

or

for the group $-\text{N}(C_1-C_6\text{-alkyl})_2$, $-\text{NH}(\text{CO})-\text{L}$, or $-\text{NCH}_3(\text{CS})\text{NHCH}_3$,

or

R^2 and R^5 together form aziridinyl, azetidiny, morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl, whereby aziridinyl, azetidiny, morpholinyl, pyrrolidinyl, piperidinyl or piperazinyl itself optionally can be substituted in one or more places, in the same way or differently, with hydroxy, $C_1-C_6\text{-alkyl}$, $C_1-C_6\text{-hydroxyalkyl}$, $C_1-C_6\text{-alkoxyalkyl}$ or with the group $-\text{CONH}_2$, $-\text{CO}-C_1-C_6\text{-alkyl}$ or $-\text{COO}-C_1-C_6\text{-alkyl}$, and/or can be substituted with phenyl, benzyl or pyridyl that is optionally substituted in one or more places, in the same way or differently, with halogen or $C_1-C_6\text{-alkoxy}$, and

R^5 stands for $C_1-C_6\text{-alkyl}$ or $C_1-C_6\text{-alkenyl}$ that is optionally substituted in one or more places, in the same way or differently, with $C_1-C_6\text{-alkoxy}$,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

5. Compounds of general formula (I), according to the above-mentioned claims, in which

Q stands for phenyl, naphthyl or indolyl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro,

or

for C₁-C₃-alkyl or C₁-C₃-alkoxy that is optionally substituted in one or more places, in the same way or differently, with pyrrolidinyl, piperidinyl,

piperazinyl or with the group -N(CH₃)₂ or -CO(NH)-(CH₂)₂-N(CH₃)₂,


whereby pyrrolidinyl, piperidinyl or piperazinyl itself optionally can be

substituted in one or more places, in the same way or differently, with C₁-C₃-alkyl or C₁-C₃-hydroxyalkyl,

or




for the group -CO-NH-(CH₂)₂-N(CH₃)₂, -CO-NH-(CH₂)₂-N(C₂H₅)₂, -CO-

N(CH₃)-(CH₂)₂-N(CH₃)₂,



-NH(CO)-C(CH₃)₃, -NH(CO)-(CH₂)-O(CH₂)₂-OCH₃, -NH(CO)-(CH₂)₂-

N(C₂H₅)₂,



or $-\text{SO}_2\text{-NH-(CH}_2)_2\text{-N(CH}_3)_2$ or $-\text{SO}_2\text{-N(CH}_3\text{)-(CH}_2)_2\text{-N(CH}_3)_2$,

X stands for $-\text{NH-}$ or $-\text{NR}^5$ -,

R^1 stands for $\text{C}_1\text{-C}_3$ -alkyl that is optionally substituted in one or more places, in the same way or differently, with halogen,


R^2 stands for hydrogen or for $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_1\text{-C}_4$ -alkenyl, $\text{C}_1\text{-C}_4$ -alkinyl, $\text{C}_3\text{-C}_6$ -cycloalkyl, piperidinyl, phenyl, pyrrolidinyl, indolyl or tetralinyl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, cyano, $\text{C}_1\text{-C}_6$ -alkyl, $\text{C}_1\text{-C}_6$ -hydroxyalkyl, methoxy, $\text{C}_3\text{-C}_6$ -cycloalkyl, tetrahydrofuranyl, pyrrolidinyl, piperazinyl, morpholinyl, phenyl, phenoxy, biphenyl, naphthyl, thienyl, furanyl, tetrazolyl or pyridyl or with the group $-\text{S-CH}_3$, $-\text{COOCH}_3$, $-\text{COOC}_2\text{H}_5$, $-\text{CO-NH}_2$, $-\text{OCF}_3$, $-\text{N(CH}_3\text{)-phenyl}$, $-\text{N(C}_1\text{-C}_4\text{-alkyl)}_2$, or $-\text{NH(CO)-CH}_3$, whereby phenyl, furanyl, $\text{C}_3\text{-C}_6$ -cycloalkyl, piperidinyl or piperazinyl optionally in each case itself can be substituted in one or more places, in the same way or differently, with cyano, halogen, hydroxy, $\text{C}_1\text{-C}_3$ -alkyl, $\text{C}_1\text{-C}_3$ -hydroxyalkyl, methoxy, morpholinyl, phenyl or benzyl,

or

for the group $-\text{N(CH}_3)_2$, $-\text{N(CH}_3\text{)(CS)NHCH}_3$, $-\text{NH(CO)-CH}_3$, $-\text{NH(CO)-pyridyl}$, or $-\text{NH(CO)-pyridinyl}$,

or

R^2 and R^5 together form one of the following rings:




[or]

and

R^5 stands for C_1 - C_3 -alkyl or C_1 - C_3 -alkenyl that is optionally substituted in one or

more places, in the same way or differently, with C₁-C₆-alkoxy, as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

6. Compounds of general formula IA



in which

Q stands for aryl or heteroaryl,

A and B, independently of one another, stand for hydrogen, halogen, hydroxy, amino or nitro

or

for C₁-C₃-alkyl or C₁-C₆-alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-

heterocycloalkyl or with the group -NR³R⁴ or -CO(NR³)-M, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen,

oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or

more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double

bonds can be contained in the ring, and/or the ring itself optionally can be

substituted in one or more places, in the same way or differently, with C₁-C₆-

alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

or

for -NR³(CO)-L, -NR³(CO)-NR³-L, -COR⁶, -CO(NR³)-M, -NR³(CS)NR³R⁴,

-NR³SO₂-M, -SO₂-NR³R⁴ or -SO₂(NR³)-M,

L stands for C₁-C₆-alkyl or heteroaryl that is optionally substituted in one or

more places, in the same way or differently, with C₁-C₆-hydroxyalkoxy, C₁-C₆-alkoxyalkoxy, C₃-C₆-heterocycloalkyl or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the ring itself optionally can be substituted in one or more places, in the same way or differently, with C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-hydroxyalkyl or with the group -NR³R⁴,

M stands for C₁-C₆-alkyl that is optionally substituted in one or more places, in the same way or differently, with the group -NR³R⁴ or C₃-C₆-heterocycloalkyl,

R¹ stands for C₁-C₄-alkyl, C₃-cycloalkyl, allyl or propargyl that is optionally substituted in one or more places, in the same way or differently, with halogen,

R^{2a} stands for allyl or propargyl,

R³ and R⁴, independently of one another, stand for hydrogen or for C₁-C₆-alkyl, C₁-C₆-alkoxy, -CO-C₁-C₆-alkyl or aryl that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy, C₃-C₆-heterocycloalkyl, C₁-C₆-hydroxyalkoxy or with the group -NR³R⁴, whereby the heterocycloalkyl itself optionally can be interrupted by one or more nitrogen, oxygen and/or sulfur atoms, and/or optionally can be interrupted by one or more -(CO)- or -SO₂- groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and whereby the C₃-C₆-heterocycloalkyl ring itself in each case optionally can be substituted in one or more places, in the same way or differently, with cyano, halogen, C₁-C₆-alkyl, C₁-C₆-hydroxyalkyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyl, or with the group -NR³R⁴ or -CO-NR³R⁴,

or

R^3 and R^4 together form a C_3 – C_6 -heterocycloalkyl ring, which is interrupted at least once by nitrogen and optionally can be interrupted in one or more places by oxygen or sulfur, and/or optionally can be interrupted by one or more $-(CO)-$ or $-SO_2-$ groups in the ring, and/or optionally one or more double bonds can be contained in the ring, and/or the heterocycloalkyl ring itself optionally can be substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkyl, C_3 – C_6 -cycloalkyl, C_1 - C_6 -hydroxyalkyl, C_1 - C_6 -alkoxyalkyl, cyano, hydroxy or with the group $-NR^3R^4$, and

R^6 stands for hydroxy, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy or the group $-NR^3R^4$, as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

7. Compounds of general formula IA, according to claim 6, in which

Q stands for phenyl, quinolinyl, indolyl or naphthyl,

A and B, independently of one another, stand for hydrogen or halogen,

or

for C_1 - C_3 -alkyl or C_1 - C_6 -alkoxy that is optionally substituted in one or more places, in the same way or differently, with halogen, hydroxy or with the group $-NC_1-C_6-alkyl)_2$ or $-CO(NH)-M$,

or

for $-NH(CO)-L$, $-NH(CO)-NH-L$, $-COR^6$, $-CO(NH)-M$, $-CO(NCH_3)-M$, $-SO_2(NH)-M$ or $-SO_2(NCH_3)-M$,

L stands for C_1 - C_6 -alkyl that is optionally substituted in one or more places, in the same way or differently, with pyrrolidinyl,

M stands for C_1 - C_6 -alkyl that is optionally substituted in one or more places, in the same way or differently, with the group $-N(C_1-C_6-alkyl)_2$ or pyrrolidinyl,

R¹ stands for C₁-C₃-alkyl,

R^{2a} stands for allyl or propargyl, and

R⁶ stands for hydroxy, C₁-C₆-alkyl or C₁-C₆-alkoxy,

as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts.

8. Compounds of the following formulas, as well as their solvates, hydrates, stereoisomers, diastereomers, enantiomers and salts:

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[4-(2-morpholin-4-yl-ethanesulfonylamino)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-({4-[(pyrrolidine-1-carbonyl)-amino]-phenylamino}-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-({4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene)-acetic acid allyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-({4-[3-(4-methyl-piperazin-1-yl)-propionylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene)-acetic acid benzyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z) -{[4-(2-pyrrolidin-1-yl-ethylcarbamoyl)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid allyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(p-tolylamino-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(m-tolylamino-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(3-nitro-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(3-Chloro-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester,

5-{[2-((E or Z)-Cyano-ethoxycarbonyl-methylene)-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-yildenemethyl]-amino}-1H-indole-2-carboxylic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-methyl-1H-indol-5-ylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(3-Carbamoyl-1H-indol-5-ylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[3-(4-methyl-piperazine-1-carbonyl)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({3-[2-(2-hydroxymethyl-pyrrolidin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[3-(2-piperidin-1-yl-ethanesulfonylamino)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[3-(2-pyrrolidin-1-yl-ethanesulfonylamino)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[4-(3-methoxy-propionylamino)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(2-methoxy-ethoxy)-acetylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[4-(2-methoxy-acetylamino)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-4-oxo-5-(E/Z)-{[4-(2-piperidin-1-yl-ethanesulfonylamino)-phenylamino]-methylene}-thiazolidin-2-ylidene)-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(4-methyl-piperazin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-methanesulfonylamino-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(2-hydroxymethyl-piperidin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[2-(2-hydroxymethyl-pyrrolidin-1-yl)-ethanesulfonylamino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid propyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-fluoro-4-hydroxy-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(3-Chloro-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-3-nitro-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{5-(E/Z)-[(3,5-dichloro-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-3,5-dimethyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{5-(E/Z)-[(3-diethylaminomethyl-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-hydroxy-3-methyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{5-(E/Z)-[(3,5-dibromo-4-hydroxy-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

5-{[2-((E or Z)-Cyano-ethoxycarbonyl-methylene)-3-ethyl-4-oxo-thiazolidin-5-(E/Z)-yildenemethyl]-amino}-2-hydroxy-benzoic acid methyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-hydroxy-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-fluoro-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(o-tolylamino-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(2-Chloro-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-(quinolin-8-ylaminomethylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-isopropyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-(naphthalen-1-ylaminomethylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-(naphthalen-1-ylaminomethylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(2-ethyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(1H-Benzimidazol-2-ylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyano-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(1-methyl-1H-benzimidazol-2-ylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

Cyano-[3-ethyl-4-oxo-5-[1-[4-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester,

Cyano-[3-ethyl-4-oxo-5-[1-{4-[3-(2-pyrrolidin-1-yl-ethyl)-ureido]-phenylamino}-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester,

4-(4-{[2-[1-Allyloxycarbonyl-1-cyano-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/ Z)-ylidenemethyl]-amino}-phenyl)-butyric acid,

Cyano-[3-ethyl-4-oxo-5-[1-[3-(3-pyrrolidin-1-yl-propionylamino)-phenylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester,

4-{[2-[1-Allyloxycarbonyl-1-cyano-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/ Z)-ylidenemethyl]-amino}-benzoic acid,

6-{[2-[1-Allyloxycarbonyl-1-cyano-meth-(E or Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-5-(E/ Z)-ylidenemethyl]-amino}-naphthalene-2-carboxylic acid,

Cyano-[5-[1-{4-[3-(2-diethylamino-ethylcarbamoyl)-propyl]-phenylamino}-meth-(E/Z)-ylidene]-3-ethyl-4-oxo-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester,

Cyano-[3-ethyl-4-oxo-5-[1-[6-(2-pyrrolidin-1-yl-ethylcarbamoyl)-naphthalen-2-ylamino]-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid allyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[3-(2-hydroxy-ethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-({4-[(pyrrolidin-1-carbonyl)-amino]-phenylamino}-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-methoxy-3-[(morpholin-4-carbothioyl)-amino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-{3-[2-(2-hydroxy-ethoxy)-ethyl]-ureido-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[(4-methyl-piperazin-1-carbothioyl)-amino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[3-(2-hydroxy-ethyl)-thioureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-{5-(E/Z)-[(4-Acetylsulfamoyl-phenylamino)-methylene]-3-ethyl-4-oxo-thiazolidin-2-ylidene}-cyanoacetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-{3-[2-(2-hydroxy-ethoxy)-ethyl]-thioureido}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-(3-ethyl-5-(E/Z)-{[2-(2-hydroxy-ethyl)-phenylamino]-methylene}-4-oxo-thiazolidin-2-ylidene)-acetic acid ethyl ester,

Cyano-{3-ethyl-5-(E/Z)-[(2-ethyl-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-fluoro-3-[3-(2-morpholin-4-yl-ethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[3-(1-ethyl-pyrrolidin-2-ylmethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-{[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-amino}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({3-[3-(2-morpholin-4-yl-ethyl)-ureido]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[5-(E/Z)-({3-[3-(3-dimethylamino-propyl)-ureido]-phenylamino}-methylene)-3-ethyl-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-{[4-(4-methyl-piperazin-1-yl)-piperidine-1-carbonyl]-amino}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[5-(E/Z)-({4-[3-(3-dimethylamino-propyl)-ureido]-phenylamino}-methylene)-3-ethyl-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[5-(E/Z)-({3-[3-(3-dimethylamino-propyl)-ureido]-4-fluoro-phenylamino}-methylene)-3-ethyl-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester,


(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-fluoro-3-{3-[2-(1-methyl-pyrrolidin-2-yl)-ethyl]-ureido}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-{3-ethyl-5-(E/Z)-[(4-fluoro-3-{[4-(2-hydroxy-ethyl)-piperazine-1-carbonyl]-amino}-phenylamino)-methylene]-4-oxo-thiazolidin-2-ylidene}-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-4-oxo-5-(E/Z)-({4-[3-(2-pyrrolidin-1-yl-ethyl)-ureido]-phenylamino}-methylene)-thiazolidin-2-ylidene]-acetic acid ethyl ester,

(E or Z)-Cyano-[3-ethyl-5-(E/Z)-({4-[(4-methyl-piperazine-1-carbonyl)-amino]-phenylamino}-methylene)-4-oxo-thiazolidin-2-ylidene]-acetic acid ethyl ester.


9. Uses of the compounds of general formula IIA or IIB



[or]

in which D stands for the group $-\text{NO}_2$, $-\text{NH}_2$ or $-\text{NH}(\text{CO})\text{OC}(\text{CH}_3)_3$ and E stands for $\text{C}_1\text{-C}_6$ -alkoxy or halogen, and R^3 and R^4 have the meaning that is described in general formula I, as intermediate products for the production of the substances of general formula I according to the invention.


10. Uses of the compounds of general formula IIIA or IIIB



[or]


in which D stands for the group $-\text{NO}_2$, $-\text{NH}_2$ or $-\text{NH}(\text{CO})\text{OC}(\text{CH}_3)_3$, and G stands for the group $-\text{NR}^3\text{R}^4$, and R^3 , R^4 and n have the meaning that is described in general formula I, as intermediate products for the production of the substances of general formula I according to the invention.

11. Uses of the compounds of general formula IVA or IVB



in which D stands for the group $-\text{NO}_2$, $-\text{NH}_2$ or $-\text{NH}(\text{CO})\text{OC}(\text{CH}_3)_3$, and K stands for C_1 - C_6 -alkyl or C_1 - C_6 -alkenyl that is optionally substituted with the group $-\text{NR}^3\text{R}^4$, and L stands for C_1 - C_6 -alkyl or C_1 - C_6 -alkenyl that is optionally substituted in one or more places, in the same way or differently, with C_1 - C_6 -alkoxy, C_1 - C_6 -alkoxy- C_1 - C_6 -alkoxy or the group $-\text{NR}^3\text{R}^4$, and R^3 and R^4 have the meaning that is described in general formula I, as intermediate products for the production of substances of general formula I according to the invention.

12. Compounds of general formula V



in which Q, A, B and R¹ have the meaning that is described in general formula I, as intermediate products for the production of the substances of general formula I according to the invention, with the proviso that cyano-[3-ethyl-4-oxo-5-[1-phenylamino-meth-(E/Z)-ylidene]-thiazolidin-(2-(E or Z))-ylidene]-acetic acid does not fall under general formula V.

13. Use of the compounds of general formula I, according to claims 1 to 5, for the production of a pharmaceutical agent for treating cancer, auto-immune diseases, chemotherapy agent-induced alopecia and mucositis, cardiovascular diseases, infectious diseases, nephrological diseases, chronic and acute neurodegenerative diseases and viral infections.

14. Use according to claim 13, characterized in that cancer is defined as solid tumors and leukemia; auto-immune diseases are defined as psoriasis, alopecia and multiple sclerosis; cardiovascular diseases are defined as stenoses, arterioscleroses and restenoses; infectious diseases are defined as diseases that are caused by unicellular parasites; nephrological diseases are defined as glomerulonephritis; chronic neurodegenerative diseases are defined as Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease; acute neurodegenerative diseases are defined as ischemias of the brain and neurotraumas; and viral infections are defined as cytomegalic infections, herpes, hepatitis B and C, and HIV diseases.

15. Pharmaceutical agents that contain at least one compound according to claims 1 to 5.

16. Pharmaceutical agents according to claim 15 for treating cancer, autoimmune diseases, cardiovascular diseases, infectious diseases, nephrological diseases, neurodegenerative diseases and viral infections.

17. Compounds according to claims 1 to 5 or pharmaceutical agents according to claim 15 or 16 with suitable formulation substances and vehicles.

18. Use of the compounds of general formula I, according to claims 1 to 5, and the pharmaceutical agents, according to claim 15 or 16, as inhibitors of the polo-like kinases.
19. Use according to claim 18, wherein the kinase is Plk1, Plk2, Plk3 or Plk4.
20. Use of the compounds of general formula I, according to claims 1 to 5, in the form of a pharmaceutical preparation for enteral, parenteral and oral administration.